

1c903 U.S. PTO  
08/24/00

8-28-00

A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Date: August 24, 2000

File No. A-68344-3/RMS/DAV

Assistant Commissioner for Patents  
Washington, DC 20231

"EXPRESS MAIL" MAILING LABEL

NUMBER EK 916 735 137 US

DATE OF DEPOSIT August 24, 2000

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO: THE ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, DC 20231.

TYPED NAME Vince Diaz

SIGNED VMD

Sir:

Transmitted herewith for filing is the patent application of Inventor(s):

Ying Luo; Alan C. Fu; Mary Shen

For: NOVEL GERMINAL CENTER KINASE CELL CYCLE PROTEINS, COMPOSITIONS AND METHODS OF USE

Enclosed are also:

☒ 25 Sheets of drawing, Informal X

	(Col. 1)			(Col. 2)		SMALL ENTITY		OTHER THAN SMALL ENTITY	
	NO. FILED			NO. EXTRA		RATE	FEE	RATE	FEE
BASIC FEE							\$ 345		\$ 690
TOTAL CLAIMS	20	-	20 =			x \$ 9	= \$	x 18	= \$ 0
INDEP CLAIMS	3	-	3 =			x \$ 39	= \$	x 78	= \$ 0
MULTIPLE DEPENDENT CLAIM PRESENTED			→			+ \$ 130	= \$	+ 280	= \$
If the difference in Col 1 is less than zero, enter "0" in Col. 2						TOTAL	\$ 345	TOTAL	\$

☒ Filing Fees are **not** enclosed.

Respectfully submitted,

8-24-00  
Date

FLEHR HOHBACH TEST  
ALBRITTON & HERBERT LLP  
Four Embarcadero Center, Suite 3400  
San Francisco, California 94111-4187  
Telephone: (415) 781-1989 Fax: (415) 398-3249

Dolly A. Vance  
Dolly A. Vance  
Reg. No. 39,054

1c903 U.S. PTO  
09/65456  
08/24/00

5

## NOVEL GERMINAL CENTER KINASE CELL CYCLE PROTEINS, COMPOSITIONS AND METHODS OF USE

### FIELD OF THE INVENTION

10 The present invention is directed to compositions involved in cell cycle regulation and methods of use. More particularly, the present invention is directed to genes encoding proteins and proteins involved in cell cycle regulation. Methods of use include use in assays screening for modulators of the cell cycle and use as therapeutics.

### BACKGROUND OF THE INVENTION

15 Cells cycle through various stages of growth, starting with the M phase, where mitosis and cytoplasmic division (cytokinesis) occurs. The M phase is followed by the G1 phase, in which the cells resume a high rate of biosynthesis and growth. The S phase begins with DNA synthesis, and ends when the DNA content of the nucleus has doubled. The cell then enters G2 phase, which ends when mitosis starts, signaled by the appearance of condensed chromosomes. Terminally differentiated cells are arrested in the G1 phase, and no longer undergo cell division.

20 The hallmark of a malignant cell is uncontrolled proliferation. This phenotype is acquired through the accumulation of gene mutations, the majority of which promote passage through the cell cycle. Cancer cells ignore growth regulatory signals and remain committed to cell division. Classic oncogenes, such as *ras*, lead to inappropriate transition from G1 to S phase of the cell cycle, mimicking proliferative extracellular signals. Cell cycle checkpoint controls ensure faithful  
25 replication and segregation of the genome. The loss of cell cycle checkpoint control results in genomic instability, greatly accelerating the accumulation of mutations which drive malignant transformation. Thus, modulating cell cycle checkpoint pathways and other such pathways with therapeutic agents could exploit the differences between normal and tumor cells, both improving the selectivity of radio- and chemotherapy, and leading to novel cancer treatments. As another  
30 example, it would be useful to control entry into apoptosis.

On the other hand, it is also sometimes desirable to enhance proliferation of cells in a controlled manner. For example, proliferation of cells is useful in wound healing and where growth of tissue is desirable. Thus, identifying modulators which promote, enhance or deter the inhibition of proliferation is desirable.

5 Proteins of general interest that have been reported on include kinases. The Ste20 family of kinases can be divided into two structurally distinct subfamilies. The first subfamily contains a C-terminal catalytic domain and an N-terminal binding site for the small G proteins Rac1 and Cdc42 (Herskowitz, *Cell*, **80**:187-197 (1995)). The yeast serine/threonine kinase Ste20 and its mammalian homologue, p21 Activated Kinase 1 (PAK1), belong to this subfamily. Ste20 initiates a  
10 mitogen-activated protein kinase (MAPK) cascade that includes Ste11 (MAPKKK), Ste7 (MAPKK), and FUS3/KSS1 (MAPK) in response to activation of the small G protein Cdc42, as well as signals from the hetero-trimeric G proteins coupled to pheromone receptors (Herskowitz, *Cell*, **80**:187-197 (1995)). Similar to Ste20, PAK1 has been reported to be a Cdc42 and Rac1 effector molecule and specifically regulates the c-Jun N-terminal kinase (JNK) pathway, one of the mammalian MAPK  
15 pathways (Bagrodia, et al., *J. Biol. Chem.*, **270**:27995-27998 (1995); Kyriakis, et al., *J. Biol. Chem.*, **271**:24313-24316 (1996)). The JNK pathway is activated by a variety of stress inducing agents, including osmotic and heat shock, UV irradiation, protein inhibitors and pro-inflammatory cytokines such as tumor necrosis factor (TNF) (Ip, et al., *Curr. Opin. Cell Biol.*, **10**:205-219 (1998)). JNKs are activated through threonine and tyrosine phosphorylation by MEK4 and MEK7 (MAPKK),  
20 which are in turn phosphorylated and activated by MAPKKKs including MEK kinase 1 (MEKK1), and mixed lineage kinases MLK2 and MLK3 (Ip, et al., *Curr. Opin. Cell Biol.*, **10**:205-219 (1998)). In addition to the activation of the JNK pathway, PAK1 has also been reported to be a regulator of the actin cytoskeleton (Sells, et al., *Curr. Biol.*, **7**:202-210 (1997)).

The second subgroup of Ste20 family of kinases is represented by the family of germinal center  
25 kinases (GCK) (Kyriakis, *J. Biol. Chem.*, **274**:5259-5262 (1999)). In contrast to Ste20 and PAK1, GCK family members have an N-terminal kinase domain and a C-terminal regulatory region. Many GCK family members, including GCK, germinal center kinase related protein (GCKR), meatopoietic protein kinase (HPK) 1, GCK-like kinase (GLK), HPK/GCK-like kinase (HGK) and NCK interacting kinase (NIK), have also been reported to activate the JNK pathway when overexpressed in 293  
30 cells (Pombo, et al., *Nature*, **377**:750-754 (1995); Shi, et al., *J. Biol. Chem.*, **272**:32102-32107 (1997); Kiefer, et al., *EMBO J.*, **15**:7013-7025 (1996); Diener, et al., *Proc. Natl. Acad. Sci. USA*, **94**:9687-9692 (1997); Yao, et al., *J. Biol. Chem.*, **274**:2118-2125 (1999); Su, et al., *EMBO J.*, **16**:1279-1290 (1997)). Among those, GCK and GCKR have been implicated in mediating TNF-induced JNK activation through TNF receptor associated factor 2 (Traf2) (Pombo, et al., *Nature*,  
35 **377**:750-754 (1995); Diener, et al., *Proc. Natl. Acad. Sci. USA*, **94**:9687-9692 (1997); Yuasa, et al., *J. Biol. Chem.*, **273**:22681-22692 (1998)). NCK interacting kinase (NIK) interacts with the SH2-SH3 domain containing adapter protein NCK and has been proposed to link protein tyrosine kinase

signals to JNK activation (Su, et al., EMBO J., 16:1279-1290 (1997)).

One study reports on a GCK family kinase from *Dictyostelium* that can phosphorylate Severin *in vitro*. (Eichinger, et al., J. Biol. Chem., 273:12952-12959 (1998)). Severin is an F-actin fragmenting and capping enzyme that regulates *Dictyostelium* motility. However, there has not  
5 been any studies indicating the involvement of mammalian GCKs in cytoskeleton regulation.

Despite the desirability of identifying cell cycle components and modulators, there is a deficit in the field of such compounds. Accordingly, it would be advantageous to provide compositions and methods useful in screening for modulators of the cell cycle. It would also be advantageous to provide novel compositions which are involved in the cell cycle.

## SUMMARY OF THE INVENTION

The present invention provides cell cycle proteins and nucleic acids which encode such proteins. Also provided are methods for screening for a bioactive agent capable of modulating the cell cycle. The method comprises combining a cell cycle protein and a candidate bioactive agent and a cell or a population of cells, and determining the effect on the cell in the presence and absence of the candidate agent. Therapeutics for regulating or modulating the cell cycle are also provided.  
15

In one aspect, a recombinant nucleic acid encoding a cell cycle protein of the present invention comprises a nucleic acid that hybridizes under high stringency conditions to a sequence complementary to that set forth in Figure 21, 22, 23, 24, 25, 26, 27 or 28. In a preferred embodiment, the cell cycle protein provided herein binds to Traf2 or Nck. Most preferably, the cell cycle protein binds to Traf2 and binds to Nck.  
20

In one embodiment, a recombinant nucleic acid is provided which comprises a nucleic acid sequence as set forth in Figure 21, 22, 23, 24, 25, 26, 27 or 28. In another embodiment, a recombinant nucleic acid encoding a cell cycle protein is provided which comprises a nucleic acid sequence having at least 85% sequence identity to a sequence as set forth in Figure 21, 22, 23, 24, 25, 26, 27 or 28. In a further embodiment, provided herein is a recombinant nucleic acid encoding an amino acid sequence as depicted in Figure 1 for Tnik, or Figure 29, 30, 31, 32, 33, 34 or 35.  
25

In another aspect of the invention, expression vectors are provided. The expression vectors comprise one or more of the recombinant nucleic acids provided herein operably linked to regulatory sequences recognized by a host cell transformed with the nucleic acid. Further provided herein are host cells comprising the vectors and recombinant nucleic acids provided herein. Moreover, provided herein are processes for producing a cell cycle protein comprising culturing a  
30

host cell as described herein under conditions suitable for expression of the cell cycle protein. In one embodiment, the process includes recovering the cell cycle protein.

Also provided herein are recombinant cell cycle proteins encoded by the nucleic acids of the present invention. In one aspect, a recombinant polypeptide is provided herein which comprises an amino acid sequence having at least 80% sequence identity with a sequence as set forth in Figure 21, 22, 23, 24, 25, 26, 27 or 28. In one embodiment, a recombinant cell cycle protein is provided which comprises an amino acid sequence as set forth in Figure 1 for Tnik, or Figure 29, 30, 31, 32, 33, 34 or 35.

In another aspect, the present invention provides isolated polypeptides which specifically bind to a cell cycle protein as described herein. Examples of such isolated polypeptides include antibodies. Such an antibody can be a monoclonal antibody. In one embodiment, such an antibody reduces or eliminates the biological function of said cell cycle protein.

Further provided herein are methods for screening for a bioactive agent capable of binding to a cell cycle protein. In one embodiment the method comprises combining a cell cycle protein and a candidate bioactive agent, and determining the binding of said candidate bioactive agent to said cell cycle protein.

In another aspect, provided herein is a method for screening for a bioactive agent capable of interfering with the binding of a cell cycle protein and a Traf, preferably Traf2, or Nck protein. In one embodiment, such a method comprises combining a cell cycle protein, a candidate bioactive agent and a Traf or Nck protein, and determining the binding of the cell cycle protein and the Traf or Nck protein. If desired, the cell cycle protein and the Traf or Nck protein can be combined first.

Further provided herein are methods for screening for a bioactive agent capable of modulating the activity of cell cycle protein. In one embodiment the method comprises adding a candidate bioactive agent to a cell comprising a recombinant nucleic acid encoding a cell cycle protein, and determining the effect of the candidate bioactive agent on the cell. In a preferred embodiment, a library of candidate bioactive agents is added to a plurality of cells comprising a recombinant nucleic acid encoding a cell cycle protein.

Other aspects of the invention will become apparent to the skilled artisan by the following description of the invention.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a sequence alignment of Tnik (top sequence) to NIK (bottom sequence). Identical

residues are shaded with black and homologous residues are shaded with gray and dotted below. The three alternatively spliced exons are marked by (–) above the Tnik sequence.

Figure 2 shows a picture of a gel showing polymerase chain reaction (PCR) products of Tnik fragments from human spleen, heart and brain cDNAs. Oligos corresponding to nucleotides 1264-1281 and nucleotides 2427-2410 were used as primers.

Figure 3 shows a diagram of NIK and Tnik spliced isoforms. The percent homology between NIK and NIK in individual domains is indicated. The three alternatively spliced exons are hatched and the amino acid boundaries corresponding to the three exons are indicated.

Figure 4 shows a picture of a gel with the results of an *in vitro* kinase assay of Tnik. Phoenix-A cells in 6-well plates were transiently transfected with 3 µg of HA-Tnik(WT) (lanes 1 and 3) or HA-Tnik(KM) (lane 2 and 4). Expressed proteins were immunoprecipitated with an anti-HA antibody. Immune complexes were subjected to *in vitro* kinase assay (lanes 1, 2) or immunoblotting with an anti-HA antibody (lanes 3, 4).

Figure 5 shows a picture of the results of expression of Tnik message in human tissues. Figure 5A: Human multi-tissue Northern blot (Clontech) was hybridized with a probe corresponding to nts 1264-2427 in the Tnik coding region. Figure 5B: The same blot was stripped and re-blotted with an β-actin probe to control for the amount of mRNA on each lane.

Figure 6 shows the interaction of Tnik with Traf2 by a gel showing co-immunoprecipitation of Tnik with endogenous Traf2. Phoenix-A cells in 100 mm dishes were transiently transfected with 10 µg of vector (lane 1) or HA-Tnik (lane 2). Top panel: Cell lysates were immunoprecipitated with an anti-HA mAb and blotted with an anti-Traf2 pAb. Middle and bottom panels: One tenth of cell lysates were blotted with an anti-HA mAb or an anti-Traf2 pAb to control for protein expression.

Figure 7 shows a schematic diagram of Tnik mutants.

Figure 8 show results which show the mapping of domains on Tnik that mediated its interaction with Traf2. FLAG-Traf2 was co-transfected into Phoenix-A cells with HA-Tnik mutants. Top panel: Cell lysates were immunoprecipitated with an anti-HA pAb and blotted with an anti-FLAG mAb. Middle and bottom panels: Cell lysates were immunoblotted with an anti-FLAG mAb or an anti-HA mAb.

Figure 9 shows a schematic diagram of Traf2 mutants.

Figure 10 shows the mapping of domains on Traf2 that mediated its interaction with Tnik. HA-Tnik was co-transfected into Phoenix-A cells with FLAG-Traf2 mutants and the cell lysates were

analyzed as in Figure 8.

Figure 11 shows the results showing interaction of Tnik with NCK by co-immunoprecipitation of Tnik with endogenous NCK. Phoenix-A cells in 100 mm dishes were transiently transfected with 10  $\mu$ g of vector (lane 1) or HA-Tnik (lane 2). Top panel: Cell lysates were immunoprecipitated with an anti-HA pAb and blotted with an anti-NCK mAb. Middle and bottom panels: One tenth of cell lysates were blotted with an anti-NCK mAb or an anti-HA mAb.

Figure 12 shows the mapping of domains on Tnik that mediated its interaction with NCK. FLAG-NCK was co-transfected into Phoenix-A cells with HA-Tnik mutants. Top panel: Cell lysates were immunoprecipitated with an anti-HA pAb and blotted with an anti-FLAG mAb. Middle and bottom panels: Cell lysates were immunoblotted with an anti-FLAG mAb or an anti-HA mAb to control for protein expression.

Figure 13 shows the results showing specific activation of the JNK pathway by Tnik by overexpression of Tnik activated JNK2. 1  $\mu$ g of Myc-JNK2 was co-transfected into Phoenix-A cells in 6-well plates with 3  $\mu$ g of vector (lanes 1-2), 1, 2 or 3  $\mu$ g of Tnik plus 2, 1 or 0  $\mu$ g of vector (lanes 3-5), or 1  $\mu$ g of Traf2 plus 2  $\mu$ g of vector (lane 6). Top panel: Myc-JNK2 was immunoprecipitated from cell lysates by an anti-Myc mAb and subjected to an *in vitro* kinase assay with GST-cJun as an exogenous substrate. In lane 2, 100 ng/ml of TNF $\alpha$  was added for 15 min before the cells were lysed. Bottom panel: One tenth of cell lysates were immunoblotted with an anti-Myc mAb to control for expression levels of Myc-JNK2.

Figure 14 shows overexpression of Tnik did not activate extracellular signal regulated kinase (ERK). 1  $\mu$ g of Myc-ERK1 was co-transfected into Phoenix-A cells in 6-well plates with 3  $\mu$ g of vector (lane 1), 1, 2 or 3  $\mu$ g of Tnik plus 2, 1 or 0  $\mu$ g of vector (lanes 2-4), or 0.05  $\mu$ g of MEKK1 plus 2.95  $\mu$ g of vector (lane 5). Top panel: Myc-ERK1 was immunoprecipitated from cell lysates by an anti-Myc mAb and subjected to an *in vitro* kinase assay with MBP as an exogenous substrate. Bottom panel: One tenth of the cell lysates were immunoblotted with an anti-Myc mAb to control for expression levels of Myc-ERK1.

Figure 15 shows overexpression of Tnik did not activate p38. 1  $\mu$ g of FLAG-p38 was co-transfected into Phoenix-A cells in 6-well plates with 3  $\mu$ g of vector (lane 1), 1, 2 or 3  $\mu$ g of Tnik plus 2, 1 or 0  $\mu$ g of vector (lanes 2-4), or 0.05  $\mu$ g of MEKK1 plus 2.95  $\mu$ g of vector (lane 5). Top panel: FLAG-p38 was immunoprecipitated from cell lysates by an anti-FLAG mAb and subjected to an *in vitro* kinase assay with GST-ATF2 as an exogenous substrate. Bottom panel: One tenth of cell lysates were immunoblotted with an anti-FLAG mAb to control for expression levels of FLAG-p38.

Figure 16 shows that the C-terminal GCKH (germinal center kinase homology region) domain of

Tnik is both necessary and sufficient for JNK activation. 1  $\mu$ g of Myc-JNK2 was co-transfected into Phoenix-A cells in 6-well plates with 3  $\mu$ g of vector (lanes 1, 2), 3  $\mu$ g of the indicated Tnik mutants (lanes 3-9) or 0.05  $\mu$ g of MEKK1 plus 2.95  $\mu$ g of vector (lane 10). *In vitro* kinase assay and immunoblotting were performed as described in A. These experiments were repeated at least three times.

Figure 17 shows the results showing regulation of the cytoskeleton by Tnik. Figures 17A-17F show the results showing inhibition of cell spreading by Tnik. 0.4  $\mu$ g of GFP was co-transfected into Phoenix-A cells with 3  $\mu$ g of Vector, Tnik(WT), Tnik(KM), Tnik(N1), Tnik(C1) or JNK2. 24 hours after transfection, cells were examined under fluorescent microscope.

Figure 18 shows the results showing Tnik overexpression did not induce apoptosis. 3  $\mu$ g of Vector, Tnik(WT), Tnik(KM) or RIP was transfected into Phoenix-A cells for 24 hours. Transfected cells were stained with Hoechst 33258 and examined under fluorescent microscope.

Figure 19 shows a picture of a gel showing Tnik overexpression induced redistribution of actin. Phoenix-A cells were transfected with 3  $\mu$ g of vector, HA-Tnik(WT) or HA-Tnik(KM) and lysed with 1% Triton X-100 as described in EXPERIMENTAL PROCEDURES. Top panel: Cell lysates (4 x 10<sup>4</sup> cells) from either Triton X-100 soluble (lanes 1-3) or insoluble (lanes 4-6) fractions were resolved on SDS-PAGE and immunoblotted with an anti- $\beta$ -actin mAb. Bottom panel: Total cell lysates were blotted with an anti-HA mAb to control for expression levels of Tnik(WT) and Tnik(KM).

Figure 20 shows a picture of a gel showing phosphorylation of Gelsolin by Tnik *in vitro*. Phoenix-A cells were transiently transfected with 3  $\mu$ g of HA-Tnik(WT) (lane 1) or HA-Tnik(KM) (lane 2). Cell lysates were subjected to anti-HA immunoprecipitation and an *in vitro* kinase assay using Gelsolin (Sigma) as an exogenous substrate.

Figure 21 shows the nucleic acid sequence of SEQ ID NO:1, encoding a cell cycle protein, Tnik, isoform 1.

Figure 22 shows the nucleic acid sequence of SEQ ID NO:2, encoding a cell cycle protein, Tnik, isoform 2.

Figure 23 shows the nucleic acid sequence of SEQ ID NO:3, encoding a cell cycle protein, Tnik, isoform 3.

Figure 24 shows the nucleic acid sequence of SEQ ID NO:4, encoding a cell cycle protein, Tnik, isoform 4.



Figure 25 shows the nucleic acid sequence of SEQ ID NO:5, encoding a cell cycle protein, Tnik, isoform 5.

Figure 26 shows the nucleic acid sequence of SEQ ID NO:6, encoding a cell cycle protein, Tnik, isoform 6.

5      Figure 27 shows the nucleic acid sequence of SEQ ID NO:7, encoding a cell cycle protein, Tnik, isoform 7.

Figure 28 shows the nucleic acid sequence of SEQ ID NO:8, encoding a cell cycle protein, Tnik, isoform 8.

Figure 29 shows the amino acid sequence of SEQ ID NO:9, of Tnik, isoform 2.

10      Figure 30 shows the amino acid sequence of SEQ ID NO:10, of Tnik, isoform 3.

Figure 31 shows the amino acid sequence of SEQ ID NO:11, of Tnik, isoform 4.

Figure 32 shows the amino acid sequence of SEQ ID NO:12, of Tnik, isoform 5.

Figure 33 shows the amino acid sequence of SEQ ID NO:13, of Tnik, isoform 6.

Figure 34 shows the amino acid sequence of SEQ ID NO:14, of Tnik, isoform 7.

15      Figure 35 shows the amino acid sequence of SEQ ID NO:15, of Tnik, isoform 8.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides cell cycle proteins and nucleic acids which encode such proteins. Also provided are methods for screening for a bioactive agent capable of modulating the cell cycle. The method comprises combining a cell cycle protein and a candidate bioactive agent and a cell or  
20      a population of cells, and determining the effect on the cell in the presence and absence of the candidate agent. Other screening assays including binding assays are also provided herein as described below. Therapeutics for regulating or modulating the cell cycle are also provided and described herein. Diagnostics, as further described below, are also provided herein.

25      A cell cycle protein of the present invention may be identified in several ways. "Protein" in this sense includes proteins, polypeptides, and peptides. The cell cycle proteins of the invention fall into two general classes: proteins that are completely novel, i.e. are not part of a public database

as of the time of discovery, although they may have homology to either known proteins or peptides encoded by expressed sequence tags (ESTs). Alternatively, the cell cycle proteins are known proteins, but that were not known to be involved in the cell cycle; i.e. they are identified herein as having a novel biological function. Accordingly, a cell cycle protein may be initially identified by its association with a protein known to be involved in the cell cycle. Wherein the cell cycle proteins and nucleic acids are novel, compositions and methods of use are provided herein. In the case that the cell cycle proteins and nucleic acids were known but not known to be involved in cell cycle activity as described herein, methods of use, i.e. functional screens, are provided.

In one embodiment provided herein, a cell cycle protein as defined herein has one or more of the following characteristics: binding to Traf, preferably Traf2, binding to Nck; and cell cycle protein activity as described herein.

In one embodiment, the cell cycle protein is termed Tnik herein. One or more of the characteristics described below can apply to any of the cell cycle proteins provided herein, however, Tnik is used for illustrative purposes. Tnik is a member of the germinal center kinases. Preferably, Tnik binds to Traf or Nck. Preferably, the Traf protein is Traf2. In a preferred embodiment, Tnik binds to Traf and Nck.

Regarding Traf, regulation of CD40 signaling through multiple Traf binding sites and Traf hetero-oligomerization is described in, e.g., Pullen, et al., Biochemistry, 37(34):11836-45 (1998); Pullen, et al., J Biol Chem, 274(20):14246-54 (1999); Ishida, et al., PNAS USA, 93(18):9437-42 (1996); Kashiwada, et al., J Exp Med, 187(2):237-44(1998). Additionally, cell cycle and apoptosis-related proteins, kinases, and carcinomas are described in Muzio, et al., J Dent Res, 78(7):1345-53 (1999); Jimenez, et al., Nature, 400(6739):81-8 3 (1999); and Hsieh, Int J Oncol, 15(2):245-252 (1999). Moreover, Traf2 mediated activation of NF-kappa B by TNF receptor 2 and CD40 has been reported on. Rothe, et al., Science, 269(5229):1424-7 (1995). Regarding Traf2, also see, Takeuchi, et al., JBC, 271(33):19935-42 (1996) and Natoli, et al., J Biol Chem, 272(42):26079-82 (1997).

Regarding Nck, Nck has been reported on. For example, it has been reported that the adaptor protein Nck links receptor tyrosine kinases with the serine-threonine kinase Pak1. Nck is an adaptor protein composed of a single SH2 domain and three SH3 domains. Upon growth factor stimulation, Nck is recruited to receptor tyrosine kinases via its SH2 domain, probably initiating one or more signaling cascades. Galisteo, et al., J Biol Chem, 271(35):20997-1000 (1996). Also see, Chen, et al., J Biol Chem, 273(39):25171-8 (1998) which reports on Nck family genes, chromosomal localization and expression.

As indicated below, Tnik shares homology with fragments of clone K1AA0551, GENBANK

Accession number AB011123. Preferred embodiments of Tnik herein include the full length protein. In another preferred embodiment, Tnik comprises one or more cell cycle bioactivities as described below. In yet other embodiments wherein bioactivities are not required, Tnik excludes portions of the sequence which overlap with K1AA0551.

5 Thus, in some embodiments, the portions of homology with K1AA0551 may be excluded. For example, in Tnik Isoform number 1, the KIAA5501 fragment begins about with base pair number 1 at about position number 82 on Tnik and ends about with base pair number 4002 at about position number 4083 on Tnik. In Tnik isoform number 2, the KIAA5501 fragment begins about with base pair number 1338 at about position number 1332 on Tnik and ends about with base pair number 4002 at about position number 3996 on Tnik. In Tnik Isoform number 3, the KIAA5501 fragment begins about with base pair number 1691 at about position number 1607 on Tnik and ends about with base pair number 4002 at about position number 3918 on Tnik. In the Tnik isoform number 4, the KIAA5501 fragment begins about with base pair number 1 at about position number 82 on Tnik and ends about with base pair number 2301 at about position number 2382 on Tnik. In Tnik isoform number 5, the KIAA5501 fragment begins about with base pair number 1691 at about position number 1520 on Tnik and ends about with base pair number 4002 at about position number 3831 on Tnik. In Tnik isoform number 6, the KIAA5501 fragment begins about with base pair number 2326 at about position number 2296 on Tnik and ends about with base pair number 4002 at about position number 3972 on Tnik. In Tnik isoform number 7, the KIAA5501 fragment begins about with base pair number 2326 at about position number 2218 on Tnik and ends about with base pair number 4002 at about position number 3894 on Tnik. In Tnik isoform number 8, the KIAA5501 fragment begins about with base pair number 2326 at about position number 2131 on Tnik and ends about with base pair number 4002 at about position number 3807 on Tnik.

15 In a preferred embodiment, the cell cycle protein has a N-terminal kinase domain corresponding approximately to positions 1-305 of Tnik shown in the figures, an intermediate region, corresponding approximately to amino acid positions 306 through 1017 of Tnik as shown in the figures, and a C-terminal germinal center kinase homology region corresponding approximately to amino acids 1018 through 1360 of Tnik as shown in the figures. In one embodiment herein, the cell cycle protein consists essentially of one or more of the N-terminal kinase domain, intermediate region, and C-terminal germinal center kinase homology region.

25 In one embodiment, the cell cycle protein has one or more of the following characteristics: an intermediate region which shares greater than 40%, more preferably greater than 65%, more preferably, greater than 75%, more preferably greater than 85%, more preferably greater than 95% homology to the corresponding amino acids as shown in Figure 1 or encoded by any of the nucleic acids of Figures 21-28; an N-terminal kinase domain of the cell cycle protein which shares greater than 90%, more preferably 95% homology to the corresponding amino acids as shown in Figure 1

or encoded by any one of the nucleic acids of Figures 21-28; a C-terminal geminal center kinase homology region which has greater than 90%, more preferably 95% homology to the corresponding amino acids as shown in any one of Figures 1 and 29-35. The embodiments provided herein explicitly include any combination of these characteristics. Moreover, the homology of the cell cycle protein may be greater in one region corresponding to one or more of the isoforms but not the other.

The homology to, for example, NIK can be found as described below. In one embodiment, homology is found using the following database and parameters.homology. The method used to generate 90% and 40% homology is: Program: DNA Star Windows 32 version 3.18; Method: Jotun Hein; Multiple Alignment Parameters: Gap Penalty = 11, Gap Length Penalty = 3; Pairwise Alignment Parameters: K tuple = 2.

In one embodiment, cell cycle nucleic acids or cell cycle proteins are initially identified by substantial nucleic acid and/or amino acid sequence identity or similarity to the sequence(s) provided herein. In a preferred embodiment, cell cycle nucleic acids or cell cycle proteins have sequence identity or similarity to the sequences provided herein as described below and one or more of the cell cycle protein bioactivities as further described below. Such sequence identity or similarity can be based upon the overall nucleic acid or amino acid sequence.

In a preferred embodiment, a protein is a "cell cycle protein" as defined herein if the overall sequence identity of the amino acid sequence of Figure 1 for Tnik, or Figure 29, 30, 31, 32, 33, 34 or 35 is preferably greater than about 75%, more preferably greater than about 80%, even more preferably greater than about 85% and most preferably greater than 90%. In some embodiments the sequence identity will be as high as about 93 to 95 or 98%.

In another preferred embodiment, a cell cycle protein has an overall sequence similarity with the amino acid sequence of Figure 1 for Tnik, or Figure 29, 30, 31, 32, 33, 34 or 35, of greater than about 80%, more preferably greater than about 85%, even more preferably greater than about 90% and most preferably greater than 93%. In some embodiments the sequence identity will be as high as about 95 to 98 or 99%.

As is known in the art, a number of different programs can be used to identify whether a protein (or nucleic acid as discussed below) has sequence identity or similarity to a known sequence.

Sequence identity and/or similarity is determined using standard techniques known in the art, including, but not limited to, the local sequence identity algorithm of Smith, et al., Adv. Appl. Math. 2:482 (1981), by the sequence identity alignment algorithm of Needleman, et al., J. Mol. Biol., 48:443 (1970), by the search for similarity method of Pearson, et al., PNAS USA, 85:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the

Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Drive, Madison, WI), the Best Fit sequence program described by Devereux, et al., Nucl. Acid Res., **12**:387-395 (1984), preferably using the default settings, or by inspection. Preferably, percent identity is calculated by FastDB based upon the following parameters: mismatch penalty of 1; gap penalty of 1; gap size penalty of 0.33; and joining penalty of 30, "Current Methods in Sequence Comparison and Analysis," Macromolecule Sequencing and Synthesis, Selected Methods and Applications, pp 127-149 (1988), Alan R. Liss, Inc.

An example of a useful algorithm is PILEUP. PILEUP creates a multiple sequence alignment from a group of related sequences using progressive, pairwise alignments. It can also plot a tree showing the clustering relationships used to create the alignment. PILEUP uses a simplification of the progressive alignment method of Feng, et al., J. Mol. Evol., **35**:351-360 (1987); the method is similar to that described by Higgins, et al., CABIOS, **5**:151-153 (1989). Useful PILEUP parameters including a default gap weight of 3.00, a default gap length weight of 0.10, and weighted end gaps.

Another example of a useful algorithm is the BLAST algorithm, described in Altschul, et al., J. Mol. Biol., **215**:403-410, (1990) and Karlin, et al., PNAS USA, **90**:5873-5787 (1993). A particularly useful BLAST program is the WU-BLAST-2 program which was obtained from Altschul, et al., Methods in Enzymology, **266**:460-480 (1996); [http://blast.wustl.edu/blast/ README.html](http://blast.wustl.edu/blast/README.html)]. WU-BLAST-2 uses several search parameters, most of which are set to the default values. The adjustable parameters are set with the following values: overlap span =1, overlap fraction = 0.125, word threshold (T) = 11. The HSP S and HSP S2 parameters are dynamic values and are established by the program itself depending upon the composition of the particular sequence and composition of the particular database against which the sequence of interest is being searched; however, the values may be adjusted to increase sensitivity.

An additional useful algorithm is gapped BLAST as reported by Altschul, et al., Nucleic Acids Res., **25**:3389-3402. Gapped BLAST uses BLOSUM-62 substitution scores; threshold T parameter set to 9; the two-hit method to trigger ungapped extensions; charges gap lengths of k a cost of 10+k;  $X_0$  set to 16, and  $X_1$  set to 40 for database search stage and to 67 for the output stage of the algorithms. Gapped alignments are triggered by a score corresponding to ~22 bits.

A % amino acid sequence identity value is determined by the number of matching identical residues divided by the total number of residues of the "longer" sequence in the aligned region. The "longer" sequence is the one having the most actual residues in the aligned region (gaps introduced by WU-Blast-2 to maximize the alignment score are ignored).

In a similar manner, "percent (%) nucleic acid sequence identity" with respect to the coding sequence of the polypeptides identified herein is defined as the percentage of nucleotide residues

in a candidate sequence that are identical with the nucleotide residues in the coding sequence of the cell cycle protein. A preferred method utilizes the BLASTN module of WU-BLAST-2 set to the default parameters, with overlap span and overlap fraction set to 1 and 0.125, respectively.

The alignment may include the introduction of gaps in the sequences to be aligned. In addition, for sequences which contain either more or fewer amino acids than the protein encoded by the sequences in the Figures, it is understood that in one embodiment, the percentage of sequence identity will be determined based on the number of identical amino acids in relation to the total number of amino acids. Thus, for example, sequence identity of sequences shorter than that shown in the Figure, as discussed below, will be determined using the number of amino acids in the shorter sequence, in one embodiment. In percent identity calculations relative weight is not assigned to various manifestations of sequence variation, such as, insertions, deletions, substitutions, *etc.*

In one embodiment, only identities are scored positively (+1) and all forms of sequence variation including gaps are assigned a value of "0", which obviates the need for a weighted scale or parameters as described below for sequence similarity calculations. Percent sequence identity can be calculated, for example, by dividing the number of matching identical residues by the total number of residues of the "shorter" sequence in the aligned region and multiplying by 100. The "longer" sequence is the one having the most actual residues in the aligned region.

As will be appreciated by those skilled in the art, the sequences of the present invention may contain sequencing errors. That is, there may be incorrect nucleosides, frameshifts, unknown nucleosides, or other types of sequencing errors in any of the sequences; however, the correct sequences will fall within the homology and stringency definitions herein.

Cell cycle proteins of the present invention may be shorter or longer than the amino acid sequence encoded by the nucleic acid shown in the Figure. Thus, in a preferred embodiment, included within the definition of cell cycle proteins are portions or fragments of the amino acid sequence encoded by the nucleic acid sequence provided herein. In one embodiment herein, fragments of cell cycle proteins are considered cell cycle proteins if a) they share at least one antigenic epitope; b) have at least the indicated sequence identity; c) and preferably have cell cycle biological activity as further defined herein. In some cases, where the sequence is used diagnostically, that is, when the presence or absence of cell cycle protein nucleic acid is determined, only the indicated sequence identity is required. The nucleic acids of the present invention may also be shorter or longer than the sequence in the Figure. The nucleic acid fragments include any portion of the nucleic acids provided herein which have a sequence not exactly previously identified; fragments having sequences with the indicated sequence identity to that portion not previously identified are provided in an embodiment herein.

In addition, as is more fully outlined below, cell cycle proteins can be made that are longer than those depicted in the Figure; for example, by the addition of epitope or purification tags, the addition of other fusion sequences, or the elucidation of additional coding and non-coding sequences. As described below, the fusion of a cell cycle peptide to a fluorescent peptide, such as Green Fluorescent Peptide (GFP), is particularly preferred.

Cell cycle proteins may also be identified as encoded by cell cycle nucleic acids which hybridize to the sequence depicted in the Figure, or the complement thereof, as outlined herein. Hybridization conditions are further described below.

In a preferred embodiment, when a cell cycle protein is to be used to generate antibodies, a cell cycle protein must share at least one epitope or determinant with the full length protein. By "epitope" or "determinant" herein is meant a portion of a protein which will generate and/or bind an antibody. Thus, in most instances, antibodies made to a smaller cell cycle protein will be able to bind to the full length protein. In a preferred embodiment, the epitope is unique; that is, antibodies generated to a unique epitope show little or no cross-reactivity. The term "antibody" includes antibody fragments, as are known in the art, including Fab Fab<sub>2</sub>, single chain antibodies (Fv for example), chimeric antibodies, etc., either produced by the modification of whole antibodies or those synthesized de novo using recombinant DNA technologies.

In a preferred embodiment, the antibodies to a cell cycle protein are capable of reducing or eliminating the biological function of the cell cycle proteins described herein, as is described below. That is, the addition of anti-cell cycle protein antibodies (either polyclonal or preferably monoclonal) to cell cycle proteins (or cells containing cell cycle proteins) may reduce or eliminate the cell cycle activity. Generally, at least a 25% decrease in activity is preferred, with at least about 50% being particularly preferred and about a 95-100% decrease being especially preferred.

The cell cycle antibodies of the invention specifically bind to cell cycle proteins. In a preferred embodiment, the antibodies specifically bind to cell cycle proteins. By "specifically bind" herein is meant that the antibodies bind to the protein with a binding constant in the range of at least  $10^{-4}$  -  $10^6$  M<sup>-1</sup>, with a preferred range being  $10^{-7}$  -  $10^{-9}$  M<sup>-1</sup>. Antibodies are further described below.

In the case of the nucleic acid, the overall sequence identity of the nucleic acid sequence is commensurate with amino acid sequence identity but takes into account the degeneracy in the genetic code and codon bias of different organisms. Accordingly, the nucleic acid sequence identity may be either lower or higher than that of the protein sequence. Thus the sequence identity of the nucleic acid sequence as compared to the nucleic acid sequence of the Figure is preferably greater than 75%, more preferably greater than about 80%, particularly greater than about 85% and most preferably greater than 90%. In some embodiments the sequence identity will

be as high as about 93 to 95 or 98%.

In a preferred embodiment, a cell cycle nucleic acid encodes a cell cycle protein. As will be appreciated by those in the art, due to the degeneracy of the genetic code, an extremely large number of nucleic acids may be made, all of which encode the cell cycle proteins of the present invention. Thus, having identified a particular amino acid sequence, those skilled in the art could make any number of different nucleic acids, by simply modifying the sequence of one or more codons in a way which does not change the amino acid sequence of the cell cycle protein.

In one embodiment, the nucleic acid is determined through hybridization studies. Thus, for example, nucleic acids which hybridize under high stringency to the nucleic acid sequence shown in the Figure, or its complement is considered a cell cycle nucleic acid. High stringency conditions are known in the art; see for example Maniatis, et al., Molecular Cloning: A Laboratory Manual, 2d Edition, 1989, and Short Protocols in Molecular Biology, ed. Ausubel, et al., both of which are hereby incorporated by reference. Stringent conditions are sequence-dependent and will be different in different circumstances. Longer sequences hybridize specifically at higher temperatures. An extensive guide to the hybridization of nucleic acids is found in Tijssen, Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Acid Probes, "Overview of principles of hybridization and the strategy of nucleic acid assays" (1993). Generally, stringent conditions are selected to be about 5-10°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength pH. The  $T_m$  is the temperature (under defined ionic strength, pH and nucleic acid concentration) at which 50% of the probes complementary to the target hybridize to the target sequence at equilibrium (as the target sequences are present in excess, at  $T_m$ , 50% of the probes are occupied at equilibrium). Stringent conditions will be those in which the salt concentration is less than about 1.0 sodium ion, typically about 0.01 to 1.0 M sodium ion concentration (or other salts) at pH 7.0 to 8.3 and the temperature is at least about 30°C for short probes (e.g. 10 to 50 nucleotides) and at least about 60°C for long probes (e.g. greater than 50 nucleotides). Stringent conditions may also be achieved with the addition of destabilizing agents such as formamide.

In another embodiment, less stringent hybridization conditions are used; for example, moderate or low stringency conditions may be used, as are known in the art; see Maniatis and Ausubel, supra, and Tijssen, supra.

The cell cycle proteins and nucleic acids of the present invention are preferably recombinant. As used herein and further defined below, "nucleic acid" may refer to either DNA or RNA, or molecules which contain both deoxy- and ribonucleotides. The nucleic acids include genomic DNA, cDNA and oligonucleotides including sense and anti-sense nucleic acids. Such nucleic acids may also contain modifications in the ribose-phosphate backbone to increase stability and half life of such



molecules in physiological environments.

The nucleic acid may be double stranded, single stranded, or contain portions of both double stranded or single stranded sequence. As will be appreciated by those in the art, the depiction of a single strand ("Watson") also defines the sequence of the other strand ("Crick"); thus the sequences depicted in the Figures also include the complement of the sequence. By the term "recombinant nucleic acid" herein is meant nucleic acid, originally formed *in vitro*, in general, by the manipulation of nucleic acid by endonucleases, in a form not normally found in nature. Thus an isolated cell cycle nucleic acid, in a linear form, or an expression vector formed *in vitro* by ligating DNA molecules that are not normally joined, are both considered recombinant for the purposes of this invention. It is understood that once a recombinant nucleic acid is made and reintroduced into a host cell or organism, it will replicate non-recombinantly, i.e. using the *in vivo* cellular machinery of the host cell rather than *in vitro* manipulations; however, such nucleic acids, once produced recombinantly, although subsequently replicated non-recombinantly, are still considered recombinant for the purposes of the invention.

Similarly, a "recombinant protein" is a protein made using recombinant techniques, i.e. through the expression of a recombinant nucleic acid as depicted above. A recombinant protein is distinguished from naturally occurring protein by at least one or more characteristics. For example, the protein may be isolated or purified away from some or all of the proteins and compounds with which it is normally associated in its wild type host, and thus may be substantially pure. For example, an isolated protein is unaccompanied by at least some of the material with which it is normally associated in its natural state, preferably constituting at least about 0.5%, more preferably at least about 5% by weight of the total protein in a given sample. A substantially pure protein comprises at least about 75% by weight of the total protein, with at least about 80% being preferred, and at least about 90% being particularly preferred. The definition includes the production of a cell cycle protein from one organism in a different organism or host cell. Alternatively, the protein may be made at a significantly higher concentration than is normally seen, through the use of a inducible promoter or high expression promoter, such that the protein is made at increased concentration levels. Alternatively, the protein may be in a form not normally found in nature, as in the addition of an epitope tag or amino acid substitutions, insertions and deletions, as discussed below.

In one embodiment, the present invention provides cell cycle protein variants. These variants fall into one or more of three classes: substitutional, insertional or deletional variants. These variants ordinarily are prepared by site specific mutagenesis of nucleotides in the DNA encoding a cell cycle protein, using cassette or PCR mutagenesis or other techniques well known in the art, to produce DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture as outlined above. However, variant cell cycle protein fragments having up to about 100-150 residues

may be prepared by *in vitro* synthesis using established techniques. Amino acid sequence variants are characterized by the predetermined nature of the variation, a feature that sets them apart from naturally occurring allelic or interspecies variation of the cell cycle protein amino acid sequence. The variants typically exhibit the same qualitative biological activity as the naturally occurring analogue, although variants can also be selected which have modified characteristics as will be more fully outlined below.

While the site or region for introducing an amino acid sequence variation is predetermined, the mutation per se need not be predetermined. For example, in order to optimize the performance of a mutation at a given site, random mutagenesis may be conducted at the target codon or region and the expressed cell cycle variants screened for the optimal combination of desired activity. Techniques for making substitution mutations at predetermined sites in DNA having a known sequence are well known, for example, M13 primer mutagenesis and PCR mutagenesis. Screening of the mutants is done using assays of cell cycle protein activities.

Amino acid substitutions are typically of single residues; insertions usually will be on the order of from about 1 to 20 amino acids, although considerably larger insertions may be tolerated. Deletions range from about 1 to about 20 residues, although in some cases deletions may be much larger.

Substitutions, deletions, insertions or any combination thereof may be used to arrive at a final derivative. Generally these changes are done on a few amino acids to minimize the alteration of the molecule. However, larger changes may be tolerated in certain circumstances. When small alterations in the characteristics of the cell cycle protein are desired, substitutions are generally made in accordance with the following chart:

Chart I

	<u>Original Residue</u>	<u>Exemplary Substitutions</u>
25	Ala	Ser
	Arg	Lys
	Asn	Gln, His
	Asp	Glu
	Cys	Ser
30	Gln	Asn
	Glu	Asp
	Gly	Pro
	His	Asn, Gln
	Ile	Leu, Val
35	Leu	Ile, Val

	Lys	Arg, Gln, Glu
	Met	Leu, Ile
	Phe	Met, Leu, Tyr
	Ser	Thr
5	Thr	Ser
	Trp	Tyr
	Tyr	Trp, Phe
	Val	Ile, Leu

Substantial changes in function or immunological identity are made by selecting substitutions that are less conservative than those shown in Chart I. For example, substitutions may be made which more significantly affect the structure of the polypeptide backbone in the area of the alteration, for example the alpha-helical or beta-sheet structure; the charge or hydrophobicity of the molecule at the target site; or the bulk of the side chain. The substitutions which in general are expected to produce the greatest changes in the polypeptide's properties are those in which (a) a hydrophilic residue, e.g. seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g. leucyl, isoleucyl, phenylalanyl, valyl or alanyl; (b) a cysteine or proline is substituted for (or by) any other residue; (c) a residue having an electropositive side chain, e.g. lysyl, arginyl, or histidyl, is substituted for (or by) an electronegative residue, e.g. glutamyl or aspartyl; or (d) a residue having a bulky side chain, e.g. phenylalanine, is substituted for (or by) one not having a side chain, e.g. glycine.

The variants typically exhibit the same qualitative biological activity and will elicit the same immune response as the naturally-occurring analogue, although variants also are selected to modify the characteristics of the cell cycle proteins as needed. Alternatively, the variant may be designed such that the biological activity of the cell cycle protein is altered. For example, glycosylation sites may be altered or removed.

Covalent modifications of cell cycle polypeptides are included within the scope of this invention. One type of covalent modification includes reacting targeted amino acid residues of a cell cycle polypeptide with an organic derivatizing agent that is capable of reacting with selected side chains or the N- or C-terminal residues of a cell cycle polypeptide. Derivatization with bifunctional agents is useful, for instance, for crosslinking cell cycle to a water-insoluble support matrix or surface for use in the method for purifying anti-cell cycle antibodies or screening assays, as is more fully described below. Commonly used crosslinking agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane, glutaraldehyde, N-hydroxysuccinimide esters, for example, esters with 4-azido-salicylic acid, homobifunctional imidoesters, including disuccinimidyl esters such as 3,3'-dithiobis-(succinimidylpropionate), bifunctional maleimides such as bis-N-maleimido-1,8-octane and agents such as methyl-3-[(p-azidophenyl)dithio]propioimide.

Other modifications include deamidation of glutamyl and asparagyl residues to the corresponding glutamyl and aspartyl residues, respectively, hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the "-amino groups of lysine, arginine, and histidine side chains [T.E. Creighton, Proteins: Structure and Molecular Properties, W.H. Freeman & Co., San Francisco, pp. 79-86 (1983)], acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.

Another type of covalent modification of the cell cycle polypeptide included within the scope of this invention comprises altering the native glycosylation pattern of the polypeptide. "Altering the native glycosylation pattern" is intended for purposes herein to mean deleting one or more carbohydrate moieties found in native sequence cell cycle polypeptide, and/or adding one or more glycosylation sites that are not present in the native sequence cell cycle polypeptide.

Addition of glycosylation sites to cell cycle polypeptides may be accomplished by altering the amino acid sequence thereof. The alteration may be made, for example, by the addition of, or substitution by, one or more serine or threonine residues to the native sequence cell cycle polypeptide (for O-linked glycosylation sites). The cell cycle amino acid sequence may optionally be altered through changes at the DNA level, particularly by mutating the DNA encoding the cell cycle polypeptide at preselected bases such that codons are generated that will translate into the desired amino acids.

Another means of increasing the number of carbohydrate moieties on the cell cycle polypeptide is by chemical or enzymatic coupling of glycosides to the polypeptide. Such methods are described in the art, e.g., in WO 87/05330 published 11 September 1987, and in Aplin and Wriston, CRC Crit. Rev. Biochem., pp. 259-306 (1981).

Removal of carbohydrate moieties present on the cell cycle polypeptide may be accomplished chemically or enzymatically or by mutational substitution of codons encoding for amino acid residues that serve as targets for glycosylation. Chemical deglycosylation techniques are known in the art and described, for instance, by Hakimuddin, et al., Arch. Biochem. Biophys., 259:52 (1987) and by Edge, et al., Anal. Biochem., 118:131 (1981). Enzymatic cleavage of carbohydrate moieties on polypeptides can be achieved by the use of a variety of endo- and exo-glycosidases as described by Thotakura, et al., Meth. Enzymol., 138:350 (1987).

Another type of covalent modification of cell cycle comprises linking the cell cycle polypeptide to one of a variety of nonproteinaceous polymers, e.g., polyethylene glycol, polypropylene glycol, or polyoxyalkylenes, in the manner set forth in U.S. Patent Nos. 4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.

Cell cycle polypeptides of the present invention may also be modified in a way to form chimeric

molecules comprising a cell cycle polypeptide fused to another, heterologous polypeptide or amino acid sequence. In one embodiment, such a chimeric molecule comprises a fusion of a cell cycle polypeptide with a tag polypeptide which provides an epitope to which an anti-tag antibody can selectively bind. The epitope tag is generally placed at the amino- or carboxyl-terminus of the cell cycle polypeptide. The presence of such epitope-tagged forms of a cell cycle polypeptide can be detected using an antibody against the tag polypeptide. Also, provision of the epitope tag enables the cell cycle polypeptide to be readily purified by affinity purification using an anti-tag antibody or another type of affinity matrix that binds to the epitope tag. In an alternative embodiment, the chimeric molecule may comprise a fusion of a cell cycle polypeptide with an immunoglobulin or a particular region of an immunoglobulin. For a bivalent form of the chimeric molecule, such a fusion could be to the Fc region of an IgG molecule as discussed further below.

Various tag polypeptides and their respective antibodies are well known in the art. Examples include poly-histidine (poly-his) or poly-histidine-glycine (poly-his-gly) tags; the flu HA tag polypeptide and its antibody 12CA5 [Field, et al., Mol. Cell. Biol., 8:2159-2165 (1988)]; the c-myc tag and the 8F9, 3C7, 6E10, G4, B7 and 9E10 antibodies thereto [Evan, et al., Molecular and Cellular Biology, 5:3610-3616 (1985)]; and the Herpes Simplex virus glycoprotein D (gD) tag and its antibody [Paborsky, et al., Protein Engineering, 3(6):547-553 (1990)]. Other tag polypeptides include the Flag-peptide [Hopp, et al., BioTechnology, 6:1204-1210 (1988)]; the KT3 epitope peptide [Martin, et al., Science, 255:192-194 (1992)]; tubulin epitope peptide [Skinner, et al., J. Biol. Chem., 266:15163-15166 (1991)]; and the T7 gene 10 protein peptide tag [Lutz-Freyermuth, et al., Proc. Natl. Acad. Sci. USA, 87:6393-6397 (1990)].

In an embodiment herein, cell cycle proteins of the cell cycle family and cell cycle proteins from other organisms are cloned and expressed as outlined below. Thus, probe or degenerate polymerase chain reaction (PCR) primer sequences may be used to find other related cell cycle proteins from humans or other organisms. As will be appreciated by those in the art, particularly useful probe and/or PCR primer sequences include the unique areas of the cell cycle nucleic acid sequence. As is generally known in the art, preferred PCR primers are from about 15 to about 35 nucleotides in length, with from about 20 to about 30 being preferred, and may contain inosine as needed. The conditions for the PCR reaction are well known in the art. It is therefore also understood that provided along with the sequences in the sequences listed herein are portions of those sequences, wherein unique portions of 15 nucleotides or more are particularly preferred. The skilled artisan can routinely synthesize or cut a nucleotide sequence to the desired length.

Once isolated from its natural source, e.g., contained within a plasmid or other vector or excised therefrom as a linear nucleic acid segment, the recombinant cell cycle nucleic acid can be further used as a probe to identify and isolate other cell cycle nucleic acids. It can also be used as a "precursor" nucleic acid to make modified or variant cell cycle nucleic acids and proteins.

Using the nucleic acids of the present invention which encode a cell cycle protein, a variety of expression vectors are made. The expression vectors may be either self-replicating extrachromosomal vectors or vectors which integrate into a host genome. Generally, these expression vectors include transcriptional and translational regulatory nucleic acid operably linked to the nucleic acid encoding the cell cycle protein. The term "control sequences" refers to DNA sequences necessary for the expression of an operably linked coding sequence in a particular host organism. The control sequences that are suitable for prokaryotes, for example, include a promoter, optionally an operator sequence, and a ribosome binding site. Eukaryotic cells are known to utilize promoters, polyadenylation signals, and enhancers.

Nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid sequence. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. As another example, operably linked refers to DNA sequences linked so as to be contiguous, and, in the case of a secretory leader, contiguous and in reading phase. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, the synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice. The transcriptional and translational regulatory nucleic acid will generally be appropriate to the host cell used to express the cell cycle protein; for example, transcriptional and translational regulatory nucleic acid sequences from *Bacillus* are preferably used to express the cell cycle protein in *Bacillus*. Numerous types of appropriate expression vectors, and suitable regulatory sequences are known in the art for a variety of host cells.

In general, the transcriptional and translational regulatory sequences may include, but are not limited to, promoter sequences, ribosomal binding sites, transcriptional start and stop sequences, translational start and stop sequences, and enhancer or activator sequences. In a preferred embodiment, the regulatory sequences include a promoter and transcriptional start and stop sequences.

Promoter sequences encode either constitutive or inducible promoters. The promoters may be either naturally occurring promoters or hybrid promoters. Hybrid promoters, which combine elements of more than one promoter, are also known in the art, and are useful in the present invention.

In addition, the expression vector may comprise additional elements. For example, the expression vector may have two replication systems, thus allowing it to be maintained in two organisms, for

example in mammalian or insect cells for expression and in a procaryotic host for cloning and amplification. Furthermore, for integrating expression vectors, the expression vector contains at least one sequence homologous to the host cell genome, and preferably two homologous sequences which flank the expression construct. The integrating vector may be directed to a specific locus in the host cell by selecting the appropriate homologous sequence for inclusion in the vector. Constructs for integrating vectors are well known in the art.

In addition, in a preferred embodiment, the expression vector contains a selectable marker gene to allow the selection of transformed host cells. Selection genes are well known in the art and will vary with the host cell used.

10 A preferred expression vector system is a retroviral vector system such as is generally described in PCT/US97/01019 and PCT/US97/01048, both of which are hereby expressly incorporated by reference.

Cell cycle proteins of the present invention are produced by culturing a host cell transformed with an expression vector containing nucleic acid encoding a cell cycle protein, under the appropriate conditions to induce or cause expression of the cell cycle protein. The conditions appropriate for cell cycle protein expression will vary with the choice of the expression vector and the host cell, and will be easily ascertained by one skilled in the art through routine experimentation. For example, the use of constitutive promoters in the expression vector will require optimizing the growth and proliferation of the host cell, while the use of an inducible promoter requires the appropriate growth conditions for induction. In addition, in some embodiments, the timing of the harvest is important. For example, the baculoviral systems used in insect cell expression are lytic viruses, and thus harvest time selection can be crucial for product yield.

Appropriate host cells include yeast, bacteria, archbacteria, fungi, and insect and animal cells, including mammalian cells. Of particular interest are *Drosophila melanogaster* cells, *Saccharomyces cerevisiae* and other yeasts, *E. coli*, *Bacillus subtilis*, SF9 cells, C129 cells, 293 cells, Neurospora, BHK, CHO, COS, and HeLa cells, fibroblasts, Schwannoma cell lines, immortalized mammalian myeloid and lymphoid cell lines, tumor lines.

In a preferred embodiment, the cell cycle proteins are expressed in mammalian cells. Mammalian expression systems are also known in the art, and include retroviral systems. A mammalian promoter is any DNA sequence capable of binding mammalian RNA polymerase and initiating the downstream (3') transcription of a coding sequence for cell cycle protein into mRNA. A promoter will have a transcription initiating region, which is usually placed proximal to the 5' end of the coding sequence, and a TATA box, using a located 25-30 base pairs upstream of the transcription initiation site. The TATA box is thought to direct RNA polymerase II to begin RNA synthesis at the

correct site. A mammalian promoter will also contain an upstream promoter element (enhancer element), typically located within 100 to 200 base pairs upstream of the TATA box. An upstream promoter element determines the rate at which transcription is initiated and can act in either orientation. Of particular use as mammalian promoters are the promoters from mammalian viral genes, since the viral genes are often highly expressed and have a broad host range. Examples include the SV40 early promoter, mouse mammary tumor virus LTR promoter, adenovirus major late promoter, herpes simplex virus promoter, and the CMV promoter.

Typically, transcription termination and polyadenylation sequences recognized by mammalian cells are regulatory regions located 3' to the translation stop codon and thus, together with the promoter elements, flank the coding sequence. The 3' terminus of the mature mRNA is formed by site-specific post-translational cleavage and polyadenylation. Examples of transcription terminator and polyadenylation signals include those derived from SV40.

The methods of introducing exogenous nucleic acid into mammalian hosts, as well as other hosts, is well known in the art, and will vary with the host cell used. Techniques include dextran-mediated transfection, calcium phosphate precipitation, polybrene mediated transfection, protoplast fusion, electroporation, viral infection, encapsulation of the polynucleotide(s) in liposomes, and direct microinjection of the DNA into nuclei.

In a preferred embodiment, cell cycle proteins are expressed in bacterial systems. Bacterial expression systems are well known in the art.

A suitable bacterial promoter is any nucleic acid sequence capable of binding bacterial RNA polymerase and initiating the downstream (3') transcription of the coding sequence of cell cycle protein into mRNA. A bacterial promoter has a transcription initiation region which is usually placed proximal to the 5' end of the coding sequence. This transcription initiation region typically includes an RNA polymerase binding site and a transcription initiation site. Sequences encoding metabolic pathway enzymes provide particularly useful promoter sequences. Examples include promoter sequences derived from sugar metabolizing enzymes, such as galactose, lactose and maltose, and sequences derived from biosynthetic enzymes such as tryptophan. Promoters from bacteriophage may also be used and are known in the art. In addition, synthetic promoters and hybrid promoters are also useful; for example, the *tac* promoter is a hybrid of the *trp* and *lac* promoter sequences. Furthermore, a bacterial promoter can include naturally occurring promoters of non-bacterial origin that have the ability to bind bacterial RNA polymerase and initiate transcription.

In addition to a functioning promoter sequence, an efficient ribosome binding site is desirable. In *E. coli*, the ribosome binding site is called the Shine-Delgarno (SD) sequence and includes an initiation codon and a sequence 3-9 nucleotides in length located 3 - 11 nucleotides upstream of



the initiation codon.

The expression vector may also include a signal peptide sequence that provides for secretion of the cell cycle protein in bacteria. The signal sequence typically encodes a signal peptide comprised of hydrophobic amino acids which direct the secretion of the protein from the cell, as is well known in the art. The protein is either secreted into the growth media (gram-positive bacteria) or into the periplasmic space, located between the inner and outer membrane of the cell (gram-negative bacteria).

The bacterial expression vector may also include a selectable marker gene to allow for the selection of bacterial strains that have been transformed. Suitable selection genes include genes which render the bacteria resistant to drugs such as ampicillin, chloramphenicol, erythromycin, kanamycin, neomycin and tetracycline. Selectable markers also include biosynthetic genes, such as those in the histidine, tryptophan and leucine biosynthetic pathways.

These components are assembled into expression vectors. Expression vectors for bacteria are well known in the art, and include vectors for *Bacillus subtilis*, *E. coli*, *Streptococcus cremoris*, and *Streptococcus lividans*, among others.

The bacterial expression vectors are transformed into bacterial host cells using techniques well known in the art, such as calcium chloride treatment, electroporation, and others.

In one embodiment, cell cycle proteins are produced in insect cells. Expression vectors for the transformation of insect cells, and in particular, baculovirus-based expression vectors, are well known in the art.

In a preferred embodiment, cell cycle protein is produced in yeast cells. Yeast expression systems are well known in the art, and include expression vectors for *Saccharomyces cerevisiae*, *Candida albicans* and *C. maltosa*, *Hansenula polymorpha*, *Kluyveromyces fragilis* and *K. lactis*, *Pichia guilliermondii* and *P. pastoris*, *Schizosaccharomyces pombe*, and *Yarrowia lipolytica*. Preferred promoter sequences for expression in yeast include the inducible GAL1,10 promoter, the promoters from alcohol dehydrogenase, enolase, glucokinase, glucose-6-phosphate isomerase, glyceraldehyde-3-phosphate-dehydrogenase, hexokinase, phosphofructokinase, 3-phosphoglycerate mutase, pyruvate kinase, and the acid phosphatase gene. Yeast selectable markers include ADE2, HIS4, LEU2, TRP1, and ALG7, which confers resistance to tunicamycin; the neomycin phosphotransferase gene, which confers resistance to G418; and the CUP1 gene, which allows yeast to grow in the presence of copper ions.

The cell cycle protein may also be made as a fusion protein, using techniques well known in the

art. Thus, for example, for the creation of monoclonal antibodies, if the desired epitope is small, the cell cycle protein may be fused to a carrier protein to form an immunogen. Alternatively, the cell cycle protein may be made as a fusion protein to increase expression, or for other reasons. For example, when the cell cycle protein is a cell cycle peptide, the nucleic acid encoding the peptide may be linked to other nucleic acid for expression purposes. Similarly, cell cycle proteins of the invention can be linked to protein labels, such as green fluorescent protein (GFP), red fluorescent protein (RFP), blue fluorescent protein (BFP), yellow fluorescent protein (YFP), etc.

In one embodiment, the cell cycle nucleic acids, proteins and antibodies of the invention are labeled. By "labeled" herein is meant that a compound has at least one element, isotope or chemical compound attached to enable the detection of the compound. In general, labels fall into three classes: a) isotopic labels, which may be radioactive or heavy isotopes; b) immune labels, which may be antibodies or antigens; and c) colored or fluorescent dyes. The labels may be incorporated into the compound at any position.

In a preferred embodiment, the cell cycle protein is purified or isolated after expression. Cell cycle proteins may be isolated or purified in a variety of ways known to those skilled in the art depending on what other components are present in the sample. Standard purification methods include electrophoretic, molecular, immunological and chromatographic techniques, including ion exchange, hydrophobic, affinity, and reverse-phase HPLC chromatography, and chromatofocusing. For example, the cell cycle protein may be purified using a standard anti-cell cycle antibody column. Ultrafiltration and diafiltration techniques, in conjunction with protein concentration, are also useful. For general guidance in suitable purification techniques, see Scopes, R., Protein Purification, Springer-Verlag, NY (1982). The degree of purification necessary will vary depending on the use of the cell cycle protein. In some instances no purification will be necessary.

Once expressed and purified if necessary, the cell cycle proteins and nucleic acids are useful in a number of applications.

The nucleotide sequences (or their complement) encoding cell cycle proteins have various applications in the art of molecular biology, including uses as hybridization probes, in chromosome and gene mapping and in the generation of anti-sense RNA and DNA. Cell cycle protein nucleic acid will also be useful for the preparation of cell cycle proteins by the recombinant techniques described herein.

The full-length native sequence cell cycle protein gene, or portions thereof, may be used as hybridization probes for a cDNA library to isolate other genes (for instance, those encoding naturally-occurring variants of cell cycle protein or cell cycle protein from other species) which have a desired sequence identity to the cell cycle protein coding sequence. Optionally, the length of the

probes will be about 20 to about 50 bases. The hybridization probes may be derived from the nucleotide sequences herein or from genomic sequences including promoters, enhancer elements and introns of native sequences as provided herein. By way of example, a screening method will comprise isolating the coding region of the cell cycle protein gene using the known DNA sequence to synthesize a selected probe of about 40 bases. Hybridization probes may be labeled by a variety of labels, including radionucleotides such as <sup>32</sup>P or <sup>35</sup>S, or enzymatic labels such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems. Labeled probes having a sequence complementary to that of the cell cycle protein gene of the present invention can be used to screen libraries of human cDNA, genomic DNA or mRNA to determine which members of such libraries the probe hybridizes.

Nucleotide sequences encoding a cell cycle protein can also be used to construct hybridization probes for mapping the gene which encodes that cell cycle protein and for the genetic analysis of individuals with genetic disorders. The nucleotide sequences provided herein may be mapped to a chromosome and specific regions of a chromosome using known techniques, such as *in situ* hybridization, linkage analysis against known chromosomal markers, and hybridization screening with libraries.

Nucleic acids which encode cell cycle protein or its modified forms can also be used to generate either transgenic animals or "knock out" animals which, in turn, are useful in the development and screening of therapeutically useful reagents. A transgenic animal (e.g., a mouse or rat) is an animal having cells that contain a transgene, which transgene was introduced into the animal or an ancestor of the animal at a prenatal, e.g., an embryonic stage. A transgene is a DNA which is integrated into the genome of a cell from which a transgenic animal develops. In one embodiment, cDNA encoding a cell cycle protein can be used to clone genomic DNA encoding a cell cycle protein in accordance with established techniques and the genomic sequences used to generate transgenic animals that contain cells which express the desired DNA. Methods for generating transgenic animals, particularly animals such as mice or rats, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009. Typically, particular cells would be targeted for the cell cycle protein transgene incorporation with tissue-specific enhancers. Transgenic animals that include a copy of a transgene encoding a cell cycle protein introduced into the germ line of the animal at an embryonic stage can be used to examine the effect of increased expression of the desired nucleic acid. Such animals can be used as tester animals for reagents thought to confer protection from, for example, pathological conditions associated with its overexpression. In accordance with this facet of the invention, an animal is treated with the reagent and a reduced incidence of the pathological condition, compared to untreated animals bearing the transgene, would indicate a potential therapeutic intervention for the pathological condition.

Alternatively, non-human homologues of the cell cycle protein can be used to construct a cell cycle protein "knock out" animal which has a defective or altered gene encoding a cell cycle protein as a result of homologous recombination between the endogenous gene encoding a cell cycle protein and altered genomic DNA encoding a cell cycle protein introduced into an embryonic cell of the animal. For example, cDNA encoding a cell cycle protein can be used to clone genomic DNA encoding a cell cycle protein in accordance with established techniques. A portion of the genomic DNA encoding a cell cycle protein can be deleted or replaced with another gene, such as a gene encoding a selectable marker which can be used to monitor integration. Typically, several kilobases of unaltered flanking DNA (both at the 5' and 3' ends) are included in the vector [see e.g., Thomas, et al., *Cell*, 51:503 (1987) for a description of homologous recombination vectors]. The vector is introduced into an embryonic stem cell line (e.g., by electroporation) and cells in which the introduced DNA has homologously recombined with the endogenous DNA are selected [see e.g., Li, et al., *Cell*, 69:915 (1992)]. The selected cells are then injected into a blastocyst of an animal (e.g., a mouse or rat) to form aggregation chimeras [see e.g., Bradley, in Teratocarcinomas and Embryonic Stem Cells: A Practical Approach, E. J. Robertson, ed. (IRL, Oxford, 1987), pp. 113-152]. A chimeric embryo can then be implanted into a suitable pseudopregnant female foster animal and the embryo brought to term to create a "knock out" animal. Progeny harboring the homologously recombined DNA in their germ cells can be identified by standard techniques and used to breed animals in which all cells of the animal contain the homologously recombined DNA. Knockout animals can be characterized for instance, for their ability to defend against certain pathological conditions and for their development of pathological conditions due to absence of the cell cycle protein.

It is understood that the models described herein can be varied. For example, "knock-in" models can be formed, or the models can be cell-based rather than animal models.

Nucleic acid encoding the cell cycle polypeptides, antagonists or agonists may also be used in gene therapy. In gene therapy applications, genes are introduced into cells in order to achieve *in vivo* synthesis of a therapeutically effective genetic product, for example for replacement of a defective gene. "Gene therapy" includes both conventional gene therapy where a lasting effect is achieved by a single treatment, and the administration of gene therapeutic agents, which involves the one time or repeated administration of a therapeutically effective DNA or mRNA. Antisense RNAs and DNAs can be used as therapeutic agents for blocking the expression of certain genes *in vivo*. It has already been shown that short antisense oligonucleotides can be imported into cells where they act as inhibitors, despite their low intracellular concentrations caused by their restricted uptake by the cell membrane. (Zamecnik, et al., Proc. Natl. Acad. Sci. USA, 83:4143-4146 [1986]). The oligonucleotides can be modified to enhance their uptake, e.g. by substituting their negatively charged phosphodiester groups by uncharged groups.

There are a variety of techniques available for introducing nucleic acids into viable cells. The techniques vary depending upon whether the nucleic acid is transferred into cultured cells *in vitro*, or *in vivo* in the cells of the intended host. Techniques suitable for the transfer of nucleic acid into mammalian cells *in vitro* include the use of liposomes, electroporation, microinjection, cell fusion, DEAE-dextran, the calcium phosphate precipitation method, etc. The currently preferred *in vivo* gene transfer techniques include transfection with viral (typically retroviral) vectors and viral coat protein-liposome mediated transfection (Dzau, et al., Trends in Biotechnology, 11:205-210 [1993]). In some situations it is desirable to provide the nucleic acid source with an agent that targets the target cells, such as an antibody specific for a cell surface membrane protein or the target cell, a ligand for a receptor on the target cell, etc. Where liposomes are employed, proteins which bind to a cell surface membrane protein associated with endocytosis may be used for targeting and/or to facilitate uptake, e.g. capsid proteins or fragments thereof tropic for a particular cell type, antibodies for proteins which undergo internalization in cycling, proteins that target intracellular localization and enhance intracellular half-life. The technique of receptor-mediated endocytosis is described, for example, by Wu, et al., J. Biol. Chem., 262:4429-4432 (1987); and Wagner, et al., Proc. Natl. Acad. Sci. USA, 87:3410-3414 (1990). For review of gene marking and gene therapy protocols see Anderson, et al., Science 256:808-813 (1992).

In a preferred embodiment, the cell cycle proteins, nucleic acids, variants, modified proteins, cells and/or transgenics containing the said nucleic acids or proteins are used in screening assays. Identification of the cell cycle protein provided herein permits the design of drug screening assays for compounds that bind or interfere with the binding to the cell cycle protein and for compounds which modulate cell cycle activity.

The assays described herein preferably utilize the human cell cycle protein, although other mammalian proteins may also be used, including rodents (mice, rats, hamsters, guinea pigs, etc.), farm animals (cows, sheep, pigs, horses, etc.) and primates. These latter embodiments may be preferred in the development of animal models of human disease. In some embodiments, as outlined herein, variant or derivative cell cycle proteins may be used, including deletion cell cycle proteins as outlined above.

In a preferred embodiment, the methods comprise combining a cell cycle protein and a candidate bioactive agent, and determining the binding of the candidate agent to the cell cycle protein. In other embodiments, further discussed below, binding interference or bioactivity is determined.

The term "candidate bioactive agent" or "exogenous compound" as used herein describes any molecule, e.g., protein, small organic molecule, carbohydrates (including polysaccharides), polynucleotide, lipids, etc. Generally a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one

of these concentrations serves as a negative control, *i.e.*, at zero concentration or below the level of detection. In addition, positive controls, *i.e.* the use of agents known to alter cell cycling, may be used. For example, p21 is a molecule known to arrest cells in the G1 cell phase, by binding G1 cyclin-CDK complexes.

- 5 Candidate agents encompass numerous chemical classes, though typically they are organic molecules, preferably small organic compounds having a molecular weight of more than 100 and less than about 2,500 daltons. Candidate agents comprise functional groups necessary for structural interaction with proteins, particularly hydrogen bonding, and typically include at least an amine, carbonyl, hydroxyl or carboxyl group, preferably at least two of the functional chemical
- 10 groups. The candidate agents often comprise cyclical carbon or heterocyclic structures and/or aromatic or polyaromatic structures substituted with one or more of the above functional groups. Candidate agents are also found among biomolecules including peptides, saccharides, fatty acids, steroids, purines, pyrimidines, derivatives, structural analogs or combinations thereof. Particularly preferred are peptides.
- 15 Candidate agents are obtained from a wide variety of sources including libraries of synthetic or natural compounds. For example, numerous means are available for random and directed synthesis of a wide variety of organic compounds and biomolecules, including expression of randomized oligonucleotides. Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant and animal extracts are available or readily produced. Additionally, natural or
- 20 synthetically produced libraries and compounds are readily modified through conventional chemical, physical and biochemical means. Known pharmacological agents may be subjected to directed or random chemical modifications, such as acylation, alkylation, esterification, amidification to produce structural analogs.
- 25 In a preferred embodiment, a library of different candidate bioactive agents are used. Preferably, the library should provide a sufficiently structurally diverse population of randomized agents to effect a probabilistically sufficient range of diversity to allow binding to a particular target. Accordingly, an interaction library should be large enough so that at least one of its members will have a structure that gives it affinity for the target. Although it is difficult to gauge the required absolute size of an interaction library, nature provides a hint with the immune response: a diversity
- 30 of  $10^7$ - $10^8$  different antibodies provides at least one combination with sufficient affinity to interact with most potential antigens faced by an organism. Published *in vitro* selection techniques have also shown that a library size of  $10^7$  to  $10^8$  is sufficient to find structures with affinity for the target. A library of all combinations of a peptide 7 to 20 amino acids in length, such as generally proposed herein, has the potential to code for  $20^7$  ( $10^9$ ) to  $20^{20}$ . Thus, with libraries of  $10^7$  to  $10^8$  different
- 35 molecules the present methods allow a "working" subset of a theoretically complete interaction library for 7 amino acids, and a subset of shapes for the  $20^{20}$  library. Thus, in a preferred

embodiment, at least  $10^6$ , preferably at least  $10^7$ , more preferably at least  $10^8$  and most preferably at least  $10^9$  different sequences are simultaneously analyzed in the subject methods. Preferred methods maximize library size and diversity.

In a preferred embodiment, the candidate bioactive agents are proteins. By "protein" herein is meant at least two covalently attached amino acids, which includes proteins, polypeptides, oligopeptides and peptides. The protein may be made up of naturally occurring amino acids and peptide bonds, or synthetic peptidomimetic structures. Thus "amino acid", or "peptide residue", as used herein means both naturally occurring and synthetic amino acids. For example, homo-phenylalanine, citrulline and noreleucine are considered amino acids for the purposes of the invention. "Amino acid" also includes imino acid residues such as proline and hydroxyproline. The side chains may be in either the (R) or the (S) configuration. In the preferred embodiment, the amino acids are in the (S) or L-configuration. If non-naturally occurring side chains are used, non-amino acid substituents may be used, for example to prevent or retard *in vivo* degradations. Chemical blocking groups or other chemical substituents may also be added.

In a preferred embodiment, the candidate bioactive agents are naturally occurring proteins or fragments of naturally occurring proteins. Thus, for example, cellular extracts containing proteins, or random or directed digests of proteinaceous cellular extracts, may be used. In this way libraries of procaryotic and eukaryotic proteins may be made for screening in the systems described herein. Particularly preferred in this embodiment are libraries of bacterial, fungal, viral, and mammalian proteins, with the latter being preferred, and human proteins being especially preferred.

In a preferred embodiment, the candidate bioactive agents are peptides of from about 5 to about 30 amino acids, with from about 5 to about 20 amino acids being preferred, and from about 7 to about 15 being particularly preferred. The peptides may be digests of naturally occurring proteins as is outlined above, random peptides, or "biased" random peptides. By "randomized" or grammatical equivalents herein is meant that each nucleic acid and peptide consists of essentially random nucleotides and amino acids, respectively. Since generally these random peptides (or nucleic acids, discussed below) are chemically synthesized, they may incorporate any nucleotide or amino acid at any position. The synthetic process can be designed to generate randomized proteins or nucleic acids, to allow the formation of all or most of the possible combinations over the length of the sequence, thus forming a library of randomized candidate bioactive proteinaceous agents.

In one embodiment, the library is fully randomized, with no sequence preferences or constants at any position. In a preferred embodiment, the library is biased. That is, some positions within the sequence are either held constant, or are selected from a limited number of possibilities. For example, in a preferred embodiment, the nucleotides or amino acid residues are randomized within a defined class, for example, of hydrophobic amino acids, hydrophilic residues, sterically biased

(either small or large) residues, towards the creation of cysteines, for cross-linking, prolines for SH-3 domains, serines, threonines, tyrosines or histidines for phosphorylation sites, etc., or to purines, etc.

In a preferred embodiment, the candidate bioactive agents are nucleic acids. By "nucleic acid" or "oligonucleotide" or grammatical equivalents herein means at least two nucleotides covalently linked together. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, as outlined below, nucleic acid analogs are included that may have alternate backbones, comprising, for example, phosphoramidate (Beaucage, et al., Tetrahedron, **49**(10):1925 (1993) and references therein; Letsinger, J. Org. Chem., **35**:3800 (1970); Sprinzl, et al., Eur. J. Biochem., **81**:579 (1977); Letsinger, et al., Nucl. Acids Res., **14**:3487 (1986); Sawai, et al., Chem. Lett., **805** (1984), Letsinger, et al., J. Am. Chem. Soc., **110**:4470 (1988); and Pauwels, et al., Chimica Scripta, **28**:141 (1986)), phosphorothioate (Mag, et al., Nucleic Acids Res., **19**:1437 (1991); and U.S. Patent No. 5,644,048), phosphorodithioate (Briu, et al., J. Am. Chem. Soc., **111**:2321 (1989)), O-methylphosphoramidate linkages (see Eckstein, Oligonucleotides and Analogues: A Practical Approach, Oxford University Press), and peptide nucleic acid backbones and linkages (see Egholm, J. Am. Chem. Soc., **114**:1895 (1992); Meier, et al., Chem. Int. Ed. Engl., **31**:1008 (1992); Nielsen, Nature, **365**:566 (1993); Carlsson, et al., Nature, **380**:207 (1996), all of which are incorporated by reference)). Other analog nucleic acids include those with positive backbones (Denpcy, et al., Proc. Natl. Acad. Sci. USA, **92**:6097 (1995)); non-ionic backbones (U.S. Patent Nos. 5,386,023; 5,637,684; 5,602,240; 5,216,141; and 4,469,863; Kiedrowski, et al., Angew. Chem. Intl. Ed. English, **30**:423 (1991); Letsinger, et al., J. Am. Chem. Soc., **110**:4470 (1988); Letsinger, et al., Nucleoside & Nucleotide, **13**:1597 (1994); Chapters 2 and 3, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook; Mesmaeker, et al., Bioorganic & Medicinal Chem. Lett., **4**:395 (1994); Jeffs, et al., J. Biomolecular NMR, **34**:17 (1994); Tetrahedron Lett., **37**:743 (1996)) and non-ribose backbones, including those described in U.S. Patent Nos. 5,235,033 and 5,034,506, and Chapters 6 and 7, ASC Symposium Series 580, "Carbohydrate Modifications in Antisense Research", Ed. Y.S. Sanghui and P. Dan Cook. Nucleic acids containing one or more carbocyclic sugars are also included within the definition of nucleic acids (see Jenkins, et al., Chem. Soc. Rev., pp. 169-176 (1995)). Several nucleic acid analogs are described in Rawls, C & E News, June 2, 1997, page 35. All of these references are hereby expressly incorporated by reference. These modifications of the ribose-phosphate backbone may be done to facilitate the addition of additional moieties such as labels, or to increase the stability and half-life of such molecules in physiological environments. In addition, mixtures of naturally occurring nucleic acids and analogs can be made. Alternatively, mixtures of different nucleic acid analogs, and mixtures of naturally occurring nucleic acids and analogs may be made. The nucleic acids may be single stranded or double stranded, as specified, or contain portions of both double stranded or single stranded sequence. The nucleic acid may be DNA, both genomic and cDNA, RNA or a hybrid, where the nucleic acid contains any combination



of deoxyribo- and ribo-nucleotides, and any combination of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, isoguanine, etc.

As described above generally for proteins, nucleic acid candidate bioactive agents may be naturally occurring nucleic acids, random nucleic acids, or "biased" random nucleic acids. For example, digests of procaryotic or eukaryotic genomes may be used as is outlined above for proteins.

In a preferred embodiment, the candidate bioactive agents are organic chemical moieties, a wide variety of which are available in the literature.

In a preferred embodiment, the candidate bioactive agents are linked to a fusion partner. By "fusion partner" or "functional group" herein is meant a sequence that is associated with the candidate bioactive agent, that confers upon all members of the library in that class a common function or ability. Fusion partners can be heterologous (i.e. not native to the host cell), or synthetic (not native to any cell). Suitable fusion partners include, but are not limited to: a) presentation structures, which provide the candidate bioactive agents in a conformationally restricted or stable form; b) targeting sequences, which allow the localization of the candidate bioactive agent into a subcellular or extracellular compartment; c) rescue sequences which allow the purification or isolation of either the candidate bioactive agents or the nucleic acids encoding them; d) stability sequences, which confer stability or protection from degradation to the candidate bioactive agent or the nucleic acid encoding it, for example resistance to proteolytic degradation; e) dimerization sequences, to allow for peptide dimerization; or f) any combination of a), b), c), d), and e), as well as linker sequences as needed.

In one embodiment of the methods described herein, portions of cell cycle proteins are utilized; in a preferred embodiment, portions having cell cycle activity are used. Cell cycle activity is described further below and includes binding activity to Traf or Nck or cell cycle protein modulators as further described below. In addition, the assays described herein may utilize either isolated cell cycle proteins or cells comprising the cell cycle proteins.

Generally, in a preferred embodiment of the methods herein, for example for binding assays, the cell cycle protein or the candidate agent is non-diffusibly bound to an insoluble support having isolated sample receiving areas (e.g. a microtiter plate, an array, etc.). The insoluble supports may be made of any composition to which the compositions can be bound, is readily separated from soluble material, and is otherwise compatible with the overall method of screening. The surface of such supports may be solid or porous and of any convenient shape. Examples of suitable insoluble supports include microtiter plates, arrays, membranes and beads. These are typically made of glass, plastic (e.g., polystyrene), polysaccharides, nylon or nitrocellulose, teflon™, etc. Microtiter plates and arrays are especially convenient because a large number of

assays can be carried out simultaneously, using small amounts of reagents and samples. In some cases magnetic beads and the like are included. The particular manner of binding of the composition is not crucial so long as it is compatible with the reagents and overall methods of the invention, maintains the activity of the composition and is nondiffusable. Preferred methods of binding include the use of antibodies (which do not sterically block either the ligand binding site or activation sequence when the protein is bound to the support), direct binding to "sticky" or ionic supports, chemical crosslinking, the synthesis of the protein or agent on the surface, etc. In some embodiments, Traf2 or Nck can be used. Following binding of the protein or agent, excess unbound material is removed by washing. The sample receiving areas may then be blocked through incubation with bovine serum albumin (BSA), casein or other innocuous protein or other moiety. Also included in this invention are screening assays wherein solid supports are not used; examples of such are described below.

In a preferred embodiment, the cell cycle protein is bound to the support, and a candidate bioactive agent is added to the assay. Alternatively, the candidate agent is bound to the support and the cell cycle protein is added. Novel binding agents include specific antibodies, non-natural binding agents identified in screens of chemical libraries, peptide analogs, etc. Of particular interest are screening assays for agents that have a low toxicity for human cells. A wide variety of assays may be used for this purpose, including labeled in vitro protein-protein binding assays, electrophoretic mobility shift assays, immunoassays for protein binding, functional assays (phosphorylation assays, etc.) and the like.

The determination of the binding of the candidate bioactive agent to the cell cycle protein may be done in a number of ways. In a preferred embodiment, the candidate bioactive agent is labelled, and binding determined directly. For example, this may be done by attaching all or a portion of the cell cycle protein to a solid support, adding a labelled candidate agent (for example a fluorescent label), washing off excess reagent, and determining whether the label is present on the solid support. Various blocking and washing steps may be utilized as is known in the art.

By "labeled" herein is meant that the compound is either directly or indirectly labeled with a label which provides a detectable signal, e.g. radioisotope, fluorescers, enzyme, antibodies, particles such as magnetic particles, chemiluminescers, or specific binding molecules, etc. Specific binding molecules include pairs, such as biotin and streptavidin, digoxin and antidigoxin etc. For the specific binding members, the complementary member would normally be labeled with a molecule which provides for detection, in accordance with known procedures, as outlined above. The label can directly or indirectly provide a detectable signal.

In some embodiments, only one of the components is labeled. For example, the proteins (or proteinaceous candidate agents) may be labeled at tyrosine positions using  $^{125}\text{I}$ , or with

fluorophores. Alternatively, more than one component may be labeled with different labels; using <sup>125</sup>I for the proteins, for example, and a fluorophor for the candidate agents.

In a preferred embodiment, the binding of the candidate bioactive agent is determined through the use of competitive binding assays. In this embodiment, the competitor is a binding moiety known to bind to the target molecule (i.e. cell cycle protein), such as an antibody, peptide, binding partner, ligand, etc. In a preferred embodiment, the competitor is Traf, preferably Traf2, or Nck. Under certain circumstances, there may be competitive binding as between the bioactive agent and the binding moiety, with the binding moiety displacing the bioactive agent. This assay can be used to determine candidate agents which interfere with binding between cell cycle proteins and Traf2 or Nck. "Interference of binding" as used herein means that native binding of the cell cycle protein differs in the presence of the candidate agent. The binding can be eliminated or can be with a reduced affinity. Therefore, in one embodiment, interference is caused by, for example, a conformation change, rather than direct competition for the native binding site.

In one embodiment, the candidate bioactive agent is labeled. Either the candidate bioactive agent, or the competitor, or both, is added first to the protein for a time sufficient to allow binding, if present. Incubations may be performed at any temperature which facilitates optimal activity, typically between 4 and 40°C. Incubation periods are selected for optimum activity, but may also be optimized to facilitate rapid high throughput screening. Typically between 0.1 and 1 hour will be sufficient. Excess reagent is generally removed or washed away. The second component is then added, and the presence or absence of the labeled component is followed, to indicate binding.

In a preferred embodiment, the competitor is added first, followed by the candidate bioactive agent. Displacement of the competitor is an indication that the candidate bioactive agent is binding to the cell cycle protein and thus is capable of binding to, and potentially modulating, the activity of the cell cycle protein. In this embodiment, either component can be labeled. Thus, for example, if the competitor is labeled, the presence of label in the wash solution indicates displacement by the agent. Alternatively, if the candidate bioactive agent is labeled, the presence of the label on the support indicates displacement.

In an alternative embodiment, the candidate bioactive agent is added first, with incubation and washing, followed by the competitor. The absence of binding by the competitor may indicate that the bioactive agent is bound to the cell cycle protein with a higher affinity. Thus, if the candidate bioactive agent is labeled, the presence of the label on the support, coupled with a lack of competitor binding, may indicate that the candidate agent is capable of binding to the cell cycle protein.

In a preferred embodiment, the methods comprise differential screening to identify bioactive agents

that are capable of modulating the activity of the cell cycle proteins. Such assays can be done with the cell cycle protein or cells comprising said cell cycle protein. In one embodiment, the methods comprise combining an cell cycle protein and a competitor in a first sample. A second sample comprises a candidate bioactive agent, an cell cycle protein and a competitor. The binding of the competitor is determined for both samples, and a change, or difference in binding between the two samples indicates the presence of an agent capable of binding to the cell cycle protein and potentially modulating its activity. That is, if the binding of the competitor is different in the second sample relative to the first sample, the agent is capable of binding to the cell cycle protein.

Alternatively, a preferred embodiment utilizes differential screening to identify drug candidates that bind to the native cell cycle protein, but cannot bind to modified cell cycle proteins. The structure of the cell cycle protein may be modeled, and used in rational drug design to synthesize agents that interact with that site. Drug candidates that affect cell cycle bioactivity are also identified by screening drugs for the ability to either enhance or reduce the activity of the protein.

Positive controls and negative controls may be used in the assays. Preferably all control and test samples are performed in at least triplicate to obtain statistically significant results. Incubation of all samples is for a time sufficient for the binding of the agent to the protein. Following incubation, all samples are washed free of non-specifically bound material and the amount of bound, generally labeled agent determined. For example, where a radiolabel is employed, the samples may be counted in a scintillation counter to determine the amount of bound compound.

A variety of other reagents may be included in the screening assays. These include reagents like salts, neutral proteins, e.g. albumin, detergents, etc which may be used to facilitate optimal protein-protein binding and/or reduce non-specific or background interactions. Also reagents that otherwise improve the efficiency of the assay, such as protease inhibitors, nuclease inhibitors, anti-microbial agents, etc., may be used. The mixture of components may be added in any order that provides for the requisite binding.

Screening for agents that modulate the activity of cell cycle may also be done. In a preferred embodiment, methods for screening for a bioactive agent capable of modulating the activity of cell cycle comprise the steps of adding a candidate bioactive agent to a sample of a cell cycle protein (or cells comprising a cell cycle protein) and determining an alteration in the biological activity of the cell cycle protein. "Modulating the activity of a cell cycle protein" includes an increase in activity, a decrease in activity, or a change in the type or kind of activity present. Thus, in this embodiment, the candidate agent should both bind to cell cycle (although this may not be necessary), and alter its biological or biochemical activity as defined herein. The methods include both in vitro screening methods, as are generally outlined above, and in vivo screening of cells for alterations in the presence, distribution, activity or amount of cell cycle protein.

Thus, in this embodiment, the methods comprise combining an cell cycle sample and a candidate bioactive agent, and evaluating the effect on the cell cycle. By "cell cycle activity" or "cell cycle protein activity" or grammatical equivalents herein is meant at least one of the cell cycle protein's biological activities, including, but not limited to, its ability to affect the cell cycle, bind to Traf2, bind to Nck, activate the JNK pathway, disrupt F-actin upon overexpression, inhibit cell spreading upon overexpression, phosphorylate targets, phosphorylate Gelsolin, and regulate of the cytoskeleton. In some embodiments, fragments of the cell cycle protein are preferred, particularly fragments having one or more cell cycle protein activities.

In a preferred embodiment, the activity of the cell cycle protein is decreased; in another preferred embodiment, the activity of the cell cycle protein is increased. Thus, bioactive agents that are antagonists are preferred in some embodiments, and bioactive agents that are agonists may be preferred in other embodiments. As used herein, increased or overexpressed means an increase of at least 10%, more preferably 25-50%, more preferably 50%-75%, and more preferably at least a 100% to 500% increase over the native state. As used herein, decreased or underexpressed means a decrease of at least 10%, more preferably 25-50%, more preferably 50%-75%, and more preferably at least a 100% to 500% decrease over the native state, i.e., compared to without administration of the cell cycle proteins, nucleic acids or candidate agents as described herein.

In a preferred embodiment, the invention provides methods for screening for bioactive agents capable of modulating the activity of an cell cycle protein. The methods comprise adding a candidate bioactive agent, as defined above, to a cell comprising cell cycle proteins. Preferred cell types include almost any cell. The cells contain a recombinant nucleic acid that encodes an cell cycle protein. In a preferred embodiment, a library of candidate agents are tested on a plurality of cells.

Detection of cell cycle regulation may be done as will be appreciated by those in the art. In one embodiment, indicators of the cell cycle are used. There are a number of parameters that may be evaluated or assayed to allow the detection of alterations in cell cycle regulation, including, but not limited to, cell viability assays, assays to determine whether cells are arrested at a particular cell cycle stage ("cell proliferation assays"), and assays to determine at which cell stage the cells have arrested ("cell phase assays"). By assaying or measuring one or more of these parameters, it is possible to detect not only alterations in cell cycle regulation, but alterations of different steps of the cell cycle regulation pathway. This may be done to evaluate native cells, for example to quantify the aggressiveness of a tumor cell type, or to evaluate the effect of candidate drug agents that are being tested for their effect on cell cycle regulation. In this manner, rapid, accurate screening of candidate agents may be performed to identify agents that modulate cell cycle regulation.

Thus, the present compositions and methods are useful to elucidate bioactive agents that can cause a cell or a population of cells to either move out of one growth phase and into another, or arrest in a growth phase. In some embodiments, the cells are arrested in a particular growth phase, and it is desirable to either get them out of that phase or into a new phase. Alternatively, it may be desirable to force a cell to arrest in a phase, for example G1, rather than continue to move through the cell cycle. Similarly, it may be desirable in some circumstances to accelerate a non-arrested but slowly moving population of cells into either the next phase or just through the cell cycle, or to delay the onset of the next phase. For example, it may be possible to alter the activities of certain enzymes, for example kinases, phosphatases, proteases or ubiquitination enzymes, that contribute to initiating cell phase changes.

In a preferred embodiment, the methods outlined herein are done on cells that are not arrested in the G1 phase; that is, they are rapidly or uncontrollably growing and replicating, such as tumor cells. In this manner, candidate agents are evaluated to find agents that can alter the cell cycle regulation, i.e. cause the cells to arrest at cell cycle checkpoints, such as in G1 (although arresting in other phases such as S, G2 or M are also desirable). Alternatively, candidate agents are evaluated to find agents that can cause proliferation of a population of cells, i.e. that allow cells that are generally arrested in G1 to start proliferating again; for example, peripheral blood cells, terminally differentiated cells, stem cells in culture, etc.

Accordingly, the invention provides methods for screening for alterations in cell cycle regulation of a population of cells. By "alteration" or "modulation" (used herein interchangeably), is generally meant one of two things. In a preferred embodiment, the alteration results in a change in the cell cycle of a cell, i.e. a proliferating cell arrests in any one of the phases, or an arrested cell moves out of its arrested phase and starts the cell cycle, as compared to another cell or in the same cell under different conditions. Alternatively, the progress of a cell through any particular phase may be altered; that is, there may be an acceleration or delay in the length of time it takes for the cells to move thorough a particular growth phase. For example, the cell may be normally undergo a G1 phase of several hours; the addition of an agent may prolong the G1 phase.

The measurements can be determined wherein all of the conditions are the same for each measurement, or under various conditions, with or without bioactive agents, or at different stages of the cell cycle process. For example, a measurement of cell cycle regulation can be determined in a cell or cell population wherein a candidate bioactive agent is present and wherein the candidate bioactive agent is absent. In another example, the measurements of cell cycle regulation are determined wherein the condition or environment of the cell or populations of cells differ from one another. For example, the cells may be evaluated in the presence or absence or previous or subsequent exposure of physiological signals, for example hormones, antibodies, peptides, antigens, cytokines, growth factors, action potentials, pharmacological agents including

chemotherapeutics, radiation, carcinogenics, or other cells (i.e. cell-cell contacts). In another example, the measurements of cell cycle regulation are determined at different stages of the cell cycle process. In yet another example, the measurements of cell cycle regulation are taken wherein the conditions are the same, and the alterations are between one cell or cell population and another cell or cell population.

By a "population of cells" or "library of cells" herein is meant at least two cells, with at least about  $10^3$  being preferred, at least about  $10^5$  being particularly preferred, and at least about  $10^8$  to  $10^9$  being especially preferred. The population or sample can contain a mixture of different cell types from either primary or secondary cultures although samples containing only a single cell type are preferred, for example, the sample can be from a cell line, particularly tumor cell lines, as outlined below. The cells may be in any cell phase, either synchronously or not, including M, G1, S, and G2. In a preferred embodiment, cells that are replicating or proliferating are used; this may allow the use of retroviral vectors for the introduction of candidate bioactive agents. Alternatively, non-replicating cells may be used, and other vectors (such as adenovirus and lentivirus vectors) can be used. In addition, although not required, the cells are compatible with dyes and antibodies.

Preferred cell types for use in the invention include, but are not limited to, mammalian cells, including animal (rodents, including mice, rats, hamsters and gerbils), primates, and human cells, particularly including tumor cells of all types, including breast, skin, lung, cervix, colonrectal, leukemia, brain, etc.

In a preferred embodiment, the methods comprise assaying one or more of several different cell parameters, including, but not limited to, cell viability, cell proliferation, and cell phase. Other parameters which can be assayed, singularly or jointly include Traf2 activity modulation, Nck activity modulation, JNK pathway activity, F-actin disruption, cell spreading, phosphorylation of Gelsolin, and cytoskeleton activity, particularly including mitosis and cytokinesis.

In a preferred embodiment, cell viability is assayed, to ensure that a lack of cellular change is due to experimental conditions (i.e. the introduction of a candidate bioactive agent) not cell death. There are a variety of suitable cell viability assays which can be used, including, but not limited to, light scattering, viability dye staining, and exclusion dye staining.

In a preferred embodiment, a light scattering assay is used as the viability assay, as is well known in the art. For example, when viewed in the FACS, cells have particular characteristics as measured by their forward and 90 degree (side) light scatter properties. These scatter properties represent the size, shape and granule content of the cells. These properties account for two parameters to be measured as a readout for the viability. Briefly, the DNA of dying or dead cells

generally condenses, which alters the 90° scatter; similarly, membrane blebbing can alter the forward scatter. Alterations in the intensity of light scattering, or the cell-refractive index indicate alterations in viability.

Thus, in general, for light scattering assays, a live cell population of a particular cell type is evaluated to determine its forward and side scattering properties. This sets a standard for scattering that can subsequently be used.

In a preferred embodiment, the viability assay utilizes a viability dye. There are a number of known viability dyes that stain dead or dying cells, but do not stain growing cells. For example, annexin V is a member of a protein family which displays specific binding to phospholipid (phosphatidylserine) in a divalent ion dependent manner. This protein has been widely used for the measurement of apoptosis (programmed cell death) as cell surface exposure of phosphatidylserine is a hallmark early signal of this process. Suitable viability dyes include, but are not limited to, annexin, ethidium homodimer-1, DEAD Red, propidium iodide, SYTOX Green, etc., and others known in the art; see the Molecular Probes Handbook of Fluorescent Probes and Research Chemicals, Haugland, Sixth Edition, hereby incorporated by reference; see Apoptosis Assay on page 285 in particular, and Chapter 16.

Protocols for viability dye staining for cell viability are known, see Molecular Probes catalog, supra. In this embodiment, the viability dye such as annexin is labeled, either directly or indirectly, and combined with a cell population. Annexin is commercially available, i.e., from PharMingen, San Diego, California, or Caltag Laboratories, Millbrae, California. Preferably, the viability dye is provided in a solution wherein the dye is in a concentration of about 100 ng/ml to about 500 ng/ml, more preferably, about 500 ng/ml to about 1 µg/ml, and most preferably, from about 1 µg/ml to about 5 µg/ml. In a preferred embodiment, the viability dye is directly labeled; for example, annexin may be labeled with a fluorochrome such as fluorescein isothiocyanate (FITC), Alexa dyes, TRITC, AMCA, APC, tri-color, Cy-5, and others known in the art or commercially available. In an alternate preferred embodiment, the viability dye is labeled with a first label, such as a hapten such as biotin, and a secondary fluorescent label is used, such as fluorescent streptavidin. Other first and second labeling pairs can be used as will be appreciated by those in the art.

Once added, the viability dye is allowed to incubate with the cells for a period of time, and washed, if necessary. The cells are then sorted as outlined below to remove the non-viable cells.

In a preferred embodiment, exclusion dye staining is used as the viability assay. Exclusion dyes are those which are excluded from living cells, i.e. they are not taken up passively (they do not permeate the cell membrane of a live cell). However, due to the permeability of dead or dying cells, they are taken up by dead cells. Generally, but not always, the exclusion dyes bind to DNA,



for example via intercalation. Preferably, the exclusion dye does not fluoresce, or fluoresces poorly, in the absence of DNA; this eliminates the need for a wash step. Alternatively, exclusion dyes that require the use of a secondary label may also be used. Preferred exclusion dyes include, but are not limited to, ethidium bromide; ethidium homodimer-1; propidium iodide; SYTOX green nucleic acid stain; Calcein AM, BCECF AM; fluorescein diacetate; TOTO® and TO-PRO™ (from Molecular Probes; supra, see chapter 16) and others known in the art.

Protocols for exclusion dye staining for cell viability are known, see the Molecular Probes catalog, supra. In general, the exclusion dye is added to the cells at a concentration of from about 100 ng/ml to about 500 ng/ml, more preferably, about 500 ng/ml to about 1 µg/ml, and most preferably, from about 0.1 µg/ml to about 5 µg/ml, with about 0.5 µg/ml being particularly preferred. The cells and the exclusion dye are incubated for some period of time, washed, if necessary, and then the cells sorted as outlined below, to remove non-viable cells from the population.

In addition, there are other cell viability assays which may be run, including for example enzymatic assays, which can measure extracellular enzymatic activity of either live cells (i.e. secreted proteases, etc.), or dead cells (i.e. the presence of intracellular enzymes in the media; for example, intracellular proteases, mitochondrial enzymes, etc.). See the Molecular Probes Handbook of Fluorescent Probes and Research Chemicals, Haugland, Sixth Edition, hereby incorporated by reference; see chapter 16 in particular.

In a preferred embodiment, at least one cell viability assay is run, with at least two different cell viability assays being preferred, when the fluors are compatible. When only 1 viability assay is run, a preferred embodiment utilizes light scattering assays (both forward and side scattering). When two viability assays are run, preferred embodiments utilize light scattering and dye exclusion, with light scattering and viability dye staining also possible, and all three being done in some cases as well. Viability assays thus allow the separation of viable cells from non-viable or dying cells.

In addition to a cell viability assay, a preferred embodiment utilizes a cell proliferation assay. By "proliferation assay" herein is meant an assay that allows the determination that a cell population is either proliferating, i.e. replicating, or not replicating.

In a preferred embodiment, the proliferation assay is a dye inclusion assay. A dye inclusion assay relies on dilution effects to distinguish between cell phases. Briefly, a dye (generally a fluorescent dye as outlined below) is introduced to cells and taken up by the cells. Once taken up, the dye is trapped in the cell, and does not diffuse out. As the cell population divides, the dye is proportionally diluted. That is, after the introduction of the inclusion dye, the cells are allowed to incubate for some period of time; cells that lose fluorescence over time are dividing, and the cells that remain fluorescent are arrested in a non-growth phase.

Generally, the introduction of the inclusion dye may be done in one of two ways. Either the dye cannot passively enter the cells (e.g. it is charged), and the cells must be treated to take up the dye; for example through the use of an electric pulse. Alternatively, the dye can passively enter the cells, but once taken up, it is modified such that it cannot diffuse out of the cells. For example, enzymatic modification of the inclusion dye may render it charged, and thus unable to diffuse out of the cells. For example, the Molecular Probes CellTracker™ dyes are fluorescent chloromethyl derivatives that freely diffuse into cells, and then glutathione S-transferase-mediated reaction produces membrane impermeant dyes.

Suitable inclusion dyes include, but are not limited to, the Molecular Probes line of CellTracker™ dyes, including, but not limited to CellTracker™ Blue, CellTracker™ Yellow-Green, CellTracker™ Green, CellTracker™ Orange, PKH26 (Sigma), and others known in the art; see the Molecular Probes Handbook, supra; chapter 15 in particular.

In general, inclusion dyes are provided to the cells at a concentration ranging from about 100 ng/ml to about 5 µg/ml, with from about 500 ng/ml to about 1 µg/ml being preferred. A wash step may or may not be used. In a preferred embodiment, a candidate bioactive agent is combined with the cells as described herein. The cells and the inclusion dye are incubated for some period of time, to allow cell division and thus dye dilution. The length of time will depend on the cell cycle time for the particular cells; in general, at least about 2 cell divisions are preferred, with at least about 3 being particularly preferred and at least about 4 being especially preferred. The cells are then sorted as outlined below, to create populations of cells that are replicating and those that are not. As will be appreciated by those in the art, in some cases, for example when screening for anti-proliferation agents, the bright (i.e. fluorescent) cells are collected; in other embodiments, for example for screening for proliferation agents, the low fluorescence cells are collected. Alterations are determined by measuring the fluorescence at either different time points or in different cell populations, and comparing the determinations to one another or to standards.

In a preferred embodiment, the proliferation assay is an antimetabolite assay. In general, antimetabolite assays find the most use when agents that cause cellular arrest in G1 or G2 resting phase is desired. In an antimetabolite proliferation assay, the use of a toxic antimetabolite that will kill dividing cells will result in survival of only those cells that are not dividing. Suitable antimetabolites include, but are not limited to, standard chemotherapeutic agents such as methotrexate, cisplatin, taxol, hydroxyurea, nucleotide analogs such as AraC, etc. In addition, antimetabolite assays may include the use of genes that cause cell death upon expression.

The concentration at which the antimetabolite is added will depend on the toxicity of the particular antimetabolite, and will be determined as is known in the art. The antimetabolite is added and the cells are generally incubated for some period of time; again, the exact period of time will depend on

the characteristics and identity of the antimetabolite as well as the cell cycle time of the particular cell population. Generally, a time sufficient for at least one cell division to occur.

5 In a preferred embodiment, at least one proliferation assay is run, with more than one being preferred. Thus, a proliferation assay results in a population of proliferating cells and a population of arrested cells. Moreover, other proliferation assays may be used, i.e., colorimetric assays known in the art.

In a preferred embodiment, either after or simultaneously with one or more of the proliferation assays outlined above, at least one cell phase assay is done. A "cell phase" assay determines at which cell phase the cells are arrested, M, G1, S, or G2.

10 In a preferred embodiment, the cell phase assay is a DNA binding dye assay. Briefly, a DNA binding dye is introduced to the cells, and taken up passively. Once inside the cell, the DNA binding dye binds to DNA, generally by intercalation, although in some cases, the dyes can be either major or minor groove binding compounds. The amount of dye is thus directly correlated to the amount of DNA in the cell, which varies by cell phase; G2 and M phase cells have twice the  
15 DNA content of G1 phase cells, and S phase cells have an intermediate amount, depending on at what point in S phase the cells are. Suitable DNA binding dyes are permeant, and include, but are not limited to, Hoechst 33342 and 33258, acridine orange, 7-AAD, LDS 751, DAPI, and SYTO 16, Molecular Probes Handbook, supra; chapters 8 and 16 in particular.

20 In general, the DNA binding dyes are added in concentrations ranging from about 1 µg/ml to about 5 µg/ml. The dyes are added to the cells and allowed to incubate for some period of time; the length of time will depend in part on the dye chosen. In one embodiment, measurements are taken immediately after addition of the dye. The cells are then sorted as outlined below, to create populations of cells that contain different amounts of dye, and thus different amounts of DNA; in this way, cells that are replicating are separated from those that are not. As will be appreciated by  
25 those in the art, in some cases, for example when screening for anti-proliferation agents, cells with the least fluorescence (and thus a single copy of the genome) can be separated from those that are replicating and thus contain more than a single genome of DNA. Alterations are determined by measuring the fluorescence at either different time points or in different cell populations, and comparing the determinations to one another or to standards.

30 In a preferred embodiment, the cell phase assay is a cyclin destruction assay. In this embodiment, prior to screening (and generally prior to the introduction of a candidate bioactive agent, as outlined below), a fusion nucleic acid is introduced to the cells. The fusion nucleic acid comprises nucleic acid encoding a cyclin destruction box and a nucleic acid encoding a detectable molecule. "Cyclin destruction boxes" are known in the art and are sequences that cause destruction via the

ubiquitination pathway of proteins containing the boxes during particular cell phases. That is, for example, G1 cyclins may be stable during G1 phase but degraded during S phase due to the presence of a G1 cyclin destruction box. Thus, by linking a cyclin destruction box to a detectable molecule, for example green fluorescent protein, the presence or absence of the detectable molecule can serve to identify the cell phase of the cell population. In a preferred embodiment, multiple boxes are used, preferably each with a different fluor, such that detection of the cell phase can occur.

A number of cyclin destruction boxes are known in the art, for example, cyclin A has a destruction box comprising the sequence RTVLGVIGD; the destruction box of cyclin B1 comprises the sequence RTALGDIGN. See Glotzer, et al., *Nature*, 349:132-138 (1991). Other destruction boxes are known as well: YMTVSIIDRFMQDSCVPKMKMLQLVGVT (rat cyclin B); KFRLLQETMYMTVSIIDRFMQNSCVPKK (mouse cyclin B); RAILLDWLQVQMKFRLLQETMYMTVS (mouse cyclin B1); DRFLQAQLVCRKKLQVVGITALLASK (mouse cyclin B2); and MSVLRGKLQLVGTAAMLL (mouse cyclin A2).

The nucleic acid encoding the cyclin destruction box is operably linked to nucleic acid encoding a detectable molecule. The fusion proteins are constructed by methods known in the art. For example, the nucleic acids encoding the destruction box is ligated to a nucleic acid encoding a detectable molecule. By "detectable molecule" herein is meant a molecule that allows a cell or compound comprising the detectable molecule to be distinguished from one that does not contain it, i.e., an epitope, sometimes called an antigen TAG, a specific enzyme, or a fluorescent molecule. Preferred fluorescent molecules include but are not limited to green fluorescent protein (GFP), blue fluorescent protein (BFP), yellow fluorescent protein (YFP), red fluorescent protein (RFP), and enzymes including luciferase and  $\beta$ -galactosidase. When antigen TAGs are used, preferred embodiments utilize cell surface antigens. The epitope is preferably any detectable peptide which is not generally found on the cytoplasmic membrane, although in some instances, if the epitope is one normally found on the cells, increases may be detected, although this is generally not preferred. Similarly, enzymatic detectable molecules may also be used; for example, an enzyme that generates a novel or chromogenic product.

Accordingly, the results of sorting after cell phase assays generally result in at least two populations of cells that are in different cell phases.

The proteins and nucleic acids provided herein can also be used for screening purposes wherein the protein-protein interactions of the cell cycle proteins can be identified. Genetic systems have been described to detect protein-protein interactions. The first work was done in yeast systems, namely the "yeast two-hybrid" system. The basic system requires a protein-protein interaction in order to turn on transcription of a reporter gene. Subsequent work was done in mammalian cells.

See Fields, et al., Nature, 340:245 (1989); Vasavada, et al., PNAS USA, 88:10686 (1991); Fearon, et al., PNAS USA, 89:7958 (1992); Dang, et al., Mol. Cell. Biol., 11:954 (1991); Chien, et al., PNAS USA, 88:9578 (1991); and U.S. Patent Nos. 5,283,173, 5,667,973, 5,468,614, 5,525,490, and 5,637,463. a preferred system is described in Serial Nos. 09/050,863, filed March 30, 1998 and 09/359,081 filed July 22, 1999, entitled "Mammalian Protein Interaction Cloning System". For use in conjunction with these systems, a particularly useful shuttle vector is described in Serial No. 09/133,944, filed August 14, 1998, entitled "Shuttle Vectors".

In general, two nucleic acids are transformed into a cell, where one is a "bait" such as the gene encoding a cell cycle protein or a portion thereof, and the other encodes a test candidate. Only if the two expression products bind to one another will an indicator, such as a fluorescent protein, be expressed. Expression of the indicator indicates when a test candidate binds to the cell cycle protein and can be identified as an cell cycle protein. Using the same system and the identified cell cycle proteins the reverse can be performed. Namely, the cell cycle proteins provided herein can be used to identify new baits, or agents which interact with cell cycle proteins. Additionally, the two-hybrid system can be used wherein a test candidate is added in addition to the bait and the cell cycle protein encoding nucleic acids to determine agents which interfere with the bait, such as Traf2 or Nck, and the cell cycle protein.

In one embodiment, a mammalian two-hybrid system is preferred. Mammalian systems provide post-translational modifications of proteins which may contribute significantly to their ability to interact. In addition, a mammalian two-hybrid system can be used in a wide variety of mammalian cell types to mimic the regulation, induction, processing, etc. of specific proteins within a particular cell type. For example, proteins involved in a disease state (i.e., cancer, apoptosis related disorders) could be tested in the relevant disease cells. Similarly, for testing of random proteins, assaying them under the relevant cellular conditions will give the highest positive results. Furthermore, the mammalian cells can be tested under a variety of experimental conditions that may affect intracellular protein-protein interactions, such as in the presence of hormones, drugs, growth factors and cytokines, radiation, chemotherapeutics, cellular and chemical stimuli, etc., that may contribute to conditions which can effect protein-protein interactions, particularly those involved in cancer.

Assays involving binding such as the two-hybrid system may take into account non-specific binding proteins (NSB).

Expression in various cell types, and assays for cell cycle activity are described above. The activity assays, such as having an effect on Traf2 or Nck binding, cytoskeleton regulation, phosphorylation activity, disruption of F-actin or JNK pathway activation, can be performed to confirm the activity of cell cycle proteins which have already been identified by their sequence

identity/similarity or binding to Traf2 or Nck as well as to further confirm the activity of lead compounds identified as modulators of the cell cycle proteins provided herein such as Tnik.

The components provided herein for the assays provided herein may also be combined to form kits. The kits can be based on the use of the protein and/or the nucleic acid encoding the cell cycle proteins. In one embodiment, other components are provided in the kit. Such components include one or more of packaging, instructions, antibodies, and labels. Additional assays such as those used in diagnostics are further described below.

In this way, bioactive agents are identified. Compounds with pharmacological activity are able to enhance or interfere with the activity of the cell cycle protein. The compounds having the desired pharmacological activity may be administered in a physiologically acceptable carrier to a host, as further described below.

The present discovery relating to the role of cell cycle proteins in the cell cycle thus provides methods for inducing or preventing cell proliferation in cells. In a preferred embodiment, the cell cycle proteins, and particularly cell cycle protein fragments, are useful in the study or treatment of conditions which are mediated by the cell cycle proteins, i.e. to diagnose, treat or prevent cell cycle associated disorders. Thus, "cell cycle associated disorders" or "disease state" include conditions involving both insufficient or excessive cell proliferation, preferably, cancer.

Thus, in one embodiment, cell cycle regulation in cells or organisms are provided. In one embodiment, the methods comprise administering to a cell or individual in need thereof, a cell cycle protein in a therapeutic amount. Alternatively, an anti-cell cycle antibody that reduces or eliminates the biological activity of the endogenous cell cycle protein is administered. In another embodiment, a bioactive agent as identified by the methods provided herein is administered. Alternatively, the methods comprise administering to a cell or individual a recombinant nucleic acid encoding an cell cycle protein. As will be appreciated by those in the art, this may be accomplished in any number of ways. In a preferred embodiment, the activity of cell cycle is increased by increasing the amount of cell cycle in the cell, for example by overexpressing the endogenous cell cycle or by administering a gene encoding a cell cycle protein, using known gene-therapy techniques, for example. In a preferred embodiment, the gene therapy techniques include the incorporation of the exogenous gene using enhanced homologous recombination (EHR), for example as described in PCT/US93/03868, hereby incorporated by reference in its entirety.

Without being bound by theory, it appears that cell cycle protein is an important protein in the cell cycle. Accordingly, disorders based on mutant or variant cell cycle genes may be determined. In one embodiment, the invention provides methods for identifying cells containing variant cell cycle genes comprising determining all or part of the sequence of at least one endogenous cell cycle

genes in a cell. As will be appreciated by those in the art, this may be done using any number of sequencing techniques. In a preferred embodiment, the invention provides methods of identifying the cell cycle genotype of an individual comprising determining all or part of the sequence of at least one cell cycle gene of the individual. This is generally done in at least one tissue of the individual, and may include the evaluation of a number of tissues or different samples of the same tissue. The method may include comparing the sequence of the sequenced cell cycle gene to a known cell cycle gene, i.e. a wild-type gene.

The sequence of all or part of the cell cycle gene can then be compared to the sequence of a known cell cycle gene to determine if any differences exist. This can be done using any number of known sequence identity programs, such as Bestfit, etc. In a preferred embodiment, the presence of a difference in the sequence between the cell cycle gene of the patient and the known cell cycle gene is indicative of a disease state or a propensity for a disease state.

In one embodiment, the invention provides methods for diagnosing a cell cycle related condition in an individual. The methods comprise measuring the activity of cell cycle in a tissue from the individual or patient, which may include a measurement of the amount or specific activity of a cell cycle protein. This activity is compared to the activity of cell cycle from either a unaffected second individual or from an unaffected tissue from the first individual. When these activities are different, the first individual may be at risk for a cell cycle associated disorder. In this way, for example, monitoring of various disease conditions may be done, by monitoring the levels of the protein or the expression of mRNA therefor. Similarly, expression levels may correlate to the prognosis.

In one aspect, the expression levels of cell cycle protein genes are determined in different patient samples or cells for which either diagnosis or prognosis information is desired. Gene expression monitoring is done on genes encoding cell cycle proteins. In one aspect, the expression levels of cell cycle protein genes are determined for different cellular states, such as normal cells and cells undergoing apoptosis or transformation. By comparing cell cycle protein gene expression levels in cells in different states, information including both up- and down-regulation of cell cycle protein genes is obtained, which can be used in a number of ways. For example, the evaluation of a particular treatment regime may be evaluated: does a chemotherapeutic drug act to improve the long-term prognosis in a particular patient. Similarly, diagnosis may be done or confirmed by comparing patient samples. Furthermore, these gene expression levels allow screening of drug candidates with an eye to mimicking or altering a particular expression level. This may be done by making biochips comprising sets of important cell cycle protein genes, such as those of the present invention, which can then be used in these screens. These methods can also be done on the protein basis; that is, protein expression levels of the cell cycle proteins can be evaluated for diagnostic purposes or to screen candidate agents. In addition, the cell cycle protein nucleic acid sequences can be administered for gene therapy purposes, including the administration of

antisense nucleic acids, or the cell cycle proteins administered as therapeutic drugs.

Cell cycle protein sequences bound to biochips include both nucleic acid and amino acid sequences as defined above. In a preferred embodiment, nucleic acid probes to cell cycle protein nucleic acids (both the nucleic acid sequences having the sequences outlined in the Figures and/or the complements thereof) are made. The nucleic acid probes attached to the biochip are designed to be substantially complementary to the cell cycle protein nucleic acids, i.e. the target sequence (either the target sequence of the sample or to other probe sequences, for example in sandwich assays), such that hybridization of the target sequence and the probes of the present invention occurs. As outlined below, this complementarity need not be perfect; there may be any number of base pair mismatches which will interfere with hybridization between the target sequence and the single stranded nucleic acids of the present invention. However, if the number of mutations is so great that no hybridization can occur under even the least stringent of hybridization conditions, the sequence is not a complementary target sequence. Thus, by "substantially complementary" herein is meant that the probes are sufficiently complementary to the target sequences to hybridize under normal reaction conditions, particularly high stringency conditions, as outlined herein.

A "nucleic acid probe" is generally single stranded but can be partially single and partially double stranded. The strandedness of the probe is dictated by the structure, composition, and properties of the target sequence. In general, the nucleic acid probes range from about 8 to about 100 bases long, with from about 10 to about 80 bases being preferred, and from about 30 to about 50 bases being particularly preferred. In some embodiments, much longer nucleic acids can be used, up to hundreds of bases (e.g., whole genes).

As will be appreciated by those in the art, nucleic acids can be attached or immobilized to a solid support in a wide variety of ways. By "immobilized" and grammatical equivalents herein is meant the association or binding between the nucleic acid probe and the solid support is sufficient to be stable under the conditions of binding, washing, analysis, and removal as outlined below. The binding can be covalent or non-covalent. By "non-covalent binding" and grammatical equivalents herein is meant one or more of either electrostatic, hydrophilic, and hydrophobic interactions. Included in non-covalent binding is the covalent attachment of a molecule, such as, streptavidin to the support and the non-covalent binding of the biotinylated probe to the streptavidin. By "covalent binding" and grammatical equivalents herein is meant that the two moieties, the solid support and the probe, are attached by at least one bond, including sigma bonds, pi bonds and coordination bonds. Covalent bonds can be formed directly between the probe and the solid support or can be formed by a cross linker or by inclusion of a specific reactive group on either the solid support or the probe or both molecules. Immobilization may also involve a combination of covalent and non-covalent interactions.



In general, the probes are attached to the biochip in a wide variety of ways, as will be appreciated by those in the art. As described herein, the nucleic acids can either be synthesized first, with subsequent attachment to the biochip, or can be directly synthesized on the biochip.

5 The biochip comprises a suitable solid substrate. By "substrate" or "solid support" or other grammatical equivalents herein is meant any material that can be modified to contain discrete individual sites appropriate for the attachment or association of the nucleic acid probes and is amenable to at least one detection method. As will be appreciated by those in the art, the number of possible substrates are very large, and include, but are not limited to, glass and modified or functionalized glass, plastics (including acrylics, polystyrene and copolymers of styrene and other  
10 materials, polypropylene, polyethylene, polybutylene, polyurethanes, TeflonJ, etc.), polysaccharides, nylon or nitrocellulose, resins, silica or silica-based materials including silicon and modified silicon, carbon, metals, inorganic glasses, plastics, etc. In general, the substrates allow optical detection and do not appreciably show fluorescence.

15 In a preferred embodiment, the surface of the biochip and the probe may be derivatized with chemical functional groups for subsequent attachment of the two. Thus, for example, the biochip is derivatized with a chemical functional group including, but not limited to, amino groups, carboxy groups, oxo groups and thiol groups, with amino groups being particularly preferred. Using these functional groups, the probes can be attached using functional groups on the probes. For example, nucleic acids containing amino groups can be attached to surfaces comprising amino groups, for  
20 example using linkers as are known in the art; for example, homo- or hetero-bifunctional linkers as are well known (see 1994 Pierce Chemical Company catalog, technical section on cross-linkers, pages 155-200, incorporated herein by reference). In addition, in some cases, additional linkers, such as alkyl groups (including substituted and heteroalkyl groups) may be used.

25 In this embodiment, oligonucleotides, corresponding to the nucleic acid probe, are synthesized as is known in the art, and then attached to the surface of the solid support. As will be appreciated by those skilled in the art, either the 5' or 3' terminus may be attached to the solid support, or attachment may be via an internal nucleoside.

In an additional embodiment, the immobilization to the solid support may be very strong, yet non-covalent. For example, biotinylated oligonucleotides can be made, which bind to surfaces  
30 covalently coated with streptavidin, resulting in attachment.

Alternatively, the oligonucleotides may be synthesized on the surface, as is known in the art. For example, photoactivation techniques utilizing photopolymerization compounds and techniques are used. In a preferred embodiment, the nucleic acids can be synthesized in situ, using well known photolithographic techniques, such as those described in WO 95/25116; WO 95/35505; U.S.

Patent Nos. 5,700,637 and 5,445,934; and references cited within, all of which are expressly incorporated by reference; these methods of attachment form the basis of the Affymetrix GeneChip™ technology.

"Differential expression," or grammatical equivalents as used herein, refers to both qualitative as well as quantitative differences in the genes' temporal and/or cellular expression patterns within and among the cells. Thus, a differentially expressed gene can qualitatively have its expression altered, including an activation or inactivation, in, for example, normal versus apoptotic cell. That is, genes may be turned on or turned off in a particular state, relative to another state. As is apparent to the skilled artisan, any comparison of two or more states can be made. Such a qualitatively regulated gene will exhibit an expression pattern within a state or cell type which is detectable by standard techniques in one such state or cell type, but is not detectable in both. Alternatively, the determination is quantitative in that expression is increased or decreased; that is, the expression of the gene is either upregulated, resulting in an increased amount of transcript, or downregulated, resulting in a decreased amount of transcript. The degree to which expression differs need only be large enough to quantify via standard characterization techniques as outlined below, such as by use of Affymetrix GeneChip™ expression arrays, Lockhart, *Nature Biotechnology*, 14:1675-1680 (1996), hereby expressly incorporated by reference. Other techniques include, but are not limited to, quantitative reverse transcriptase PCR, Northern analysis and RNase protection.

As will be appreciated by those in the art, this may be done by evaluation at either the gene transcript, or the protein level; that is, the amount of gene expression may be monitored using nucleic acid probes to the DNA or RNA equivalent of the gene transcript, and the quantification of gene expression levels, or, alternatively, the final gene product itself (protein) can be monitored, for example through the use of antibodies to the cell cycle protein and standard immunoassays (ELISAs, etc.) or other techniques, including mass spectroscopy assays, 2D gel electrophoresis assays, etc.

In another method detection of the mRNA is performed *in situ*. In this method permeabilized cells or tissue samples are contacted with a detectably labeled nucleic acid probe for sufficient time to allow the probe to hybridize with the target mRNA. Following washing to remove the non-specifically bound probe, the label is detected. For example a digoxigenin labeled riboprobe (RNA probe) that is complementary to the mRNA encoding an cell cycle protein is detected by binding the digoxigenin with an anti-digoxigenin secondary antibody and developed with nitro blue tetrazolium and 5-bromo-4-chloro-3-indoyl phosphate.

In another preferred method, expression of cell cycle protein is performed using *in situ* imaging techniques employing antibodies to cell cycle proteins. In this method cells are contacted with from one to many antibodies to the cell cycle protein(s). Following washing to remove non-specific

antibody binding, the presence of the antibody or antibodies is detected. In one embodiment the antibody is detected by incubating with a secondary antibody that contains a detectable label. In another method the primary antibody to the cell cycle protein(s) contains a detectable label. In another preferred embodiment each one of multiple primary antibodies contains a distinct and detectable label. This method finds particular use in simultaneous screening for a plurality of cell cycle proteins. The label may be detected in a fluorometer which has the ability to detect and distinguish emissions of different wavelengths. In addition, a fluorescence activated cell sorter (FACS) can be used in this method. As will be appreciated by one of ordinary skill in the art, numerous other histological imaging techniques are useful in the invention and the antibodies can be used in ELISA, immunoblotting (Western blotting), immunoprecipitation, BIACORE technology, and the like.

In one embodiment, the cell cycle proteins of the present invention may be used to generate polyclonal and monoclonal antibodies to cell cycle proteins, which are useful as described herein. Similarly, the cell cycle proteins can be coupled, using standard technology, to affinity chromatography columns. These columns may then be used to purify cell cycle antibodies. In a preferred embodiment, the antibodies are generated to epitopes unique to the cell cycle protein; that is, the antibodies show little or no cross-reactivity to other proteins. These antibodies find use in a number of applications. For example, the cell cycle antibodies may be coupled to standard affinity chromatography columns and used to purify cell cycle proteins as further described below. The antibodies may also be used as blocking polypeptides, as outlined above, since they will specifically bind to the cell cycle protein.

The anti-cell cycle protein antibodies may comprise polyclonal antibodies. Methods of preparing polyclonal antibodies are known to the skilled artisan. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired, an adjuvant. Typically, the immunizing agent and/or adjuvant will be injected in the mammal by multiple subcutaneous or intraperitoneal injections. The immunizing agent may include the cell cycle protein or a fusion protein thereof. It may be useful to conjugate the immunizing agent to a protein known to be immunogenic in the mammal being immunized. Examples of such immunogenic proteins include but are not limited to keyhole limpet hemocyanin, serum albumin, bovine thyroglobulin, and soybean trypsin inhibitor. Examples of adjuvants which may be employed include Freund's complete adjuvant and MPL-TDM adjuvant (monophosphoryl Lipid a, synthetic trehalose dicorynomycolate). The immunization protocol may be selected by one skilled in the art without undue experimentation.

The anti-cell cycle protein antibodies may, alternatively, be monoclonal antibodies. Monoclonal antibodies may be prepared using hybridoma methods, such as those described by Kohler, et al., Nature, 256:495 (1975). In a hybridoma method, a mouse, hamster, or other appropriate host

animal, is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized *in vitro*.

The immunizing agent will typically include the cell cycle protein or a fusion protein thereof.

5 Generally, either peripheral blood lymphocytes ("PBLs") are used if cells of human origin are desired, or spleen cells or lymph node cells are used if non-human mammalian sources are desired. The lymphocytes are then fused with an immortalized cell line using a suitable fusing agent, such as polyethylene glycol, to form a hybridoma cell [Goding, Monoclonal Antibodies: Principles and Practice, Academic Press, (1986) pp. 59-103]. Immortalized cell lines are usually  
10 transformed mammalian cells, particularly myeloma cells of rodent, bovine and human origin. Usually, rat or mouse myeloma cell lines are employed. The hybridoma cells may be cultured in a suitable culture medium that preferably contains one or more substances that inhibit the growth or survival of the unfused, immortalized cells. For example, if the parental cells lack the enzyme hypoxanthine guanine phosphoribosyl transferase (HGPRT or HPRT), the culture medium for the  
15 hybridomas typically will include hypoxanthine, aminopterin, and thymidine ("HAT medium"), which substances prevent the growth of HGPRT-deficient cells.

Preferred immortalized cell lines are those that fuse efficiently, support stable high level expression of antibody by the selected antibody-producing cells, and are sensitive to a medium such as HAT medium. More preferred immortalized cell lines are murine myeloma lines, which can be obtained,  
20 for instance, from the Salk Institute Cell Distribution Center, San Diego, California and the American Type Culture Collection, Rockville, Maryland. Human myeloma and mouse-human heteromyeloma cell lines also have been described for the production of human monoclonal antibodies [Kozbor, J. Immunol., 133:3001 (1984); Brodeur, et al., Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., New York, pp. 51-63 (1987)].

25 The culture medium in which the hybridoma cells are cultured can then be assayed for the presence of monoclonal antibodies directed against cell cycle protein. Preferably, the binding specificity of monoclonal antibodies produced by the hybridoma cells is determined by immunoprecipitation or by an *in vitro* binding assay, such as radioimmunoassay (RIA) or enzyme-linked immunosorbent assay (ELISA). Such techniques and assays are known in the art. The  
30 binding affinity of the monoclonal antibody can, for example, be determined by the Scatchard analysis of Munson, et al., Anal. Biochem., 107:220 (1980).

After the desired hybridoma cells are identified, the clones may be subcloned by limiting dilution procedures and grown by standard methods [Goding, supra]. Suitable culture media for this purpose include, for example, Dulbecco's Modified Eagle's Medium and RPMI-1640 medium.  
35 Alternatively, the hybridoma cells may be grown *in vivo* as ascites in a mammal.

The monoclonal antibodies secreted by the subclones may be isolated or purified from the culture medium or ascites fluid by conventional immunoglobulin purification procedures such as, for example, protein a-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.

- 5 The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Patent No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies). The hybridoma cells of the invention serve as a preferred  
10 source of such DNA. Once isolated, the DNA may be placed into expression vectors, which are then transfected into host cells such as simian COS cells, Chinese hamster ovary (CHO) cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of monoclonal antibodies in the recombinant host cells. The DNA also may be modified, for example, by substituting the coding sequence for human heavy and light chain constant domains in place of  
15 the homologous murine sequences [U.S. Patent No. 4,816,567; Morrison, et al., supra] or by covalently joining to the immunoglobulin coding sequence all or part of the coding sequence for a non-immunoglobulin polypeptide. Such a non-immunoglobulin polypeptide can be substituted for the constant domains of an antibody of the invention, or can be substituted for the variable domains of one antigen-combining site of an antibody of the invention to create a chimeric bivalent antibody.
- 20 The antibodies may be monovalent antibodies. Methods for preparing monovalent antibodies are well known in the art. For example, one method involves recombinant expression of immunoglobulin light chain and modified heavy chain. The heavy chain is truncated generally at any point in the Fc region so as to prevent heavy chain crosslinking. Alternatively, the relevant cysteine residues are substituted with another amino acid residue or are deleted so as to prevent  
25 crosslinking.

*In vitro* methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art.

- 30 The anti-cell cycle protein antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab', F(ab')<sub>2</sub> or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient  
35 are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or

rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin [Jones, et al., Nature, 321:522-525 (1986); Riechmann, et al., Nature, 332:323-329 (1988); and Presta, Curr. Op. Struct. Biol., 2:593-596 (1992)].

Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed following the method of Winter and co-workers [Jones, et al., Nature, 321:522-525 (1986); Riechmann, et al., Nature, 332:323-327 (1988); Verhoeyen, et al., Science, 239:1534-1536 (1988)], by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Patent No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

Human antibodies can also be produced using various techniques known in the art, including phage display libraries [Hoogenboom, et al., J. Mol. Biol., 227:381 (1991); Marks, et al., J. Mol. Biol., 222:581 (1991)]. The techniques of Cole, et al. and Boerner, et al. are also available for the preparation of human monoclonal antibodies (Cole, et al., Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, p. 77 (1985); Boerner, et al., J. Immunol., 147(1):86-95 (1991)]. Similarly, human antibodies can be made by introducing of human immunoglobulin loci into transgenic animals, e.g., mice in which the endogenous immunoglobulin genes have been partially or completely inactivated. Upon challenge, human antibody production is observed, which closely resembles that seen in humans in all respects, including gene rearrangement, assembly, and antibody repertoire. This approach is described, for example, in U.S. Patent Nos. 5,545,807; 5,545,806; 5,569,825; 5,625,126; 5,633,425; 5,661,016, and in the following scientific publications: Marks, et al., Bio/Technology, 10:779-783 (1992); Lonberg, et al., Nature, 368:856-859 (1994); Morrison, Nature, 368:812-13 (1994); Fishwild, et al., Nature Biotechnology, 14:845-51 (1996); Neuberger, Nature Biotechnology, 14:826 (1996); Lonberg, et al., Intern. Rev. Immunol., 13:65-93

(1995).

Bispecific antibodies are monoclonal, preferably human or humanized, antibodies that have binding specificities for at least two different antigens. In the present case, one of the binding specificities is for the cell cycle protein, the other one is for any other antigen, and preferably for a cell-surface protein or receptor or receptor subunit.

Methods for making bispecific antibodies are known in the art. Traditionally, the recombinant production of bispecific antibodies is based on the co-expression of two immunoglobulin heavy-chain/light-chain pairs, where the two heavy chains have different specificities [Milstein, et al., Nature, 305:537-539 (1983)]. Because of the random assortment of immunoglobulin heavy and light chains, these hybridomas (quadromas) produce a potential mixture of ten different antibody molecules, of which only one has the correct bispecific structure. The purification of the correct molecule is usually accomplished by affinity chromatography steps. Similar procedures are disclosed in WO 93/08829, published 13 May 1993, and in Traunecker, et al., EMBO J., 10:3655-3659 (1991).

Antibody variable domains with the desired binding specificities (antibody-antigen combining sites) can be fused to immunoglobulin constant domain sequences. The fusion preferably is with an immunoglobulin heavy-chain constant domain, comprising at least part of the hinge, CH2, and CH3 regions. It is preferred to have the first heavy-chain constant region (CH1) containing the site necessary for light-chain binding present in at least one of the fusions. DNAs encoding the immunoglobulin heavy-chain fusions and, if desired, the immunoglobulin light chain, are inserted into separate expression vectors, and are co-transfected into a suitable host organism. For further details of generating bispecific antibodies see, for example, Suresh, et al., Methods in Enzymology, 121:210 (1986).

Heteroconjugate antibodies are also within the scope of the present invention. Heteroconjugate antibodies are composed of two covalently joined antibodies. Such antibodies have, for example, been proposed to target immune system cells to unwanted cells [U.S. Patent No. 4,676,980], and for treatment of HIV infection [WO 91/00360; WO 92/200373; EP 03089]. It is contemplated that the antibodies may be prepared *in vitro* using known methods in synthetic protein chemistry, including those involving crosslinking agents. For example, immunotoxins may be constructed using a disulfide exchange reaction or by forming a thioether bond. Examples of suitable reagents for this purpose include iminothiolate and methyl-4-mercaptobutyrimidate and those disclosed, for example, in U.S. Patent No. 4,676,980.

The anti-cell cycle protein antibodies of the invention have various utilities. For example, anti-cell cycle protein antibodies may be used in diagnostic assays for an cell cycle protein, e.g., detecting

its expression in specific cells, tissues, or serum. Various diagnostic assay techniques known in the art may be used, such as competitive binding assays, direct or indirect sandwich assays and immunoprecipitation assays conducted in either heterogeneous or homogeneous phases [Zola, Monoclonal Antibodies: a Manual of Techniques, CRC Press, Inc. pp. 147-158 (1987)]. The antibodies used in the diagnostic assays can be labeled with a detectable moiety. The detectable moiety should be capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as  $^3\text{H}$ ,  $^{14}\text{C}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ , or  $^{125}\text{I}$ , a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin, or an enzyme, such as alkaline phosphatase, beta-galactosidase or horseradish peroxidase. Any method known in the art for conjugating the antibody to the detectable moiety may be employed, including those methods described by Hunter, et al., Nature, 144:945 (1962); David, et al., Biochemistry, 13:1014 (1974); Pain, et al., J. Immunol. Meth., 40:219 (1981); and Nygren, J. Histochem. and Cytochem., 30:407 (1982).

Anti-Cell cycle protein antibodies also are useful for the affinity purification of cell cycle protein from recombinant cell culture or natural sources. In this process, the antibodies against cell cycle protein are immobilized on a suitable support, such as a Sephadex resin or filter paper, using methods well known in the art. The immobilized antibody then is contacted with a sample containing the cell cycle protein to be purified, and thereafter the support is washed with a suitable solvent that will remove substantially all the material in the sample except the cell cycle protein, which is bound to the immobilized antibody. Finally, the support is washed with another suitable solvent that will release the cell cycle protein from the antibody.

The anti-cell cycle protein antibodies may also be used in treatment. In one embodiment, the genes encoding the antibodies are provided, such that the antibodies bind to and modulate the cell cycle protein within the cell.

In one embodiment, a therapeutically effective dose of an cell cycle protein, agonist or antagonist is administered to a patient. By "therapeutically effective dose" herein is meant a dose that produces the effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques. As is known in the art, adjustments for cell cycle protein degradation, systemic versus localized delivery, as well as the age, body weight, general health, sex, diet, time of administration, drug interaction and the severity of the condition may be necessary, and will be ascertainable with routine experimentation by those skilled in the art.

A "patient" for the purposes of the present invention includes both humans and other animals, particularly mammals, and organisms. Thus the methods are applicable to both human therapy and veterinary applications. In the preferred embodiment the patient is a mammal, and in the most



preferred embodiment the patient is human.

The administration of the cell cycle protein, agonist or antagonist of the present invention can be done in a variety of ways, including, but not limited to, orally, subcutaneously, intravenously, intranasally, transdermally, intraperitoneally, intramuscularly, intrapulmonary, vaginally, rectally, or intraocularly. In some instances, for example, in the treatment of wounds and inflammation, the composition may be directly applied as a solution or spray. Depending upon the manner of introduction, the compounds may be formulated in a variety of ways. The concentration of therapeutically active compound in the formulation may vary from about 0.1-100 wt.%. 5

The pharmaceutical compositions of the present invention comprise an cell cycle protein, agonist or antagonist (including antibodies and bioactive agents as described herein) in a form suitable for administration to a patient. In the preferred embodiment, the pharmaceutical compositions are in a water soluble form, such as being present as pharmaceutically acceptable salts, which is meant to include both acid and base addition salts. "Pharmaceutically acceptable acid addition salt" refers to those salts that retain the biological effectiveness of the free bases and that are not biologically or otherwise undesirable, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid and the like. "Pharmaceutically acceptable base addition salts" include those derived from inorganic bases such as sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Particularly preferred are the ammonium, potassium, sodium, calcium, and magnesium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. 10 15 20 25

The pharmaceutical compositions may also include one or more of the following: carrier proteins such as serum albumin; buffers; fillers such as microcrystalline cellulose, lactose, corn and other starches; binding agents; sweeteners and other flavoring agents; coloring agents; and polyethylene glycol. Additives are well known in the art, and are used in a variety of formulations. 30

Combinations of the compositions may be administered. Moreover, the compositions may be administered in combination with other therapeutics, including growth factors or chemotherapeutics and/or radiation. Targeting agents (i.e. ligands for receptors on cancer cells) may also be combined with the compositions provided herein.

In one embodiment provided herein, the antibodies are used for immunotherapy, thus, methods of immunotherapy are provided. By "immunotherapy" is meant treatment of cell cycle protein related disorders with an antibody raised against a cell cycle protein. As used herein, immunotherapy can be passive or active. Passive immunotherapy, as defined herein, is the passive transfer of antibody to a recipient (patient). Active immunization is the induction of antibody and/or T-cell responses in a recipient (patient). Induction of an immune response can be the consequence of providing the recipient with an cell cycle protein antigen to which antibodies are raised. As appreciated by one of ordinary skill in the art, the cell cycle protein antigen may be provided by injecting an cell cycle protein against which antibodies are desired to be raised into a recipient, or contacting the recipient with an cell cycle protein nucleic acid, capable of expressing the cell cycle protein antigen, under conditions for expression of the cell cycle protein antigen.

In a preferred embodiment, a therapeutic compound is conjugated to an antibody, preferably an cell cycle protein antibody. The therapeutic compound may be a cytotoxic agent. In this method, targeting the cytotoxic agent to apoptotic cells or tumor tissue or cells, results in a reduction in the number of afflicted cells, thereby reducing symptoms associated with apoptosis, cancer cell cycle protein related disorders. Cytotoxic agents are numerous and varied and include, but are not limited to, cytotoxic drugs or toxins or active fragments of such toxins. Suitable toxins and their corresponding fragments include diphtheria A chain, exotoxin A chain, ricin A chain, abrin A chain, curcin, crotin, phenomycin, enomycin and the like. Cytotoxic agents also include radiochemicals made by conjugating radioisotopes to antibodies raised against cell cycle proteins, or binding of a radionuclide to a chelating agent that has been covalently attached to the antibody.

In a preferred embodiment, cell cycle protein genes are administered as DNA vaccines, either single nucleic acids or combinations of cell cycle protein genes. Naked DNA vaccines are generally known in the art; see Brower, Nature Biotechnology, 16:1304-1305 (1998). Methods for the use of nucleic acids as DNA vaccines are well known to one of ordinary skill in the art, and include placing an cell cycle protein gene or portion of an cell cycle protein nucleic acid under the control of a promoter for expression in a patient. The cell cycle protein gene used for DNA vaccines can encode full-length cell cycle proteins, but more preferably encodes portions of the cell cycle proteins including peptides derived from the cell cycle protein. In a preferred embodiment a patient is immunized with a DNA vaccine comprising a plurality of nucleotide sequences derived from a cell cycle protein gene. Similarly, it is possible to immunize a patient with a plurality of cell cycle protein genes or portions thereof, as defined herein. Without being bound by theory, following expression of the polypeptide encoded by the DNA vaccine, cytotoxic T-cells, helper T-cells and antibodies are induced which recognize and destroy or eliminate cells expressing cell cycle proteins.

In a preferred embodiment, the DNA vaccines include a gene encoding an adjuvant molecule with

the DNA vaccine. Such adjuvant molecules include cytokines that increase the immunogenic response to the cell cycle protein encoded by the DNA vaccine. Additional or alternative adjuvants are known to those of ordinary skill in the art and find use in the invention.

The following example serves to more fully describe the manner of using the above-described invention, as well as to set forth the best modes contemplated for carrying out various aspects of the invention. It is understood that this example in no way serve to limit the true scope of this invention, but rather are presented for illustrative purposes. All references cited herein are expressly incorporated by reference in their entirety. Moreover, all sequences displayed, cited by reference or accession number in the references are incorporated by reference herein.

#### 10 **Example 1: Cloning, tissue distribution, binding, activation and regulation functions of Tnik**

*Antibodies and cytokines* –Antibodies used in this report include: anti-HA mAb (Babco) and pAb (Santa Cruz Biotechnology); anti-FLAG mAb (Sigma) and pAb (Santa Cruz); anti-Myc mAb (Babco); anti-Traf2 pAb (Santa Cruz); anti-NCK mAb (Transduction Labs); anti- $\beta$ -actin mAb (Sigma).  $\text{TNF}\alpha$  was purchased from Calbiochem.

*Cloning of full length Tnik and Northern blotting* - Using yeast two-hybrid screening, overlapping cDNA fragments were identified that interacted with Traf2 and NCK. The sequences of the fragments were contained in a partial cDNA clone, KIAA0551 (Accession number AB011123), at GenBank. Antisense oligos TGCGCTTATATTCCAGAAGTAGAGCT and CTGTCTCTGCTCCTCTCTA were designed according to the 5' end sequence of KIAA0551 and the full length Tnik cDNA was cloned from reverse transcribed human brain mRNA by RACE-PCR. Northern blotting was performed on human multi-tissue Northern blot according to the manufacturer's recommendations (Clontech). A PCR product amplified from nucleotide 1264 to nucleotide 2427 of Tnik coding region was used as a probe.

*Plasmid construction* – Full length human Tnik was cloned into pCI (Promega) derived expression vector pYCI under the control of the CMV promoter with an HA epitope tag (AYPYDVDPYA) inserted on the N-terminus by PCR. A kinase mutant form of Tnik was constructed using the QuikChange mutagenesis kit (Stratagene) with Oligos AGCTTGACGCCATCAGGTTATGGATGTCAC and GTGACATCCATAACCTTGATGGCTGCAAGCT to change the highly conserved lysine 54 in the kinase domain to arginine. Full length human Traf2 was cloned into pYCI with a FLAG epitope tag (DYKDDDDKG) inserted on the N-terminus by PCR. Full length human NCK was similarly cloned into pYCI with a FLAG epitope tag at the N-terminus. Myc-JNK2 and Myc-ERK1 were constructed in the pCR3.1 vector with a Myc epitope tag (ASMEQKLISEEDLN) inserted on the N-terminus of JNK2 and ERK1, respectively. All the truncation mutants were constructed by PCR. For

construction of the GFP-Tnik fusion protein, full length Tnik was PCR amplified from pYCI-Tnik and inserted in frame onto the 3' end of GFP. All constructs were verified by DNA sequencing.

*Cell culture, transfection of Phoenix-A cells and immunoprecipitation* - Phoenix-A cells (derivatives of 293 cells) (Coligan, et al., Current Protocols in Immunology [supplement], 31:10.28.1-10.28.17 (1999)) were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum. Transfection of Phoenix-A cells was performed using the standard calcium phosphate method (Coligan, et al., Current Protocols in Immunology [supplement], 31:10.28.1-10.28.17 (1999)). Either  $4 \times 10^5$  cells in a 6-well plate or  $3 \times 10^6$  cells in a 100 mm tissue culture dish were seeded 16 hours before transfection. 3  $\mu$ g of DNA was used in the transfection for each well of a 6-well plate, and 10  $\mu$ g DNA was used for each 100 mm dish. Media was changed 8 hours after transfection. Cells were lysed in lysis buffer (1% NP-40, 20 mM Tris-HCl, pH 8.0, 150 mM NaCl) with protease inhibitors (Boehringer Mannheim) and analyzed 24 hours after transfection. Cell lysates were cleared by centrifugation (14,000 RPM x 10 min). For immunoprecipitation studies, cell lysates (2 x  $10^6$  cells /lane) were rotated with 2-3  $\mu$ g of desired antibodies and 20  $\mu$ l 50% slurry of protein A Sepharose (Pharmacia) for 1.5 hrs. Immune complexes were precipitated and the pellets washed three times with lysis buffer. Washed precipitates were subjected to SDS-PAGE analysis and Western blotting. Supersignal and Supersignal West Duro substrates (Piers) were used as detection systems for the Western blotting.

*In vitro kinase assays* - For the JNK *in vitro* kinase assay, Myc-JNK2 was co-transfected into Phoenix-A cells with Tnik mutants, Traf2 or MEKK as described above. 24 hours after transfection, cells were lysed with lysis buffer supplemented with 20 mM  $\beta$ -glycerophosphate, 1 mM NaF, 1 mM  $\text{Na}_3\text{VO}_4$ , and protease inhibitors. Myc-JNK2 was precipitated from clarified cell lysates with an anti-Myc mAb and the pellets were washed three times with lysis buffer and two times with kinase buffer (20 mM HEPES, pH 7.4, 10 mM  $\text{MnCl}_2$ , 10 mM  $\text{MgCl}_2$ , 20 mM  $\beta$ -glycerophosphate, 1 mM NaF, 1 mM  $\text{Na}_3\text{VO}_4$ , 0.5 mM DTT). For the kinase reactions, immunoprecipitates were incubated with 1  $\mu$ g glutathione S-transferase (GST) c-Jun (1-79) (Santa Cruz Biotechnology) in 20  $\mu$ l kinase buffer supplemented with 1  $\mu$ M PKI peptide (Sigma), 10  $\mu$ M ATP, 5  $\mu$ Ci  $\gamma\text{-P}^{32}$  ATP for 20 minutes at 30  $^\circ\text{C}$ . Kinase reactions were stopped by addition of 20  $\mu$ l 2 x SDS sample buffer (Norvex), heated at 95 $^\circ\text{C}$  for 5 minutes and then loaded onto SDS-PAGE. ERK and p38 *in vitro* kinase assays were conducted in a similar fashion. For ERK kinase assays, an anti-Myc mAb was used to immunoprecipitate Myc-ERK1 and Myelin Basic Protein (MBP, Sigma) was used as an exogenous substrate. For p38 kinase assays, an anti-FLAG mAb was used to immunoprecipitate FLAG-p38 and GST-ATF2 (Santa Cruz) was used as an exogenous substrate. For *in vitro* kinase assays on Tnik, 3  $\mu$ g wild type HA-Tnik or 3  $\mu$ g kinase mutant form of HA-Tnik was expressed in Phoenix-A cells and immunoprecipitated with an anti-HA antibody. Immune complexes were subjected to kinase assays as described above in the absence or presence of 0.5  $\mu$ g Gelsolin as an exogenous substrate.

*Fluorescent microscopy* – Phoenix-A cells seeded in 6-well plates were co-transfected with GFP and Tnik constructs as described above. 24 hours after transfection, cells were observed using a Nikon Eclipse TE 300 fluorescent microscope. For detection of apoptosis, Hoechst 33258 (sigma?) was added to transfected Phoenix-A cells (final concentration 5 µg/ml) and the cells were incubated for 30 min at 37°C before microscopic observation.

*Determination of actin distribution* –  $4 \times 10^5$  Phoenix-A cells in 6-well plate were transfected with 3 µg of control vector, HA-Tnik(WT) or HA-Tnik(KM). 24 hours after transfection, culture media were carefully removed. Cells were lysed directly on the plate using 250 µl Triton X-100 lysis buffer (1% Triton X-100, 150 mM NaCl, 20 mM Tris-HCl, pH 7.4) with protease inhibitors. Cell lysates were centrifuged at 14,000 RPM for 10 min. Supernatants represented the Triton X-100 soluble fraction. Pellets were washed once with 500 µl Triton X-100 lysis buffer and dissolved in 500 µl of 1 x SDS sample buffer. DNA was sheared by sonication. This represented the Triton X-100 insoluble fraction. Triton X-100 soluble and insoluble fractions derived from the same number of cells were resolved on SDS-PAGE and blotted with an anti-β-actin mAb to determine the content of F- and G-actin.

*Molecular cloning of Tnik* - Using a human brain cDNA library and a T/B cell library in our yeast two-hybrid pathway mapping effort, we identified a novel Germinal Center Kinase family member that interacted with both TRAF2 and NCK. The 5' end sequence was cloned from cDNAs prepared from human brain mRNA by RACE-PCR and full length cDNA clones of were obtained by RT-PCR. (Figure 1).

The longest Tnik clone was encoded by a polypeptide of 1360 amino acids. It had an N-terminal kinase domain, an intermediate domain and a C-terminal Germinal Center Kinase Homology (GCKH) region. It shared about 90% amino acid identity with a previously cloned GCK family member, NCK Interacting Kinase (NIK), in both the kinase domain and the GCKH domain (Su, et al., *EMBO J.*, 16:1279-1290 (1997)). However, Tnik was only 40% identical to NIK in the intermediate region (Figure 1, 3). Two shorter clones of Tnik were also obtained: one lacked nucleotides 1338-1424 (amino acids 447-475) and nucleotides 2383-2406 (amino acids 795-802), and the other lacked those two regions plus nucleotides 1609-1773 (aa 537-591) (Figure 3).

Primers encompassing these three alternatively spliced regions were designed and used for PCR from spleen, heart and brain cDNAs. The relative amounts of the different isoforms, seen as multiple bands amplified from both spleen and brain, varied among the different tissues (Figure 2). Amplified DNA fragments were cloned into a TA cloning vector and the inserts sequenced. All eight combinations from the alternative splicing of these three regions were identified. These eight spliced isoforms of Tnik were designated as Tnik<sub>1</sub> to Tnik<sub>8</sub> (Figure 3). Tnik<sub>1</sub> was used in all the experiments described herein.

To determine kinase activity, a putative kinase mutant form of Tnik, designated as Tnik(KM), was constructed with a conserved lysine (Lys-54) residue in the ATP binding pocket mutated to arginine. An HA epitope tag was inserted on the N-terminal portion of Tnik(WT) and Tnik(KM). Both proteins were transiently expressed in Phoenix-A cells, and the expressed proteins were subjected to immunoprecipitation and an *in vitro* kinase assay. A strong phosphorylated band at 150 kD was detected in the Tnik(WT) expressed lane, but not in the Tnik(KM) expressed lane (Figure 4, lanes 1, 2). Immunoblotting with an anti-HA antibody showed equal levels of expression of both Tnik(WT) and Tnik(KM) at 150 kD (Figure 4, lanes 3, 4). Therefore, the phosphorylated band in the *in vitro* kinase assay represented autophosphorylated Tnik, and the Tnik(KM) mutant was deficient in protein kinase activity.

*Tissue distribution of Tnik* - The expression pattern of the Tnik message was examined by human multi-tissue Northern blot. Since Tnik shared high homology with NIK, a probe corresponding to nucleotides 1264-2427 of Tnik was used to rule out any potential cross-hybridization. This region shared only 40% amino acid identity with NIK. Three major bands of sizes 6.5 kb, 7.5kb and 9.5 kb were detected (Figure 5). Alternative splicing in the coding region described above is unlikely to account for the size differences among the three messages, since the largest isoform is only 273 bps bigger than the smallest isoform. Alternative splicing in the untranslated region or alternative usage of polyA sites could be possible explanations. This phenomenon is not unique to Tnik. NIK and HGK also have multiple message sizes. Tnik is ubiquitously expressed, with higher levels of message detected in heart, brain and skeletal muscle. Interestingly, heart and skeletal muscle predominantly expressed the 6.5 kb form; placenta, kidney and pancreas predominantly expressed the 7.5 kb form; brain, lung and liver expressed all three forms at a similar level. It is currently unknown whether these messages have different functional roles.

*Interaction of Tnik with TRAF2 and NCK* - To confirm the interaction of Tnik with TRAF2, N-terminal HA-tagged Tnik was transiently expressed in Phoenix-A cells and HA-Tnik was immunoprecipitated by an anti-HA antibody. The immune complexes were resolved on SDS-PAGE and immunoblotted with an anti-TRAF2 antibody. Endogenous TRAF2 specifically co-immunoprecipitated with HA-Tnik (Figure 6, top panel). To map the interaction domain on Tnik that mediated its interaction with TRAF2, we constructed several truncated forms of HA-tagged Tnik (Figure 7) and co-expressed them with FLAG-tagged TRAF2. Anti-HA immunoprecipitates were then blotted with an anti-FLAG antibody to detect the co-immunoprecipitated FLAG-TRAF2. Tnik(WT), Tnik(N2), Tnik(C1) and Tnik(M) all co-immunoprecipitated with FLAG-TRAF2, suggesting that the intermediate domain of Tnik is sufficient for Tnik to interact with TRAF2 (Figure 8, top panel, lanes 1, 3, 4, 6). However, Tnik(C2) consistently showed weak interaction with TRAF2 (lane 5), suggesting that the GCKH domain was also involved in the interaction with TRAF2. Tnik(N1), the Tnik mutant with only the kinase domain, failed to interact with TRAF2 (lane 2). Expression levels of the transfected proteins were controlled by immunoblotting cell lysates with anti-HA and anti-FLAG antibodies

(Figure 8, middle and bottom panels). In addition, Tnik<sub>8</sub>, the shortest form of Tnik, was still able to interact with Traf2 (data not shown), suggesting that the three alternatively spliced exons were not required for Tnik to interact with Traf2.

We then mapped the domains on TRAF2 that mediated the interaction with Tnik. FLAG-tagged TRAF2 mutants (Figure 9) were co-expressed with HA-Tnik and the lysates were subjected to anti-HA immunoprecipitation. The immune complexes were then blotted with an anti-FLAG antibody. TRAF2(WT), TRAF2(87-501) and TRAF2(272-501) were all able to co-immunoprecipitate with HA-Tnik, while TRAF2(1-272) failed to interact with HA-Tnik (Figure 10, top panel). Immunoblotting cell lysates with anti-HA and anti-FLAG antibodies showed comparable expression levels of the transfected proteins (Figure 10, middle and bottom panels). This result suggested that the TRAF domain is required for TRAF2 to interact with Tnik. However, since the interaction of full-length TRAF2 with Tnik is stronger than that of either TRAF2(87-501) or TRAF2(272-501), the N-terminal ring finger may directly contribute to the interaction or may stabilize the configuration of the TRAF2 molecule to facilitate this interaction.

*Interaction of Tnik with NCK* - The interaction of Tnik with NCK was investigated in a similar fashion. Following transient expression of HA-Tnik in Phoenix-A cells, the cell lysates were immunoprecipitated with an anti-HA antibody and blotted with an anti-NCK antibody. Endogenous NCK specifically co-immunoprecipitated with HA-Tnik (Figure 11, top panel). To map the domains on Tnik required for this interaction, HA-tagged Tnik mutants were co-expressed with FLAG-tagged NCK and the HA-Tnik mutants were immunoprecipitated with an anti-HA antibody. The immune complexes were then blotted with an anti-FLAG antibody. Tnik(WT), Tnik(N2), Tnik(C1) and Tnik(M) were all able to associate with NCK, suggesting that the intermediate domain is also sufficient for Tnik to bind NCK (Figure 12, top panel, lanes 1, 3, 4, 6). Neither the GCKH domain nor the kinase domain showed any detectable binding to NCK (lanes 2, 5). Immunoblotting cell lysates with anti-HA and anti-FLAG antibodies showed equivalent levels of expression of the transfected preteins (Figure 12, middle and bottom panels).

*Activation of JNK2 by Tnik* - We further examined whether Tnik was able to activate the JNK pathway. 1 µg, 2 µg or 3 µg of Tnik expression plasmid was co-transfected into Phoenix-A cells with Myc-JNK2. 24 hours after transfection, Myc-JNK2 was immunoprecipitated from cell lysates and its kinase activity measured using GST-cJun(1-79) as a substrate. Co-transfection of Tnik enhanced JNK2 kinase activity in a dose dependent fashion (Figure 13, top panel, lanes 1, 3-5). When 3 µg of Tnik was transfected, JNK2 activity was enhanced 3-4 fold. A similar magnitude of JNK2 activation was observed when cells were treated for 15 minutes with 100 ng/ml of TNF (lanes 1, 2 and 5). Also consistent with published result (Natoli, et al., *Science*, 275:200-203 (1997)), TRAF2 potentially activated JNK2 activity (lane 6). The expression levels of Myc-JNK2 were controlled by immunoblotting cell lysates with an anti-Myc antibody (Figure 13, bottom panel).

To determine whether Tnik can also activate the ERK and p38 pathways, Myc-ERK1 and FLAG-p38 were co-transfected into Phoenix-A cells with different doses of Tnik. The transfected kinases were then immunoprecipitated from cell lysates and the kinase activities measured using MBP and GST-ATF2 as exogenous substrates. In contrast to JNK2, neither ERK1 nor p38 was activated by Tnik overexpression, while co-transfection of MEKK1 potentially activated both kinases (Figure 14, 15). In addition, Tnik did not activate NF- $\kappa$ B (data not shown).

To further investigate the mechanism of this activation, the cohort of Tnik mutants were co-transfected into Phoenix-A cells with Myc-JNK2 and the ability of these mutants to up-regulate JNK2 kinase activity was examined by the *in vitro* kinase assay. Tnik(WT), Tnik(KM), Tnik(C1) and Tnik(C2) were all able to activate Myc-JNK2, while Tnik(N1), Tnik(N2), Tnik(M) were not (Figure 16). This result suggested that the C-terminal GCKH region is both necessary and sufficient for activation of the JNK pathway, while the kinase domain is dispensable.

*Regulation of the cytoskeleton by Tnik* - When Tnik was overexpressed in Phoenix-A cells, the cells showed a striking morphological change. In control GFP transfected cells, more than 80% of GFP positive cells were adherent and well-spread (Figure 6A, top row, left panel). In contrast, in Tnik and GFP co-transfected cells, more than 80% of GFP positive cells showed inhibited cell spreading. These cells rounded up and lost attachment to the plate (Figure 6A, top row, right panel). Similar morphologic change was also observed in Hela and NIH-3T3 cells transfected with Tnik(data not shown). We then transfected the cohort of Tnik mutants into Phoenix-A cells to determine which domain of Tnik was involved in inducing the morphologic change. Tnik(KM), Tnik(C1) and Tnik(C2), which lacked the kinase activity, failed to induce the morphologic change (left column, middle and bottom panels and data not shown), while Tnik(N1) and Tnik(N2) were both competent in inducing the inhibition of cell spreading (Figure 6A, right column, middle panel and data not shown). Therefore, the kinase domain, rather than the GCKH domain required for JNK activation, was both necessary and sufficient for Tnik to regulate cell spreading. This result suggested that the JNK pathway was not involved in this regulation. Consistent with this hypothesis, overexpression of Myc-JNK failed to inhibit cell spreading (Figure 6A, right column, bottom panel). Since JNK has been implicated in inducing apoptosis in some cells (Basu, et al., *Oncogene*, 17:3277-3285 (1998)), we examined whether cells transfected with Tnik were undergoing apoptosis. Nuclei of phoenix-A cells transfected with control vector, Tnik(WT), Tnik(KM) or RIP were stained with Hoechst 33258(Figure 6B). No apoptotic body was observed in vector, Tnik(WT) or Tnik(KM) transfected cells, while apoptotic bodies were readily detected in greater than 60% of cells transfected with a control RIP cDNA(Figure 6B). In addition, no activation of caspases was observed in Tnik transfected cells (data not shown). Taken together, these results suggested that Tnik did not induce apoptosis in transfected phoenix-A cells.

These observations raised the possibility that overexpression of Tnik might have disrupted



intracellular F-actin structure. We therefore examined actin distribution in the Triton X-100 soluble (G-actin) and insoluble (F-actin) fractions in control vector, Tnik and Tnik(KM) transfected Phoenix-A cells. Overexpression of wild type Tnik, but not Tnik(KM), resulted in the enhanced distribution of actin in Triton X-100 soluble fraction, consistent with the reduced spreading observed in these cells (Figure 6C). We hypothesized that overexpression of Tnik may lead to phosphorylation of cytoskeletal components. Recently, a GCK family protein kinase that could phosphorylate the actin-fragmenting protein Severin was purified and cloned from *Dictyostelium* (Eichinger, et al., J. Biol. Chem., 273:12952-12959 (1998)). We therefore decided to test whether Tnik was able to phosphorylate the mammalian Severin homologue, Gelsolin (Yin, et al., Nature, 281:583-586 (1979)). Tnik and Tnik(KM) were expressed in Phoenix-A cells, immunoprecipitated and incubated in an *in vitro* kinase assay with purified Gelsolin. Wild type Tnik, but not the kinase mutant form of Tnik, phosphorylated Gelsolin *in vitro* (Figure 6D).

Unlike any other GCK family members, both the kinase mutant form of Tnik and the GCKH domain of Tnik were as effective as the wild type protein in JNK2 activation, and the kinase domain alone of Tnik was virtually ineffective (Figure 16). This result suggested that the C-terminal GCKH domain was solely responsible for the activation. This is in contrast to other GCK family kinases, which activate the JNK pathway either using the kinase domain alone, as is seen with GCKR, HGK and HPK1, or using the kinase domain plus the GCKH region, which is seen with GCK, GLK and NIK (Pombo, et al., Nature, 377:750-754 (1995); Shi, et al., J. Biol. Chem., 272:32102-32107 (1997); Kiefer, et al., EMBO J., 15:7013-7025 (1996); Diener, et al., Proc. Natl. Acad. Sci. USA, 94:9687-9692 (1997); Yao, et al., J. Biol. Chem., 274:2118-2125 (1999); Su, et al., EMBO J., 16:1279-1290 (1997)). The GCKH domain of NIK interacted with MEKK1, and the dominant negative mutant of MEKK1 inhibited NIK induced JNK activation (Su, et al., EMBO J., 16:1279-1290 (1997)). Given the high level of sequence identity between the GCKH of NIK and the GCKH of Tnik, Tnik likely activated the JNK pathway through MEKK1.

NIK was cloned by its ability to interact with the adapter protein NCK. It associated with NCK SH3 domains via two PxxPxR sequences in the intermediate domain, PCPPSR (aa 574-579) and PRVPVR (aa 611-616). Both sequences were required for efficient interaction (Su, et al., EMBO J., 16:1279-1290 (1997)). Similar to NIK, Tnik also interacted with NCK via the intermediate domain. However, PCPPSR is not conserved in Tnik. Instead, Tnik contained two other PxxPxR sequences, PNLPPR (aa 562-567) and PPLPTR (aa 647-652), in addition to the conserved PKVPQR (aa 670-675). Tnik likely interacted with NCK through the cooperative interaction with these three PxxPxR sequences. NCK is an adapter protein involved in many growth factor receptor mediated signal transduction pathways (McCarthy, Bioessays, 20:913-921 (1998)). It has been proposed that the NIK-NCK interaction may recruit NIK to receptor or non-receptor tyrosine kinases to regulate MEKK1 (Su, et al., EMBO J., 16:1279-1290 (1997)). Tnik may be recruited in a similar fashion.

Tnik also interacts via its intermediate domain with the TRAF domain of TRAF2. Both GCK and GCKR have been previously reported to interact with TRAF2 and it has been suggested that they mediate TRAF2 induced JNK activation (Pombo, et al., Nature, 377:750-754 (1995); Diener, et al., Proc. Natl. Acad. Sci. USA, 94:9687-9692 (1997); Yuasa, et al., J. Biol. Chem., 273:22681-22692 (1998)). More recently, a *Drosophila* GCK family member, Misshapen (Msn), has been reported to interact with D-TRAF1 and mediate D-TRAF1 induced JNK activation (Liu, et al., Curr. Biol., 9:101-104 (1998)). Msn has highest homology to NIK and Tnik. Similar to NIK and Tnik, Msn also interacted with Dock, the *Drosophila* homologue of NCK (Liu, et al., Curr. Biol., 9:101-104 (1998)). In *Drosophila*, deficiency in Dock results in defective photoreceptor guidance (Garrity, et al., Cell, 85:639-650 (1996)), and in mammalian cells, NCK interacts with WASP, a CDC42 effector protein involved in the regulation of cytoskeleton (Symons, et al., Cell, 84:723-734 (1996); Rivero-Lezcano, et al., Mol. Cell Biol., 15:5725-5731 (1995)). These findings strongly suggest that the NCK pathway is closely linked to the cytoskeletal changes. Consistently, Msn deficiency leads to defective dorsal closure that requires extensive cell migration and cell shape changes in addition to the activation of the JNK pathway (Treisman, et al., Gene, 186:119-125 (1997)). Interaction of Msn with Dock may regulate these cell shape changes. Tnik may participate in the regulation of a similar pathway in mammalian cells.

Supporting this hypothesis, overexpression of Tnik inhibited cell spreading in Phoenix-A cells, NIH-3T3 cells and Hela cells (Figure 6 and data not shown). This effect is likely due to the disruption of filamentous actin structure. No F-actin fiber could be detected by staining with TRITC-Phalloidin of NIH-3T3 cells transfected with a GFP-Tnik fusion protein, while F-actin fibers were abundant in cells transfected with GFP alone (data not shown). Consistent with this notion, overexpression of Tnik resulted in a decreased proportion of actin in the Triton X-100 insoluble fraction (Figure 19). The Triton X-100 insoluble fraction contains the filamentous actin pool, while the Triton X-100 soluble fraction contains the globular actin monomers. This is the first evidence that a mammalian GCK family member exerts an effect on cytoskeletal organization. A *Dictyostelium* GCK member was recently cloned that can phosphorylate the *Dictyostelium* actin fragmenting protein, Severin, *in vitro* (Eichinger, et al., J. Biol. Chem., 273:12952-12959 (1998)). Interestingly, Tnik can phosphorylate the mammalian Severin homologue, Gelsolin, *in vitro* (Figure 20). Gelsolin is also an F-actin fragmenting and capping enzyme that can reduce the content of F-actin. This result suggests that Tnik regulates F-actin assembly through Gelsolin or other related actin severing enzymes. This is consistent with the result that the kinase domain of Tnik is responsible for the regulation of cell spreading (Figure 17). The mammalian p21-activated kinase, PAK1, which is distantly related to GCK family members and an effector protein of small G proteins Rac1 and CDC42, has been reported to regulate actin cytoskeleton organization. One proposed mechanism of the regulation is through phosphorylation and inhibition of the Myosin Light Chain Kinase (Sanders, et al., Science, 283:2083-2085 (1999)). Overexpression of a constitutively active form of

PAK1 also resulted in the inhibition of cell spreading (Garrity, et al., Cell, 85:639-650 (1996)), an effect similar to that caused by overexpression of Tnik (Figure 17 and 18).

## CLAIMS

We claim:

1. A recombinant nucleic acid encoding a cell cycle protein comprising a nucleic acid that hybridizes under high stringency conditions to a sequence complementary to that set forth in Figure 21, 22, 23, 24, 25, 26, 27 or 28.
2. The recombinant nucleic acid of claim 1 wherein said protein binds to at least one of Traf2 and Nck.
3. The recombinant nucleic acid of claim 1 comprising a nucleic acid sequence as set forth in Figure 21, 22, 23, 24, 25, 26, 27 or 28.
4. A recombinant nucleic acid encoding a cell cycle protein comprising a nucleic acid having at least 90% sequence identity to a N-terminal kinase domain or C-terminal germinal center kinase homology region, and greater than 45% sequence identity to an intermediate region sequence as set forth in Figure 21, 22, 23, 24, 25, 26, 27 or 28.
5. A recombinant nucleic acid encoding an amino acid sequence as shown in Figure 1 for Tnik or Figure 29, 30, 31, 32, 33, 34 or 35.
6. An expression vector comprising the recombinant nucleic acid according to any one of claims 1, 2, 3, 4, or 5, operably linked to regulatory sequences recognized by a host cell transformed with the nucleic acid.
7. A host cell comprising the recombinant nucleic acid according to any one of claims 1, 2, 3, 4, or 5.
8. A host cell comprising the vector of claim 6.
9. A process for producing a cell cycle protein comprising culturing the host cell of claim 7 or 8 under conditions suitable for expression of a cell cycle protein.

10. A process according to claim 9 further comprising recovering said cell cycle protein.
11. A recombinant cell cycle protein encoded by the nucleic acid of any of claims 1, 2, 3, 4, or 5.
12. A recombinant polypeptide comprising an amino acid sequence having at least 90% sequence identity to a N-terminal kinase domain or C-terminal germinal center kinase homology region, and greater than 45% sequence identity to an intermediate region sequence as set forth in Figure 21, 22, 23, 24, 25, 26, 27 or 28.
13. The recombinant polypeptide of claim 12 wherein said polypeptide binds to at least one of Traf2 and Nck.
14. The recombinant polypeptide of claim 12 wherein said sequence is set forth in Figure 1 for Tnk1 or Figure 29, 30, 31, 32, 33, 34 or 35.
15. An isolated polypeptide which specifically binds to a cell cycle protein according to claim 13.
16. A polypeptide according to claim 15 that is an antibody.
17. A polypeptide according to claim 16 wherein said antibody is a monoclonal antibody.
18. The monoclonal antibody of claim 17 wherein said antibody reduces or eliminates the biological function of said cell cycle protein.
19. A method for screening for a bioactive agent capable of binding to a cell cycle protein, said method comprising:
- a) combining a cell cycle protein and a candidate bioactive agent; and
  - b) determining the binding of said candidate bioactive agent to said cell cycle protein.
20. A method for screening for a bioactive agent capable of interfering with the binding of a cell cycle protein and a Traf2 or Nck protein, said method comprising:

- a) combining a cell cycle protein, a candidate bioactive agent and a Traf2 or Nck protein;  
and
- b) determining the binding of said cell cycle protein and said Traf2 or Nck protein.

5      21.      A method according to Claim 20, wherein said cell cycle protein and said Traf2 or Nck protein are combined first.

22.      A method for screening for a bioactive agent capable of modulating the activity of cell cycle protein, said method comprising:

- a) adding a candidate bioactive agent to a cell comprising a recombinant nucleic acid encoding a cell cycle protein; and
- 10      b) determining the effect of said candidate bioactive agent on said cell.

23.      A method according to Claim 22, wherein a library of candidate bioactive agents is added to a plurality of cells comprising a recombinant nucleic acid encoding a cell cycle protein.


#### Abstract of the Disclosure

- 5 The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.







**FIGURE 2**




**FIGURE 3**




**FIGURE 4**

# FIGURE 2



# FIGURE 3




# FIGURE 4


09815455-082400





# FIGURE 6



# FIGURE 7




# FIGURE 9




## FIGURE 10

# FIGURE 11




# FIGURE 12


B.




# FIGURE 13




# FIGURE 15



B.



D.



# FIGURE 14

# FIGURE 16

09545455.082400

A.

Vector



TNIK



TNIK(KM)



TNIK(N1)



TNIK(C1)



JNK2




FIGURE 17.



**FIGURE 18**


**Vector**



**TNIK(WT)**




**TNIK(KM)**



**RIP**



# FIGURE 19



# FIGURE 20

D.




Figure 21

ATGGCGAGCGACTCCCGGCTCGAAGCCTGGATGAAATAGATCTCTCGGCTCTGAGGGACCCCTGCAGGGATCTTT  
GAATTGGTGGAACTTTGTTGGAAATGGAACATACGGGCAAGTTTATAAGGGTCGTGTCATGTCAAAACGGGGCAGCTT  
CGAGCCATCAAGGTTATTGGATGTCTCAGGGGATGAAGAGGAAGAAATCAAAACAAGAAATTAACATGTTTGAAGAAA  
TATTCTCATCACCGGGAATTATTGCTACATATGTTGCTTTTATCAAAAAGAACCCACAGGCATGGATGACCCAA  
CTTTGGTTGGTGTGGAGTTTGTGGTGTGGCTCTGTCAACGACCTGATCAAGAACCAAAAGGTGAACGCTTG  
AAAGAGGAGTGGATTGCATACATCTGCAGGGAATCTTACGGGGCTGAGTCACCTGCACAGCATAAAGTGATT  
CATCGAGATTATAAAGGGCAAAATGTCTTGCTGACTGAAAATGCAGAAGTTAAACTAGTGGACTTTGGAGTCAGT  
GCTCAGCTTGATCGAACAGTGGGCGAGGAGGAATCTTTCATTGGAACTCCCTACTGGATGGCACAGAAGTTATT  
GCCTGTGATGAAAACAGGATGCCATATGATTTCAGAAGTGACTTGTGGTCTTTGGGTATTCCACGCCATTGAA  
ATGCGAGAAGGTGCTCCCCCTCTCTGTGACATGCACCCCATGAGAGCTCTCTCTCATCCCGGCAAGTCCAGCG  
CCTCGGCTGAAGTCTAAGAAGTGGTCAAAAAAATCCAGTCATTATTAGAGAGCTGCTGGTAAAGRATCAACAGC  
CAGCGACCGACAGAACAGAACATTTGATGAAGCATCCATTATACAGAGACCAACTAATGAGCGACAGGTCGCAT  
CAACTCAAGGACCATATTGATGAACAAAAGAAAGCGAGGAGAAAAGATGAGACAGAGTATGAGTACAGTGGGA  
ATGAGGGAAGAAGAGGAGGAGAGATGACTCAGGAGAGCCAGCTCCATCTCTGAATCTGCCAGGGGAGTCGACGCTG  
CGAGAGGACTTTCTGAGGCTCGAGCTGGCCAAACAAGGAGCGTTCTGAGGCCCTACGAGGCGACAGCTGGAGCAG  
CAGCAGCGGAGAATGAGGAGCAACAAGCGGCAGCTGTGCGCGAGCGTCAGAGAAGCGCATGAGGAGCAGAAAGAG  
CAGAGGCGGCGCTGGAGGAGCAACAAGGCGAGAGAAGGAGCTGCGGAAGCAGCAGGAGGAGGAGCGCGCGG  
CACTATGAGGAGCAGATGCGCGGGAGGAGGAGGAGGCGGTGCGGAGCATGAACAGGAATACATTCAGGCGACAG  
TTAGAGGAGGAGCAGAGACAGTATTAGAGATCTTGACAGCAGCAGCTACTGTCATGAACAGGCTCTACTTTGGAATAT  
AAGCGCAAAACATTTGGAAGAACAGAGCAAGCAGAAAGACTTGACAGGCGAGCTTAAAGCAAGAAGAGACTACTTA  
GTCTTCCTTCAGCATCAGCGGCAGGAGCAGAGGCGCTGTGGAGAAAGAGCCACTGTACCATTAACAAGAGGAATG  
AGTCCCTAGTGAAGCAGATGAGGCGCAGGAGGTAGAAGAAGCGTCAAGGCTCAACCGGCAAGTTCCCTCGCC  
ATGCCCTACAAGGTTGCCAAACAGGATATCTGACCCCAACCTGCCCCAAGGTCGGAGTCTCAGCATATTAGTGA  
GTTGAGCCTGTGCAACACCCCCCATGCTCAGACCAAGTCGATCCCCAGATCCACATCTGTAGCTGTAAATCC  
CAGGACCTGTGCTTACCGGCTCCAGTCAGTCGACGAGCAGCCCAAGGGCCCTCTCGGTTTCAGGAGGCT  
CTGAAGCTGACCTCCCAACCGCTGGAGATGCCACGCCAGACTCAGATCCCCACTTCGGAATAATCTCTCTCCCC  
ATCGCATTTGAAAAGTTTTCGCGAAGCTCTTGGTTACGACAGGAAGAAGCATTCACCAAGGCTGCTCTCAAGAA  
ACAATCTTATATCCCAAGCATTAACCGAGAAAGAAATTTCTCTGGGAATGGTAGTGTCTTGGGACCCAGCATAGGA  
TCTCAACCCATCAGAGCAAGCAACCTGATCTCCGAGAACTGAGCCCATCTTGGAGAGGCCCTTGCAGAGGACC  
AGCAGTGGCAGTTCTCTCGAGCTCCAGCACCCCTAGCTCCAGGCCAGCTCCCAAGGAGGCTCCAGGCTGGATCA  
CAAGCAGGATCCAGTGAACGCACAGAGGTTGAGCGCAACAGTAAGTCAGAAGGATGAGCTGTGCTTCCCCATGAG  
CCTGCCAAGGTGAACACAGAAAGATCCAGGGACATTACCOCGCCAGTCGACGATAGCTACAACAAAAGCTATA  
GTAGGAGTCTGACGGCATTAGCCAAAGAACTAAGAGAACTCCGATTTGAAGAAACAACCGCCCAATGAAGAAG  
GATGATGATTACTCTCTCTCCAGTGAAGGATCAGAAAGTAGCGAGGAAGAGGAGGAGGAGAGCGAGCAC  
CATGATGGGACAGTGGCTGTGTCAGCGACATACCCAGACTGATACCAACAGGAGGCTCCAGGACGACAGCAGCATC  
AATGTGGGAATGGTGGGAGCGCATGGGCTGGAGACTCTTCATCGGACAGTTTCAGCGGCAAGTTTCAGGAGAA  
GGAACCTTGATGATTAGAGAGAGCTGAGAGAGAAGAAGCATCTGGCCACAGTGACAGCAATGGCTTTGTCTGGC  
CACATCAACCTCCCTGACCTGGTGGCAGCAGAGCCATTCTCCAGCTGGAAACCCGACTGAGGAGCTGGGGCGGCTC  
TCAACCCATTCCAGGAGATGGACTCTGGGACTGAATATGGCATGGGAGCAGCACCAAGGCTCTCTCACCCCC  
TTTTTGGACCCCAAGATATCCAGGACGCTCTCCCATGTGAAGATGAAGAGGATGAGGAATCATCAGCCGAGCT  
CTGTTTACTAGCAAGTCTTAGGCGAAGAAGGCCAACTCAATGAAGCAGAAAGATTTCGGTGGTAATGTGA  
AACCCAAACCAATCTCGGCTCATAGCGACACACAGAAATCAGAAATACAAGAAACGATTCACTCAGAAATA  
CTTTGTGCACTCTGTGGGGTGTAAACCTTTGTGGTGGGACTGAAAATGGCTGTATGCTTTTGGACCGAAGTGGG  
CAGGCGAAAGTCTATAAGTCTGATCAACCGAGGCGGATTTACAGAGATGGATGTGTCAGAGGACTGAATGTCTCT  
GTGACAAATTTCAAGAAAGAAGATAAGCTACGATTTACTATCTTTCATGGTTAAGAAACAGATACTACATATAT  
GACCCAGAAGTGAAGAAAGAACAGGCTGGATCTACTGTTGGGACTTGAAGCTGTATACATATTATAAGTTGTT  
AAATATGAAGGATCAAAATTTTGTGGATTGCTTAAAGAAATGCTGTGGAATAATATGCTTGGGCTCTAAACCG  
TATCATAAATTCATGGCATTTAAGCTTTTGCAGATCTCCAGCAACAGGCTCTGCTAGTTGATCTACGGTAGAA  
GAAGGTCAAAGATTAAAGGTTATTTTGGTTCAACACTGGTTTCCATGTGAATGTAGTGTGATTCAGGAAACTCT  
TATGATATCTACATACCATCTCATATTCAGGGCAATATCACTCCTCATGCTATTGTCTATCTGGCTTAAACAGAT  
GGAATGGAATGCTGTTTGTCTATGAGGATGAGGGGTTGATGTAAACCACTATGGCCGAGTAACATAGGATGTG  
GTGCTTCAATGGGAGAAATCCGCCAGCTCTGTGGCTCATCATTCCTCAATCAGATATGGGCTCGAGGCGAGAA  
GCTATTAGATCTCGGTGAGTGGAAACAGGACATTTGGATGGAGTTTATGCTAAGAGGCTCAAGGTTAAAG  
TTTCTATGTGAAGAAATGATAAGGTATTTTGTGATCCGTGCGATCTGAGGAGAGTAGCCAGGTGTTTTTCATG  
ACCTCAACAGAAATTCATGATGAACCTGGTAA

Figure 22

ATGGCGAGCGACTCCCGGCTCGAAGCCTGGATGAAATAGATCTCTCGGCTCTGAGGGGACCCCTGCAGGGATCTTT  
GAATTGGTGGAACTTGTGGAAATGGAACTACGGGCAAGTTTATAAGGTCGTGATGTCATAAAGCGGGCCAGCTT  
GCAGCCATCAAGGTTATGGATGTCTACAGGGGATGAGAGGAGAAATCAAAACAGAAATTAACATGTTTGAAGAAA  
TATTTCTCATCCCGGAATATTGCTACATCTATGTGTCTTTTATCAAAAAGAACCCACCGAGCATGGATGACCAA  
CTTTGGTGTGGTATGGAGTTTGTGGTGTGGCTCTGTACCGACCTGATCAAGAAACAAGAAAGTTAAACAGTTG  
AAGAGGAGTGGATTGATACATCTGACAGGAAATCTTACGGGGCTGAGTCACCTGCACACAGCATAAAGTGATT  
CTCAGATATTTAAAGGGCAAAATGTCTGTGACTGAAAATGCAGAAATTAACATAGTGGACTTTGGAGTCAGT  
GCTCGACTGTATCGAAACAGTGGGCGAGGAAATCTTTTATGGAACTCCCTCATCTGGATGGCCACCAAGTTATT  
GCCTGTGATGAAAACCCAGATGCCACATATGATTTCAAGAGTGACTTTGTGTCTTTGGGTATCACCGCCATTGAA  
ATGGCAGAAGGTGCTCCCCCTCTCTGTGACATGCACCCCATGAGAGCTCTCTTCTCATCCCCCGGAATCCAGCG  
CCTCGCTGAAGTCTAAGAAGTGGTCAAAAATTCAGTCAATTTATTGAGAGCTGCTTGGTAAAGAAATCACAGC  
CAGCGACCGCAACAGAACATTTGATGAAGCATCCATTATACGAGACCAACCTAATGAGCGACAGGTCCGCATT  
CAACTCAAGGACCATATTGATAGAACAAAGAAAGCGAGGAGAAAAGATGAGACAGATGATGATACAGTGGAA  
AGTGAGGAAGAAGAGGAGGAGAATGACTCAGGAGAGCCAGCTCCATCTGAATCTGCCAGGGGAGTCGACGCTG  
CGGAGGGACTTTCTGAGGCTGCAGCTGGCCCAACAGGAGCGTTCTGAGGCCCTACGAGGCGAGCTGGAGCAG  
CAGCAGCGGAGAAATGAGGAGCACAAGCGGCAGCTGTGGCCGAGCGTCAAGCGCATCGAGGAGCAGAAAGAG  
CAGAGCGCGCGCTGGAGGAGCAACAAAGGCGAGAGAGGAGCTCGGGAAGCAGCAGGAGAGGGGAGCAGCGCGG  
CATATTGAGGAGCAGATGCGCCGGGAGGAGGAGGAGGCGTGCAGGACATGAACAGGAATTAAGCGCAACAA  
TTGGAAGACAGAGCAACAGCAAGAGACTGCAGAGCAGCTTAAGCAAGAAAGAGACTACTAGTTTCCCTTCAG  
CATCAGCGCAGGAGCGAGGCCCTGTGGAGAAGGCCACTGTACCATTAAGAAAGGAATGAGTCTCATGTAGGAG  
AAGCCAGCATGGGCCAAGGAGGTAGAAGAACGCTCAAGGCTCAACCGGCAAGTTCCCTGCCATGCTCACAGAG  
GTGGCCAAACAGGATATCTGACCCCACTGCCCCAGGTCGGAGTCTTTCAGCATATTAGTGGAGTTTCAGCTGCT  
CGAACCCCCCATCTGCAGACCATGATCCCCAGATCCCCACTCTGGTAGCTGTAAGATCCCCAGGACCTGCCC  
TTGACCGCTCCCGCTCAGTGCACAGCAGCCCAAGAGGCGCTCTCTGGGTTTCAGGAGCTCTGAACGTCAGCC  
TCCCAACCGGTGGAGATGCCAGCGCAGAACTCAGATCCCACTCGGAAATCTCTCTCCCTCAGCTGGAATGAA  
AAGTTTGAACCGAGCTCTGGTTATCAGCAGGAAGAAGACTCCACCAAGGTGCTCAAGAAACAACTCTCTATA  
TCCCCAGCATTAGCCAGAAAGAAATCTCTGGGAATGGTAGTGTCTGGGACCCAGATGAGTCTCAACCCATC  
AGAGCAAGCAACCTGATCTTCGGAGAACTGAGCCCATCTTGGAGAGCCCCCTGCAGAGGACCGAGCTGGCAGT  
TCTCTCAGCTCCAGCACCCCTAGCTCCAGCCGACGCTCCCAAGGAGGCTCCAGCCTGGATCAACAGCAGGATCC  
AGTGAACGCCACAGAGTTTCAGGCCAAGTAACTGAGAAGGATCACTGTGCTTCCCCATGAGCTGCCAAGGTG  
AAACCAGAAAGATCCAGGACATTACCCGCGCCAGTCGACCACTAGCTACAAAAGAGTATAGATGAGGATCTG  
ACGGCATTTAGCCAAAGAACTAAGAGAACTCCGGATTGAAGAAACAAACCGCCATGAAGAAGGTGACTGATTAC  
TCTCTCTCAGTGAGGAGTCAAGAGTAGCGAGGAAGAGGAGGAAGATGGAGAGAGCAGAGCCCATGATGGGACA  
GTGGCTGTACAGCAGATACCCAGACTGATACCAACAGGAGCTCCAGGCGACACGAGCAGTACAATTTGGGAATG  
GTGGGGCTCAGCTGGGCTGGAGCCTCTCATGCGGACAGTTTCAGCGGCGATTTTCAAGAGAAGAACTTTGATG  
ATTAGAGAGAGCTGTGGAGAGAAGAAGCGATCTGGCCACAGCTGACAGCAATGGCTTTGGTGGCCATCAACCTC  
CTGACCTGGTGCAGAGAGCCATTCTCAGCTGGAACCCGACTGAGGAGTGGGGCGGTCTCAACCCATTCC  
CAGGAGATGAGACTCTGGGAGTGAATGGCATGGGAGCAGCACCAGGCTCTCTCACCCCTTTTGGTGGAGCC  
AGAGTATACAGAGCTCTCCACTGATGAAGATGAAGAGGATGAGGAATCACTACGCGCGAGTCTGTTTACTAGC  
GAAGTCTTATAGGCAAGAACAGGCCAACTCAATGAAGCAAGAAAGATTTCCGTGGTAAATGTAACCCCAACCAAC  
ATTCGGGCTCATAGCGACACACAGAAATCAGAAAATCAAGAAACGATTTCAACTCAGAAATCTTTGTCAGCT  
CTGTGGGTGTAAACCTTTCTGGTGGGAGCTGAAATGGCTGATTTTGAACCAAGATGGGCAAGGCAAGATC  
TATAATCTGATCAACCGGAGGCGATTTCAGCAGATGGATGTCTAGAGGGAGCTGAATGTCTCTGTGCAAAATTTCA  
GGAAGAGAAATAAAGTCAAGGTTTACTATTCTTCTATGGTTAAGAAACAGAACTACATATGACCCAGAAAGTA  
GAAAGAAACCAAGGCTGATCTGTTGGGGACTTGGAAAGCTGTATACATTTATAAGTTGTTTAAATATGAAGG  
ATCAAAATTTTGGTGTATGCTTAAAGAAATGCTGTGGAATATATGCTTGGGCTCTTAAACCGTATCATAAATTC  
ATGGCATTTAAAGCTTTTTCAGATCTCCAGCACAGCCCTCTGATGTTGATCTACCGGTAGAGAAAGGTCAAGA  
TTAAAGGTTATTTTGGTTTCAACACTGGTTTCCATGTAATTTGATGTTGATTCAGGAAATCTTTATGATATCTAC  
ATACACTCATATATCAGGCGCAATATCACTCTCATGCTATTGTCACTCTGCTTAAACACAGATGGAATGGAATG  
CTGTTTGGTATGAGGATGAGGGGGTGTATGTAACACCTATGGCCGCGTAACCTAGGAGGTGGGTGCTTCAAGTGG  
GGAGAAATGCCACGCTGTGGGCTCACTTCACTTCAATCAGATTAATGGGCTGGGCGAGAAAGCTATTGGAATG  
CGGTGAGTGAACAGGACATTTGGATGGAGTATTTATGCTAAGCGAGCTCAAGGTTAAAGTTTCTATGTGAA  
AGAAATGATAGGTATTTTTCATCCGTGCGATCTGGAGGAAGTAGCCAGGTGTTTTTCATGACCTCAACAGA  
AATCCATGATGAACCTGTTAA

Figure 23

ATGGCGAGCGACTCCCCGGCTCGAAGCTGGATGAAATAGATCTCTCGGCTCTGAGGGACCCCTGCAGGGATCTTT  
GAATTGGTGGAACTTGGTTGGAATGGAAACATACGGGCAAGTTTATAAGGGTCGTCACTGTCAAACGGGCGAGCTT  
GCAGCCATCAAGGTTATGGATGTACACAGGGGATGAAGAGGAAGAAATCAACACGAATAATTACATGTTTGAAGAAA  
TATTCTCATACCCGGAATATTGTCATACATACTATGGTGGCTTTTATCAAAAAGAACCCACCGCATGGATGACCAA  
CTTTGGTGGTGGATGGATTTTGGTGGTCTGGCTCTGTACCGACCTGATCAAGAACACAAAAGGTAACACGTTG  
AAAGAGGAGTGGATTGCATACATCTGCAGGGGAATCTTACGGGGGCTGAGTCACCTGCACAGCATAAAGTGATT  
CATCGAGATTTAAAGGGCAAAATGTCTTGTGACTGAAAATGCAGAAAGTTAAACTAGTGGACTTTGGAGTCACT  
GCTCAGCTTGATGCAGACGTGGCGAGGAGGAATACTTTCAITGGAACTCCCTCATCTGGATGGCACAGGAAGTTT  
GCCTGTGATGAAAACCCAGATGCCACATATGATTTCAAGAGTGACTTGTGGTCTTTGGGTATCACCGCCATTGAA  
ATGGCAGAAGGTGCTCCCCCTCTCTGTGACATGCACCCCATGAGAGCTCTCTTCTCATCCCCGGAAATCCAGCG  
CCTCGGCTGAAGTCTAAGAAGTGGTCAAAAAAATCCAGTCATTATTAGAGAGCTGCTTGGTAAAGAAATCACAGC  
CAGCGACCGACACAGAACAAATGATGAAGCATCCATTATACGAGACCAACCTAATGAGCGACAGGTCGCGCATT  
CAACTCAAGGACCATATTGTATGAACAAAGAAAGACGAGGAGAAAAAGATGAGACAGATATGATACAGTGGAA  
AGTGAGGAAGAAAGAGGAGGAGAAATGACTCAGGAGAGCCAGCTCCATCCTGAATCTGCCAGGGGAGTCGACGCTG  
CGGAGGGGACTTTCTGAGGCTGCAGCTGGCCAAACAGGAGCGTTCTGAGGCCCTACGAGGCGAGCAGCTGGAGCAG  
CAGCAGCGGGAGAAATGAGGAGACACAGCGGCGAGCTGCTGCCGAGCTCAGAGAGCCGATCGAGGAGCAGAAAGAG  
CAGAGGCGCGCGCTGGAGGAGCAACAAGGCGAGAGAAGGAGCTGCGGAGACAGCAGGAGAGGGAGCAGCGCCGAG  
CACTATGAGGCGCAGATCGCGCGGGAGGAGGAGGAGCGTGCAGGACATGAACAGGAATACTCAGGCGCAGC  
TAGCGAGGAGGAGCAGACAGTATAGAGATCTTGACGACGAGCTACTGCTATGAACAGCTCTACTTTCTGGAATAT  
AAGCGCAACAATTTGAAGAACAACGACACAAGCAGAAAGACTGCAGAGGCACTAAAGCAGAAAGAGACTACTTA  
GTTTCCCTTTCAGCATCAGCGGCAGGAGCAGAGGCCCTGTGGAGAAGAGCCACTGTACCATTACAAGAAGGAATG  
AGTCTAGTGAAGGCCAGATAGGGCCAAGGAGATCCCACATCTGGTAGCTGTAAATCCAGGGAGCTCGCTTTT  
ACCGCCTCCAGTCACTGAGTGCAGCAGCCCAAAAGGGCCTCTCTGGGTTTCAGAGGCTCTTCAAGCTGACCTTC  
CACCGCTGGAGATGCCACGCCAGAACTCAGATCCCACCTCGGAAAAATCCTCCTCCCCACTCGCATTGAAAAG  
TTTGACGGAAGCTCTTGGTTACGACAGGAAGAGCAATCCACAAAGGTGCCTCAAGAAACAACTCTATATCC  
CCAGCATTAGCCAGAAAGAAATTCCTCGGAATGCTAGTGTCTTGGGACCCAGATAGGATCTCAACCCATCAGA  
GCAAGCAACCTGATCTCGGAGAAGTGAAGCCATCTTGGAGAGCCCTTCGAGAGGACCCAGCATGCGAGTCC  
TCCAGCTCCAGACACCCCTAGCTCCACGCCAGCTCCCAAGGAGGCTCCAGGCTGGATACAAAGCAGGATCCAGT  
GAACGCACACAGAGTTCGAGCCAACAGTAAGTCAGAAGGATCACTGTGCTTCCCATGAGCCTGCCAAGGTGAAA  
CCAGAAAGAAATCCAGGGACATTACCCGGGCCAGTCGACAGCTAGCTACAAAAAGCTATAGATGAGGATCTGACG  
GCATTAGCCAAAGAACTAAGAGAACTCCGGATTGAAGAAACAAACCGCCCAATGAAGAAGGTGACTGATTACTCC  
TCCTCCAGTGGAGAGTCAAGAAAGTGAAGGAGGAGGAGGAAGATGGAGAGAGCGAGACCATGATGGGACAGTG  
GCTGTACGACATACCCAGACTGATACCAACAGAGCTTCAAGGACAGCAACAGAGCAGTACAATGTGGGAATGGTG  
GGGACGCATGGGCTGGAGACCTCTCATGCGGACAGTTTCAGCGGCAGTATTTCAAGAGAAGGAACCTTGATGATT  
AGAGAGACGCTCGGAGAGAAGAAGCGATCTGGCCACAGTGACAGCAATGGCTTTGCTGGCCACATCAACCTCCCT  
GACCTGGTGCAGCAGAGCCATTCTCAGCTGGAACCCGACTGAGGGAGCTGGGGCGCTCTCAACCCATCCAG  
GAGATGGAATCTGGGAGTGAATATGGCATGGGAGCAGCAGCAAGGCTCCTTCAACCCCTTTTGGAGCCCCAGA  
GTATACAGACGCTCTCCCACTGATGAAGATGAAGAGGATGAGGAATCATCAGCGCGAGCTCTGTTTACTAGCGAA  
CTTCTTAGGCAAGAACAGGCCCAACTCAATGAAGCAAGAAAGATTTCGGTGTAAATGTAAACCACCAACATTT  
CGGCCCTCATAGCGACACACCGAAATCAGAAAAACAGAAACAGTTCAACTCAGAAATCTTTTGTGACGCTCTG  
TGGGTGTAAACCTCTTGGTGGGAGTGAAATGGCTGATGCTTTTGGACCGAAGTGGGCAAGGCAAGCTTAT  
AATCTGATCAACCGGAGGCAATTCAGCAGATGTGCTAGAGGAGCTGAATGCTCTGTGTGACAAATTTACAGAA  
AAGAAGAAATAGCTACGAGTTTACTATCTTTCACTGGTTAAGAAACAGAAATACATAATGACCCAGCAAGTAGAA  
AAGAAACAGGCTGGATCACTGTGTGGGACTTGGAAAGGCTATACATTTAAGTTTGGTTAAATATGAAGAGCT  
AAATTTTGGTGATTGCTCTAAGAAATGCTGTGGAATATATGCTTGGGCTCCTAAACCGTATCATAAATTCATG  
GCATTTAAGTCTTTTGGTATCTCCAGCACAGCCCTCTGCTAGTTGATCTCAGCGTAGAAGAGGTCAGAAAGTA  
AAGGTTATTTTGGTTTACACACTGGTTTCCATGTAATGATGTTGATTCAGGAACCTCTTATGATATCTACATA  
CCATCTCATATTCAGGGCAATATCACTCTCATGCTATTGTCACTCTTGCTCAAAACAGATGGAATGGAATGCTT  
TTTGGCTATGAGGATGAGGGGGGTATGTAACACCTATGGCCGGATCAACTAAGAGTGGTGCTCAATGGGGA  
GAAATGCCACGCTGTGGCTCATTTTCAATCCAATCAGATAATGGGCTGGGCGAGAAAGCTATGAGATCGGG  
TCAGTGGAAACAGGACATTTGGATGGAGTATTTATGCATAAGCGAGCTCAAGGTTTAAAGTTTCTATGTGAAGA  
AATGATAAGGTATTTTTTGCATCCGTGCGATCTGGAGGAAGTAGCCAAGTGTTTTCTATGACCCCTCAACAGAAAT  
TCCATGATGAAGTGTAA

Figure 24

ATGGCGAGCGACTCCCCGGCTCGAAGCCTGGATGAAATAGATCTCTCGGCTCTGAGGGACCTGCGAGGATCTTT  
GAAATGGTGGAACTTGTGTGAAATGGAAACATACGGGCAAGTTTATAAGGGTCGTCAATGTCAAAACGGGGCAGCTT  
GCAGCCATCAAGGTTATGGATGTCAACAGGGGATGAAGAGGAAGAAATCAAAACAAGAAATTAACCATGTGTTGAAGAAA  
TATTCTCATACCCGGAATATTGCTACATACACTATGGTGTCTTTATCAAAAAGAACCCACAGGCATGGATGACCAA  
CTTTGGTGTGGTATGGATTTTGTGGTGTCTGGCTCTGTCAACGACCTGATCAAGAACACAAAAGGTAAACAGCTTG  
AAAGAGGAGTGGATGTGATCATACTCTGACGGGAAATCTTACGGGGGCTGAGTCACTCCACACAGCATAAAGTGATT  
CATCGAGATTTAAAGGGCAAAATGTCTTGTGACTGAAAATGCAGAAGTTAAACTAGTGGACTTTGGAGTCACT  
GCTCAGTGTGATCGAACCTGGGCGAGGGAATACCTTTCATTGGAATCCCTCATCTGATGGATGGCCACAGAGTTATT  
GCCTGTGATGAAAACCCAGATGCCACATATGATTTCAAGAGTGAATTTGGTGTCTTTGGGTATCACCCGCATTGAA  
ATGGCAGAAGGTGCTCCCCCTCTCTGTGACATGCACCCCATGAGAGCTCTCTTCTCATCCCCCGGAATCCAGCG  
CCTCGGCTGAAGTCTAAGAAGTGGTCAAAAAATTCAGTCAATTTATGAGAGCTGCTTGGTAAAGAAATCACAGC  
CAGCGACAGCAACAGAAACATTTGATGAAGCATCCATTTATACGAGACCACTTAAATGAGCGACAGGTCGCGCAT  
CAACTCAAGGACCATATTGATAGAACAAAGAAAGCGAGGAGAAAAAGATGAGACAGATATGAGTACAGTGGAA  
AGTGAGGAAGAAGAGGAGGAGATGACTCAGGAGAGCCAGCTCCATCTGAATCTGCCAGGGGAGTGCAGCGCTG  
CGGAGGGACCTTTCTGAGGCTGCAGCTGGCCACAAAGAGCGTCTGAGGCTACGAGGCGACAGCTGGAGCGT  
CAGCAGCGGAGAATTGAGGAGCACAAAGCGGAGCTGCTGGCCGAGCGTCAGAAGCGCATCGAGGAGCAGAAAGAG  
CAGAGGCGCGCGCTGGAGAGGACACAAAGGCGAGAGGAAGAGCTGCGGAAGCAGCAGGAGAGGGAGCGCGCGG  
CACTATGAGGAGCAGATGCGCGCGGAGGAGGAGGAGGCGTGCAGGACATGAACAGGAATACATCAGGCGACAG  
TACAGGAGGAGGAGCAGACAGTATGAGATCTTGCAGCAGCAGTACTGCTATGAACAGCTTACTTCTTGGAAATAT  
AAGCGAAACAAATTTGAAGAACAGAGACAAGCAGAAAGACTGCAGAGGCAGTCAAGCAAGAAAGAGACTCATTTA  
GTTTCCCTTCAGCATCAGCGGCAGGAGCAGAGGCGTGTGGAGAGAAGCCACTGTATCATTTACAAAGAAAGGAATG  
ATGCTTAGTGAAGGCCAGCATGGGCCAAGGAGGTAGAAGAACGGTCAAGGCTCAACCCGCAAAGTTCCCCCTGCC  
ATGCTTCAAGAGTTGCCACACAGGATATCTGACCCAACTCGCCCCAGGTCGAGGTCTCTCAGCATATGTTGGA  
GTTGACGCTGCTCGAACACCCCCCATGTCTCAGACCACTCGATCCCCAGATCCCACTCTGGTAGCTGTAAAAATCC  
CAGGAGCTGCTTGCAGCGCTCCAGTCACTGTCAGGAGCAGCGACAAAGAGGCGCTCTCTGGGTTTTCAGGAGGCT  
CTGAACGTGACTCTCCACCGCGTGGAGATGCCACGCCAGAACTCAGATCCCACTCGGAAAAATCTCTCTCTGCCCC  
ACTCGATTGAAAAGTTTGACCGAACTTGTGTTACGACAGGAAGAAGACATTCACCAAAGGTGCTCTCAAGGA  
ACAACCTCTATATCCCCAGCATTAGCCAGAAAGATTTCTCTGGGAATGGTAGTGCTCTGGGACCCAGACTAGGA  
TGCTCAACCCATCAGAGCAAGCAACCTGATCTCCGGAGAACTGAGCCCATCTTGGAGAGGCCCTCTGCAGAGGACC  
AGCAGTGGCAGTTCTCTCAGCTCCAGCACCCCTAGTCTCCAGCCAGCTCCAAGGAGGCTCCAGCTGTGATCA  
CAAGCAGGATCCAGTGAACGACACAGAGTTGAGAGCCAAAGTAAAGTCAGAAAGATCACTGTGCTTCCCCATGAG  
CTTGCCAAGGTGAAACCCAGAAATGCCAGGACATTACCGGCGCAGTGCAGGAGCTATCTGACGGCATTAGCCG  
AAAGAACTAAGAGAAGCTCCGGATTGAAGAAACAAACCCGCCAATGAAGAAAGTGACTGATTACTCTCTCCAGT  
GAGGAGTCAGAAAGTAGCGAGGAAGAGGAGGAAGTGGAGAGAGCGAGACCCATGATGGGACAGTGCGCTCTCAGC  
GACATACCCAGACTGATACCAACAGGAGCTCCAGGCAAGAACAGCAGTACATATGTGGAAATGGTGGGGGCGCAT  
GGGCTGGAGACTCTCTCATCGGACAGTTTACGCGGCGAGTATTCAAGAGAAGGAACCTTGATGATATGAGAGAGT  
CTCGAGAGAGAAAGCGATCTGGCCACAGTGACACGAATGGCTTGTGGCCAGCATCAACCTCTCTGAGGCTGGT  
CAGCAGGATCAATCTTCAGCTGGAACCCGACTGAGGAGCTGGGGCGGCTCTCAACCACTTCCAGGAGATGGAAC  
TCTGGAGCTGAATTTGCGGACTGGGGGACGACACCAAGGCTCTCTTCTTGTGGACCCAGAGTATACACAG  
ACGCTCTCCCATGATGAAGATGAAGAGGATGAGGAATCATCAGCCGAGCTCTGTTTACTAGCGAACTTCTTAGG  
CAGAACAGGCCAAACTCAATGAAGCAGAAAGATTTCCGTTGGTAAATGTAAACCAACCAACATCTCGGCCTCAT  
AGCGACACACAGAAATCAGAAATACAGAAACGATTCAAGTACAGAAATATCTTGTGACGCTCTGTGGGGTGTA  
AACTCTTCTGGTGGGACTGAAAATGGCTGTATGCTTTTGGACCGAAGTGGGCAAGGCAAGTCTATAATCTGATC  
AACCGGAGGCGATTTCCAGCAGATGGATGTGCTAGAGGAGCTGAATGTCCTTGTGACAAATTCAGGAAGAAGAAAT  
AAGCTACGAGTTTATCTATCTTTATCGTTAAGAAACAGAAATCTACATATGACCCAGAGTAGAAAGAAACAA  
GGCTGACTCACTGTGGGACTTGGGAGGCTGTATACATTAAAGTTGTAAATGAAAGGATCAAAATTTTGTG  
GTGATTGCGCTTAAAGAAATGCTGTGGAAATATATGCTTGGGCTCTTAACCGTATACATAAATCTATGGCATTTAAG  
CTATTTTGCAGATCTCAGCACAACGCTCTGTGATGTGATCTCAGGTCAGAAAGAGGCTCAAGATTAAGGTTATT  
TTTGGTTACACACACTGGTTTCCATGTAAATGTATGTGATTGATTCAGGAAACTCTATGATCTACATACCATCTCAT  
ATTCAGGCGCAATATCACTCTCATGTATTTGTCTTGTCTTAAACAGATGGAGTGAAGTCTGTGTTGTGAT  
GAGGATGAGGGGGTGATGTGAACACCTATGGCCGGATAAATAAGGATGTGGTGTCTCAATGGGAGAAATGCC  
ACGTCTGTGSGCTTACATTCATTCCAATCAGATAATGGGCTGGGGCGAGAAAGCTATTGAGATCCGTCAGTGGAA  
ACAGGACATTTGGATGGAGATTTATGTCATAAGCGAGCTCAAGGTTAAAGTTCTTATGTGAAGAAATGATAAG  
GTATTTTTCGATCTCGTGGCATCTGGAGGAAGTAGCCAGTGTTTTTCATGACCCTCAACAGAAATTCATGATG  
AACTGGTAA

Figure 25

ATGGCGAGCGACTCCCGGCTCGAAGCCTGGATGAAATAGATCTCTCGGCTCTGAGGGACCCCTGCAGGGATCTTT  
GAATTGGTGGAACTTGTGGAAATGGAAACATACGGGCAAGTTTATAGGGTGCATCTGTCAAACGGGCGAGCTT  
GCAGCCATCAAGGTTTATGGATGTCAAGGGGATGAAGAGGAAGAAATCAAACAGAAATTAACATGTTGAAGAAA  
TATTTCTCATACCCGGAATATTGTCATACATCTATGGTGCTTTTATCAAAGAACCCACCGCATGGATGACCAA  
CTTTGGTGGTATGGAGTTTGTGGTGTGGCTCTGTCAACCGACCTGATCAAGAACACAAAAGGTAAACCGTTG  
AAAGAGGAGTGGATGTCATACATCTGCAGGGGAAATCTTACGGGGGCTGAGTCACCTGCACAGCATTAAGTGATT  
CTCGAGATTTAAAGGGCAAAATGTTCTGCTGACTGAAAATGCAGAAGTTCAACTATGGAGCTTTGGAGTCAGT  
GCTCAGCTTGATCGAACAGTGGGCGAGGAGGAATACTTTCATTGGAACTCCCTACTGGATGGCACAGAAAGTTATT  
GCCTGTGATGAAAACCCAGATGCCACATATGATTTCAAGAGTGACTTGTGGTCTTTTGGTATCACCCGCCATTGAA  
ATGGCAGAAGGTGCTCCCCCTCTGTGACATGCACCCCATGAGAGCTCTCTTCTCATCCCCGGAAATCCAGCG  
CCTCGGCTGAAGTCTAAGAAAGTGGTCAAAAAAATCCAGTCATTATTATGAGAGCTGCTTGGTAAAGAAATCACAGC  
CAGCGACCCAGCAACAGAACAAATTGATGAAGCATCCATTTATACGAGACCAACCTAATGAGCGCAGCGTCCGCACT  
CAACTCAAGGACCATATTGATAGAACAAAGAAAGCGAGGAGAAAGATGAGACAGATATGATACAGTGGA  
AGTGAGGAAGAAGAGGAGGAAATGACTCAGGAGAGCCAGCTCCATCCTGATCTGCCAGGGAGTCGACGCTG  
CGGAGGACTTTCTGAGGCTGCAGCTTGGCCAAACAAGGAGCTTCTGAGGCCCTACGGAGGCGAGCAGCTGGAGCAG  
CAGCAGCGGGAAGTGAAGAGCAACAAGCGGCGAGCTGCTGGCCGAGCGTCAGAAAGCGCATCGAGGAGCAGAAAGAG  
CAGAGGCGCGGCTGGAGGAGCAACAAGGCGAGAGGAGCTGCGGAAGCAGCAGGAGAGGAGGAGCGCCGCG  
CATCTAGGAGGAGCAGTGCCTCGGCGAGGAGGAGGAGGAGCGCTGCGGAGCATGAACAGGAATTAAGCGCAAAACAA  
TTGAAAGAAAGTACGACCAAGCAGAAAGATGCTCAGAGGCGAGCTAAAGCAAGAAAGAGACTACTTAGTTTCCCTTCAG  
CATCAGCGCGCAGGAGCAGAGGCTCTGTGAGAAGAAAGCCACTGTACCATTAACAAAGAGGAATGAGTCCTAGTGAG  
AAGCCAGCATGGGCGCAAGGAGATCCACATCTGGTAGCTGTAATAATCCGAGGACCTGCTCTGACCGCTCCAG  
TCAGTGCAGAGCAGCCGCCCAAAAGGCGCTCTCTGGGTTTTCAGAGGCTCTGAACTGACCTCCCAACCGGCTGGAG  
ATGCCAGCGCAGAACTCAGATCCCACTCGGAAAAATCCCTCTCTCCCCACTCGCATGAAAGGTTTGAACGGAAGC  
TTTGGTTTACGACAGGAAGAAGCATTTCCACCAAAGGTGCTCAAAGAAACACTTCTATATCCCGCAGCATATGCC  
AGAAAGAAATCTCCTGGGAATGTTAGTGCTCTGGGACCCAGCACTAGGATCTCAACCCCATCAGAGCAAGCAACCTC  
GATCTCGGAGAACTGAGCCCATCTTGGAGAGCCCTTTCAGAGGACCCAGCAGCAGTGGCAGTTCTCCACGCTCAGC  
ACCCCTAGCTCCAGCCCGAGCTCCCAAGGAGGCTCCAGCGCTGGATCACAAGCAGGATCCAGTGAACGCCACCA  
GTTTCGAGCCAAACAGTAAGTCAGAAAGGATCACTGTGCTTCCCCATGAGCTGCCAAGGTGAAACAGAAAGATCC  
AGGGACATTACCCGCGCCAGTCAGACAGCTAGCTACAAAATAAGCTATAGATGAGGATCTGACGGCATTAGCCAAA  
GAACTAAGAGAACTCCGAGTTGAAGAAACAAACCGCCCAATGAAGAAGGTGACTGATTACTCTCTCCCTCCAGTGAG  
GAGTCAGAAAGTATGACGAGGAAGAGGAGGAAGATGGAGAGAGCGAGACCCATGATGGGAACAGTGCTGCAGCGAC  
ATACCCAGACTGATACCAACAGAGAGCTCCAGGCGACCAAGAGCAGTACAATGTGGGAATGGTGGGAGCGCATGGG  
CTGGAGACCTCTCATGCGGACAGCTTTCAGCGGCAGTATTTCAAGAGAAGGAACCTTGATGATATGAGAGACGCTCT  
GGAGAGAAGAAAGCATTCGCCACAGTGAACAGCTGACAGCAATGGCTTTGTGGCCACATCAACCTCCCTGACCTGGTGAG  
CAGAGCGACTTCTCAGCTGGAAACCCGACTGAGGAGCTGGGCGCGCTCTCAACCTGATCCAGGAGATGGAGCTCT  
GGGACTGAATATGGCATGGGAGGAGCAGCACAAGGCTCTCTCACCCCTTTGTGGAGCCCAAGAGTATACACAGC  
TCTCCCACTGATGAAGATGAAGAGGATGAGGAATCATCAGCGCAGCTCTGTTTACTAGCGAACTCTTAGGCAA  
GAACAGGCCAACTCAATGAAGCAAGAAAGATTTCCGGTGGTAAATGTAAACCCACAGGATTCGCGCTCATAGC  
GACRACCCAGAAATCAGAAAAATACAAGAAACGATTCAACTCAGAAATACTTTGTGCAGCTCTGTGGGGTGTAAAC  
CTTTGTGGTGGGAGTGAATAATGCCTGATGCTTTTGACCCGAAGTGGGCAAGGCAAGGTCTATAATCTGATCAAC  
CGGAGCGCATTTACGACAGTGTGTCTGAGGGAGCTGAATGCTCTTGATCAAAATTTCAGGAAGAAGAATAAG  
CTACAGAGTTTACTATCTTTCATGGTTAAGAAACAGAAATACTACATAATGACCCAGAAGTAGAAGAAGAACAGGCG  
TGGATCACTGTTGGGAGCTTGGAGGCTGTATACATTATAAGTTGTTAACTGAAAGGATCAAAATTTTGTGGT  
ATTGCCCTTAAAGAAATGCTGTGGAAATATATGCTTGGGCTCTTAAACCGTATCATTAATTCATGGCATTTAAGTCT  
TTTGCAGATCTCCGACAGACGCTCTGCTAGTTGATCTCAGCGTGAAGAAGGTCAAGATATAAGGTTATTTT  
GGTTACACACTGGGTTTCCATGTCTTATGTATGTTGATTCAGGAACCTTATGATATCTACATACACTCTATATT,  
CAGGCGAATATCACTCTCATGCTATTGTCTATCTTGCTTAAACAGATGGAATGGAATCTGTTTGTCTATGAG  
GATGAGGCGGCTGTATGTAACACCATATGGCCGGATAAAGGATGTGGTCTCAAAATGGGAGGAAATGCCACG  
CTCTGTGCTCATCATCTCAATTCAGATAATGGGCTGGGCGGAGAAAGCTATTGAGATCCGGTCAAGTGAAGAAC  
GGACATTTGGATGGAGTATTTATGAGTAAAGCGAGCTCAAAGGTTAAAGTTTCTATGTGAAGAAGATGATAAGGTA  
TTTTTTCATCCGTCGATCTGGAGGAAGTAGCCAGTGTTTTTTCATGACCCCTCAACAGAAATCCATGATGAAC  
TGGTAA

Figure 26

AAGCGAGCGCATCCCCGCGTCGAAGACCTGGATGAATATAGATCTTCTCGGCTCTGAGGACCCCTGCAGGGATCTTT  
GAATTGGTGGGAATCTTTGTGAAATGGAAACATACGGCGAAGTTTATAAGGGTCGTCTATGCAATCCAAACGGCCGACCTG  
CGACCGCATCAAGGTTATGATGATCTACAGGGGATGAAGAGAGGAATATCAACACGAATTAACATGTTTGAAGAAA  
TATTTCTCATACCGGAATATTGCTACATACATATGGTGCTTTTATCAAAAGAACCCACAGAGCTGGATGACCTAA  
CTTTGGTGTGGTATGGAAGTTTGTGGTGCTGGCTCTGTCAACCGATGTATCAAGAACACAAAGAGTTACAGCTTG  
AAAGAGAGCTGGATTGTACATACATCTGCAGGGAATCTCTACGGGGGCTGAGTCACTCTGCACGACATAAAGTTAT  
CATCGAGAGATTAAAGGGCAAAATGCTTTGGTACTGTAATAACAGAAAGTTAAACTGTGGAGTCTTTGGAGTCAGT  
GCTCAAGCTTGATGAAACAGGTGGGACGAGGAATATTTCAATGTGAACTCCCTACTGGATGGCACCGAAGTTATG  
GCTCTGTGATGAAACCCGATGCCACATATGATTTTCAAGATGAGCTTGTGGTTTGTGGGTATCACCGGATTTAG  
ATGGCAGAAGGTGCTCCCTCTCTGTGACATGACCCCCATGAGAGCTCTTCTCTCACTCCCCGGATCCAGCG  
CTCTGGCTGAAGTCTAAGAGGTGTCAAAAATTCAGTCAATTTATGAGAGCTGTTGGTAAAGATACAGCG  
ACCGACAGCAGCAACAGCAACTTGTATGAGCATCTCAATTTATCAGAGAACCACTTAAGCAGAGGTCCGCTAT  
AACTCAAGGCCATATTGTATAGAACAAAGAGAAGCGAGAGAGAAAAGATGAGACAGAGTATGAGTACAGTGGGA  
ATGTAGGAAGAAGAAGGAGAGATGATCAGGAGAGGCGGACCTCCATCTGTAATTCGCCAGGGGATCGACGCTG  
CGAGGGAGCTTTCTGAGGCTGAGCTGGCCCAACAAAGAGCGGTTCTGAGGCCCTACGAGAGCAGCAGCTGTGAGCAG  
CAGCAGCGGGAGATAGAGAGACAGACCGGCACGCTGCTCGCGCAGCGCTCAGAGCGCATCGAGGAGAGCAAGAAAG  
CAGAGCGCGGAGCTGGAGAGGACAAACAAAGCGAGAGAGAGTCTCGGAAGCAGCAGGAGAGGGAGCAGCGCGGG  
CACTATGAGGAGCAGATGCGCCGGGAGGAGGAGAGGCGCTGCGGAGCATGAACAGGAATATAAGCGCAACAACT  
TTGGAAGAACAGAGACAGCAAGAGACTCGAGAGGCGAGCTAAAGCAAGAAAGAGACTACTTGTTCCTTCAG  
CATTCAGCGGCAGGAGCAGAGGCTCTGGGAGAAGAAGCCACTGTACATTTACAAGAGGAATGAGTCTAGTGTAG  
AAGCCAGCATATGGGCCAAGAGAGATGAGAAGACGCTCAAGGCTCAACCGCAAGTTTCCCTCTGCATGCTCCAAAG  
TGTTGCCACAGGATATCTGACCCCAACTGCCCCAGAGTGGAGTCTTTCAGCATATTAGTGGATTTCAAGCTGCT  
CGAACACCCCCCTGCTCAGGACAGCTGATCCCGAGTCCCAACTCTGTGAGTCTTAATATCCCGAGGACCTGCC  
TTGAGCCCTCCAGTACGTACGACAGCGACCCCAAAAGGCGCTCTGGGTTACAGAGGCTCTGAACGTGACC  
TCCCACCGCGTGGAGATGCCAGCGCCATCAGATCCAGCCACTCGGAAATCTCTCTCTCCCACCTCGCATTTGAA  
AAGTTTGTACCGAAAGCTCTGGTTTACGACAGGAAGAAGACATCCACCAAGGTGCTCTCAAGAAACAATCTTAT  
TCCCAGAGATTAGCAGGAAGAATTTCTCTGGGAATGGTAGTGTCTGTGGACCCAGCATAGGATCTCAACACCT  
AGAGCAAGCAACCTGTATCTGACCCATATGAGGCCATCTTTGGAGAGCCCCCTTGCAGAGACGACAGGTGGCAGT  
TCTCCAGCTCCAGACCCCTAGCTCCGACCGAGCTCCCAAGGAGGCTCCAGGCTGTGATCAACAGCAGATGCT  
AGTGAACGACCAAGAGTTTCGAGCCATTAAGTCAAGAGGATCACTCTGTCTCCCCATAGGCTGCCAAGGTG  
AAACCAGAAGAATCCAGGAGCAATCCCGGCCAGCTCAGCCAGCTGATCTGACCGCATAGGCCAAAGCAATAGA  
GACTCCGGATTGAAGAAACAAACCGCCCAATGAAGAAGGTGATGATTACTCTCTCCAGTGAAGAGTACAGAA  
AGTGAAGGAGGAAGGAGGAATGGAGAGAGCGAGCAACCATATGGGACATGTGGCTCTCAGCAGCATACCCAGA  
CTGATACCAACAGAGCTCTCAGGCGACAACGACAGTACATAATGTGGAAATGTGGGAGCCGATGGCTGTGAGACC  
TCTCATTCGGGACAGTTTCAGCGCGAGTATTTCAAGAGAAGGAACCTTGATGATAGAGAGAAGCTGTGAGAGAAG  
AACGATCTGGCCACAGTACAGCAATGGCTTTGTGCGCCATCAACTCCTCGACTGGTGACGTCGACAGGCAT  
TCTCCAGCTGGAACCCGCACTGAGGAGCTGGGCGCGCTCAAGCCATCCAGGAGATGGACTCTGGGACTGAA  
TATGGCATGGGAGCAGCACCAAGGCTCTCTCACCCCTTTGTGGAACCCAGAGTATACCGAGCTCTCCCAT  
GATGAAGATGAAGAAGATAGGAATCATACGCGCAGCTCTGTGTTTATAGCAACTCTTACAGGAACAGACGCC  
AAACTCAATGAAGACAGAAAGATTTCCGTGGTAAATGTAACCCCAACCACTCGGCTCTATGACGACACACCA  
GARATCAAGAAATACAGAAAGCAATCACTCAGAATACTTTGTGCACTCTGTGGGGTGAAACCTTTCTGTG  
GGGACTGAAATATGCTGTATGCTCTTTGAGCCAGAGTGGGCAAGGCAAGTCTATAATCTGATCAACCCGAGCGCA  
TTTTCAGCAGATGGATGTCTAGAGGGACTGAATGTCTCTGTGACAAATTCAGGAAGAAGAAATTAAGCTACAGTT  
TACTATCTTCTAGGTTAAGAAACAGATATACATAATGACCAAGTGAAGAAAGAAACAGGCTGGATCTACT  
TGTGGGAGCTTGGAAAGCTGTATACATATAAAGTTGTTAAATATGAAGGATCAAAATTTTGGTGAATGCGCTTA  
AGAAATGCTGTGGAAATATGCTTTGGGCTCTTAAACGGTATATAAATTCATGCAATTTAAGTCTTTTGAGAT  
CTCCGACAGCAACCTCTGTGATGTGATCTCAGGTAGAAGAGGTCAAGAGTTAAAGTTATTTTGTGTCCACAC  
ACTSGTTTCCATGTCTTATGATGTGATTTACAGAAACTCTTATGATATCTACATCAACTCTCATATTACGGCAAT  
ATCACTCCTCATGTTATGTTCATCTTGCCCTAAACACAGATGGAATGGAAATGCTGTTTGTATGAGGATGAGGGG  
GTGATGTGAATACCACTATGGCCGGATACATAAGATGTGGTGCTCCATGGGGAAGATCCGACGCTCTGGCCG  
TACATTTCTCCATCAGATATAAGGCTGGGGCGAGAAAGCTATTGAGATCGGCTGAGGAACAGACATTTG  
GTGAGGATATTATGACATAAGCGAGCTCAAAGGTAAAGTTTCTATGACAGAAATGTAAGATTTTTCGAC  
TCGGTGCAGCTTCGAGGAGAGCTGCAGAGTGTTTTTCTAGCCCTACAGAAATTTCTATGATGATTTGTAAT  
>



Figure 27

ATGGCGAGCGACTCCCCGGCTCGAAGCCTGGATGAAATAGATCTCTCGGCTCTGAGGGACCTGCGAGGATCTTT  
GAATTTGGTGGAACTTGTGTGAAATGGAAACATACGGGCAAGTTTATAAGGGTCGTATGTCACAAACGGGCGAGCTT  
GCAGCCATCAAGGTTATGGATGTCACAGGGGATGAAGAGGAAGAAATCAAAACAGAAATTAACATCTGTTTGAAGAAA  
TATTCTCATCACCGGAATATTGTCATACACTATGTTGCTTTTATCAAAAAGAACCCACCAGGCATGGATGACCAA  
CTTTGGTTGGTGATGGAGTTTGTGGTGCTGGCTCTGTCACCGACCTGATCAGAAACACAAAAGGTAACACGTTG  
AAAGAGAGTGGATTGTCATCATCTGCGAGGGAAATCTTACGGGGCTGAGTCACTCGCACCGACATAAAGTGATT  
CATCGAGATTATAAAGGGCAAAATGCTTGTCTGACTGAAAAATGCAGAAAGTTAAACTAGTGGACTTTGGAGTCACT  
GCTCAGCTTATGTCGAACAGTGGGACGAGGAGGAATCTTTTATTGGAACCTCCCTCATCTGATGGACACGAGAGTTATT  
GCCTGTGATGAAAACCCAGATGCCACATATGATTCAAGAGTGACTTGTGGTCTTTGGGTATCACCGCCATTGAA  
ATGGCAGAAGGTGCTCCCCCTCTCTGTGACATGCACCCCATGAGAGCTCTCTCTCATCCCCCGGAATCCAGCG  
CCTCGGCTGAAGTCTAAGAAGTGGTCAAAAAAATCCAGTCATTATTGAGAGCTGCTTGGTAAAGAAATCACAGC  
CAGCGACCGACGACAGCAACAAATTTGATGAAGCATCCATTATACGAGACCAACCTAATGAGCGACAGGTCCGCATT  
CAACTCAAGGACCATATTGATAGAACAAGAAAGAGCGAGGAGAAAAGATGAGACAGAGTATGAGTACAGTGGAA  
GTGAGGAGGAGAGGAGGAGAGATGACTCAGGAGAGCCAGCTCCATCTGTAATCTGCCAGGGGAGTGCAGCGCTG  
CGAGGGACTTTCTGAGGCTGGCCCTGGCCCAACAGGAGCGTCTGAGGCCCTACGAGGAGCGAGCTGGAGCAG  
CAGCAGCGGGAGATGAGGAGCACAAGCGCGAGCTGCTGGCCGAGCGTCAGAAAGCGCATCGAGGAGCAGAAAGAG  
CAGAGGCGCGCGCTGGAGGAGCAACAAAGGCGAGAGGAGGCTGCGGAGACGAGCAGGAGAGGGAGACGCGCGG  
CACTATGAGGAGCAGATGTCCTCGGAGGAGGAGGAGGAGCGCTGCGGAGCATGAACAGGAATACCTCAGGCGACAG  
TAGAGGAGGAGGAGCAGACAGTATTAGAGATCTTGACGACGACGACTACTGATGAACAGAGCTTACTTCTGGAATAT  
AAGCGCAACAAATTTGAAGAACAGACAGCAAGCAGAAAGACTGCGAGGCGAGCTAAAGCAGAAAGAGACTACTTA  
GTTTCCCTCTCAGCATCAGCGGACGAGGAGCAGAGGCGTGTGGAGAGAAAGCCACTGTACCATACAAAGAGGAATG  
AGTCTTAGTGAAGAGCCAGATGGGCCAAGGAGATCCCACATCTGGTAGCTGTAAATCCCAGGGACCTGCCCTTG  
ACCGCTCTCCAGTCTGAGTGCACGACGAGCCACAAAGGGCTCTTGGGTTTTCAGAGGCTCTGAACGTGACCTCC  
CACCGCGTGAGATGCCACCGCCAGAACTCAGATCCACCTCGGAAAAATCCTCTCTCCCCACTGCCATTTGAAAG  
TTGACCGAAGCTCTTGGTTACGACAGGAGAGAGACATTCACCAAAGGTGGCTCAAGAGACAACTCTATATCC  
CGACGATTCGCGAGAAAGATTTCTCTGGGAATGGTAGTGTCTTGGGACCCAGACTAGGATCTCAACCCATCAGA  
CCAGCAACCTGTATCTCCGAGAACTGAGCCCATCTTGGAGAGCCCTTGCAGAGACAGCAGCATGTGCAGTTCC  
TCCAGCTCCAGCACCCCTAGCTCCAGCCAGCTCCCAAGGAGGCTCCAGCGCTGGATCAAGCAGGATCCAGT  
GAACGCACAGAGTTCGAGCCACACAGTAAGTCAGAAAGGATCACTGTGCTTCCCATGAGCCTGCCAAGGTGAAA  
CCAGAAAGATCCAGGACATTACCGGCCCCAGTCGACCACTGTCTGACGGATTAGGCCAAAAGAAATGAAGAA  
CTCCGGATTGAAGAAACAAACCGCCCAATGAAGAAGGTGACTGATTACTCTCTCCAGTGAGGAGTCAAGAAAT  
AGCGAGGAAGAGGAGGAAGATGGAGAGAGCGGAGACCCATGATGGGACAGTGGCTGTACGACGATACCCAGCATG  
ATACCAACAGGAGCTCCAGGCAGCAACAGGAGTACAATGTGGGAATGGTGGGGACGCATGGGCTGGAGACCTCT  
CATGCGGACAGTTTCAAGCGGAGTATTCAAGAGAAAGGAACCTTGATGATTAGAGAGACGTCTGGAGAGGAAG  
CGATCTGGCCAGCATGAGCAATGTTGCTGTGGCCACATCAACCTCCTGACCTGGTGCGAGGAGCAATCTCT  
CCAGCTGGAAACCCCGACTGAGGAGTGGGGCGCGTCAACCCATTCCAGGAGATGACTCTGGGACTGAATAT  
GGCATGGGGAGCAGCACCAAGGCTCTTCAACCCCTTTGTGGAGCCGAGATACACGAGGCTTCCCACTGAT  
GAAGATGAAGAGGATGAGGAATCATCAGCCGAGCTGTGTTTACTAGCGAACTCTTAGGCAAGAACAGGCCAAA  
CTCAATGAAGCAAGAAAGATTTCGGTGGTAAATGTAAACCAACCAACATCTGGCCCTTAGTGAGCACAACAGAA  
ATCAGAAATACAAGAAACGATTCAACTCAGAAATACTTTGTGCAGCTCTGTGGGGTGTAAACCTTCTGGTGGG  
ACTGAAAAATGGCTGATGCTTTTGGACCGAAGTGGGCAAGGCAAGTCTATATCTGATCAACCCGAGGGGATTT  
CAGCATGGATGTTGCTAGAGGACTGAATGTCTTGTGACAAATCTCAGGAAGAGAAATAGCTACAGATTAC  
TATCTTTTCACTGGTTAAGAAACAGAACTACATATAATGACCCAGAGTAGAAAGAGAAACAGGCTGGATCACTGTT  
GGGACTTTGAAGGCTGTATACATATAAAGTTGTAAATATGAAGGATCAAAATTTTGGTATGTGCTTAAAG  
AATGCTGTGAAATATATGCTTGGGCTCTAAACCGTATCATAAATTCATGCAATTAAGTCTTTTGCAGATCTC  
CAGCACAAAGCTCTGCTAGCTTCACGCTCAGGAGAGGTCARAGATTAAAGGTTATTTTGGTTCACACACT  
GGTTTCCATGTAATTGATGTTGATTGAGGAACTCTTATGATATCATACATCTCATATTACGGGCAATATC  
ACTCTCATGCTATGTCATCTTGCTTAAACAGATGGAATGGAATGCTTTGTTGCTATGAGGATGAGGGGGT  
TATGTAAACACCTTAATGGCCGATTAACAGGATGTTGCTCAATGGGAGAAATGCCACAGTCTGTGGGCTAC  
GGATTCCTCAATCAGATGAATGGGCTGGGCGAGAAAGCTTATGAGATCCGGCTGAGTGAACAGGACATGTTGGAAT  
AGGATTATTATGATCAAGCGCTCAAAGGTTAAAGTTTCTATGTGAAGAAATGATAGGATATTTTTCATCC  
GTGCGATCTGGAGGAAGTAGCCAAGTGTTTTTCATGACCTCAACAGAAATTCATGATGAACCTGGTAA

Figure 28

ATGGCGAGCGACTCCCCGGCTCGAAGCCTGGATGAAATAGATCTCTCGGCTCTGAGGGACCCCTGACGGGATCTTT  
GAATTGGTGGAACTTGTGTGAAATGGAAACATACGGGCAAGTTTATAAGGGTCGTCATGTCAAAACGGGCGAGCTT  
GCAGCCATCAAGGTTATGGATGTCCACGGGGATGAAGAGGAAGAAATCAAACAAGAAATTAACATGTGTAAGAAA  
TATTCTCATCACCCGAATATTGTCTACATACTATTGGTGTCTTTTATCAAAAAGAACCCACAGGCATGGATGACCAA  
CTTTGGTTGGTGATGGAGTTTGTGGTGCTGGCTCTGTCCAGCCTGATCAAGAACACAAAAGGTAACACGTTG  
AAAGAGGAGTGATGTCATACATCTGCAAGGGAATCTTACGGGGCTGAGTCACCTGCACCGCATAAAGTGATT  
CATCGAGATATTAAAGGGCAAAATGCTTGTCTGACTGAAAAATGCAAGAATTAAACTAGTGGACTTTGGAGTCAGT  
GCTCAGCTTGTATGCAACAGTGGGCGAGGAGAACTTTTCAATTGGAATCCCTACTGGATGGCACCAAGAGTTATT  
GCCTGTGATGAAAACCCAGATGCCACATGATTTTCAAGAGTGACTTGTGGTCTTTGGGTATCACCCGCATGAA  
ATTGCGAGAAGGTGCTCCCCCTCTCTGTGACATGCACCCCATGAGAGCTCTCTTCTCATCCCCGGAAATCCAGCG  
CTCCGGCTGAAGTCTAAGAAGTGGTCAAAAAATTTCCAGTCATTTTATTGAGAGCTGCTTGGTAAAGAAATCACAGC  
CAGCGACACAGCAACAGAACAATTTGATGAAGCATCCATTATACGAGACCACTAATGAGCGACAGGTCCCGCATT  
CAACTCAAGGACCATATTGTATAGAACAAGAAAGAGCGGAGGAGAAAAGATGAGACAGAGTATGAGTACAGTGGAA  
AGTGAGGAAGAAGAGGAGGAGAATGACTCAGGAGAGCCAGCTCCATCTCTGAATCTGCCAGGGGAGTCAGCGCTG  
CGAGGGGACTTTCTGAGGCTGCGAGCTGGCCAACAAGGAGCGTTCTGAGGCCCTACGAGGAGCAGCTGGAGCAG  
CAGCAGCGGGAGAAATGAGGAGCACAAGCGCGAGCTGCTGGCCGAGCGCTCAGAAGCGCATCGAGAGCAGAAAAGAG  
CAGAGGCGCGCGCTGGAGGAGCAACAAGGCGAGAGAAAGGAGCTGCGGAAGCAGCAGGAGAGGGAGCAGCGCCGG  
CATATGAGGAGCAGATGTCGCCGGGAGGAGGAGGAGCGCTGCGGAGCATGACAGGAATATAAGCAAGAACAA  
TTGGAAGAACACAGAGCAAGCAGAGAAAGACTGTCAGAGGCGAGCTAAAGCAAGAAAGAGACTACTTAGTTTCCCTTAC  
CATCAGCGGCGAGGACAGGAGGCTGGGAGAAAGAACCACTGTACCATACAAAGAGGAATGAGTCTCTAGTGAG  
AAGCCAGCATGGGCCCAAGGAGATCCACATCTGGTAGCTGTAAATCCAGGGAGCTGCGCTTGACCGCTCCAG  
TCAGTGCACGAGCAGCCACAAGAGGCGCTCTCTGGGTTTTCAGGAGGCTGTGAACCTCCCACTCCCAAGCTGGAG  
ATGCCGCGCAGAGACTGAGTCCCACTCGGAAAAATCTCTCTCTCCCACTCGCATGTAAAGAAATTTGACCGAAGC  
TCTTGGTTACGACAGGAAGAAGACATTTCCACAAAGGTGCTCAGGAAGCAACTCTATATCCCCAGCATTAGCC  
AGAAAGAAATTTCTCTGGGAATGGTAGTGCTCTGGGACCCAGACTAGGATCTCAACCCCATCAGAGCAACCACT  
GATCTCCGAGAACTGAGGCCATCTTGGAGAGCCCTTGCAGAGGACGAGCAGTGGCAGTCTCTCCAGCTCAGC  
ACCCCTAGCTCCCAGCCCGAGCTCCCAAGGAGGCTCCAGCGCTGGATCAACAAGCAGGATCTCAGTGAACGCACAGA  
GTTCCAGGCCAACAGTAAGTCAGAAGGATCACCTGTGCTTCCCATGAGCTGCCAAGGTGAACACAGAAGAAATCC  
AGGGACATTACCCGGGCCAGTCGACAGCCTGATCTGACGGCATTAGCCAAAGAACTAAGGAAGACTCCGGATTGAA  
GAAACAACCCGCCAATGAAGAAGGTGACTGATTACTCTCTCCAGTGAGGAGTCAGAAAGTAGCGGAGGAGAG  
GAGGAAGATGGAGAGAGCGAGACCCATGATGGGACAGTGGCTGTGAGGACATACCCAGACTGATACCAACAGGA  
GCTCCAGGCAGCAACGAGCAGTACAAATGTGGGAATGGTGGGACGCAATGGGCTGGAGAACCTCTATGCGGACAG  
TTCAGCGGCAGTATTTGACAGAAGAAACCTTGTATGATTAGAGAGCGTCTGGAGAGAGAACGCGATCTGGCCAC  
AGTCAGCAGCAATGGTTTCTGTGCCACATCAACTCCCTGACCTTGTGTCAGCAGAGCAACTTCTCAGTGCAGGCG  
CCGACTGAGGGACTGGGGCGGCTCTCAACCCATTCCAGGAGATGGACTCTGGGACTGAATATGGCATGGGGAGC  
AGCACCAAGGCTCTCTCACCCCTTTGTGGACCCAGAGTATACGAGCTCTCCCACTGATGAAGATGAAGAG  
GATGAGAAATCATAGCCGCGAGCTCTGTTTACTAGCAAGATTTTAGGCAAGCAAGGCCAAACTCAATGAAGCA  
AGAAAGATTTCCGTTGGTAAATGTAAACCAAACCAACTTCGGCTCATAGCGACACACCGAAGAAATCAGAAAAATAC  
AAGAAACGATTAACCTCAGAAATACTTTGTGACGCTCTGTGGGGTGTAAACCTTCTGTGGGACTGGAAATGGC  
CTGATGCTTTTGGACCGAAGTGGGCAAGGCAAGGTCTATAATCTGATCAACCGGAGGCGATTTACGAGATGAT  
GTGCTAGAGGAGACTGAATGCTCTTGTGACAAATTTCAAGAAAGAAGAAATAGCTACGAGTTTACTATCTTTCATG  
TTAAGAAACAGAAATACTACATAATACCCAGAATGAAAAAGAAACAGGCTGGATCACTGTGTGGGAAATTTGAA  
GGCTGTATACATTTATAAGTTGTGTAATATGAAGAGTCAAAATTTTGGTGATTGCTTAAAGAAATGCTGTGGAA  
ATATATGCTTTGGGCTCTTAAACCGTATCAATAATTTAGCTTTTTCAGATCTCCAGCAACAGGCTCTGCT  
CTGCTAGTTGATCTCACGGTAGAAGAGGTCAAAGATTTAAGGCTTATTTTGGTTTCAACATGCTTTTCCATGT  
ATTGATGTTGATTTTCAAGAACTCTTATGATATCTACATACCATCTATATTCAGGCAACTACTCTCATGCT  
ATTGTCTCTTGCCTTAAACAGATGGAATGGAATGCTTTGTTGCTATGAGGATGAGGGGGTGTATGTAAACACC  
TTGGGCGGGATAACTAAGGATGTGGTGTCCAATGGGGAAGAAATGCCACGCTGTGTGGCTACATTTCAATCCAA  
CAGATTAATGGCTGGGGCGAGAAAGCTTTGAGATCCGCTCAGTGAGAACAGGACATTTGGATGGAGATTATTATG  
CATAAGCGAGCTCAAAGGTAAAGTTTCTATGTGAAAGAAATGATAAGGTATTTTGTGATCCGTGCGATCTGGA  
GGAAGTAGCCAGTGTTTTCTAGTACCCTCAACAGAAATTCATGATGACTGGTAA

Figure 29

```

1      MASDSPARSLDEIDLALRDPAGIFELVELVNGNGTYGVYKGRHVKTGQLAAIKVMDVTG
61     DEEEEEIKQEIINMLKKYSHHRNIATYGYAFIKKNPPGMDQQLWVMEFCGAGSVTDLIKNT
121    KGNTLKEEWIAYICREILRGLSHLHQHKVIRHDIKGQNVLLTENAELVLDVFGVSAQLDR
181    TVGRRNTFIGTTPYWMapeviACDENPDATYDFKSDLWSLGITAIEMAEgapPLCDMHMPMR
241    ALFLIPRNPAPRLKSKKKSKFQSFIESCLVKNHSQRpATEQLMKHPPIRDQPNERQVRI
301    QLKDHIDRTKKKRGEKDETEYEGSGEEEEENDSGEPSSIINLPGESTLRRDFLRLQLA
361    NKERSEALRRQQLQQQORENEEHKRQLLAERQKRIEEQKEQRRRLLEEQQRRREKELRKQOE
421    REQRRHYEEQMRREEERRRAEHEQEYKRKQLEEQRQAERLQRQLKQERDYLVSLLQHQRE
481    QRPEVKKPLYHYHEGMSPEKPAWAKEVEERSRLNRQSSPAMPHKVANRISDPNLPPRQE
541    SFSISGVQPARTFPMLRPVDPQIPHLVAVKSGQPALTASQSVHEQPTKGLSGFQeALNVT
601    SHRVEMPRONSDPTSENPPPLTRIEKFDRSSSWLRQeEDIPFKVPQRTTSSISPALARKNSP
661    GNGSALGPRLGSPPIRASNPDLRRTPEILESPLQRTSSGSSSSSTPSSQPSQQGSGSQPG
721    SQAGSSERTVRANSKSEGSPVLPHEPAKVKEESRDITRPSRPASYKKAIDEDLTALAK
781    ELRELRIEETNRPMCKVTDYSSSSSEESSEEEEEDEGESETHDGTVAVSDIPRLIPTGAP
841    GSNEQYNVGMVGTHGLETSADSFSGSISREGTLMIRETSGEKKRSGHSDSNGFAGHINL
901    PDLVQQSHSPAGTPTeGLGRVSTHSQeMDSGTEYGMGSSTKASFTPFVDPRVQTSPTDE
961    DEEDEESAAALFTSELLRQEQAKLINEARKISVVNVNPTNIRPHSDTPEIRKYKKRFNSE
1021  ILCAALWGVNLLVGTENGLMLLDRSGGQKVYNLINRRRFQQMDVLEGLNVLTISGKKNK
1081  LRVVYLSWLRNRIILHNDPEVEKKQGWITVGDLGGCIHYKVVKYERIKFLVIALKNAVEIY
1141  AWAPKPYHKFMAFKSFADLQHKPLLVLDLTVEEGQRKLVIFGSHTGfHVIDVDSGNSYDIY
1201  IPSHIQGNITPHAIVILPKTDGMEMLVCYEDEGVVYNTYGRITKDVVLQWGeMPTSVAYI
1261  HSNQIMGWGEKAIEIRSVETGHLdGVFMHKRAQLKFLCERNdKVFFASVRSGSSQVFF
1321  MTLNRRNSMMNNWZ

```

Figure 30

1 MASDSPARSLDEIDLSALRDPAGIFELVELVNGNTYGGQVYKGRHVKTGQLAAIKVMDVTG  
61 DEEEEIKQEIINMLKKYSHHRNIATYYGAFIKKNPPGMDQLWLVMFEFCGAGSVTDLIKNT  
121 KGNTLKEEWIAYICREILRGLSHLHQHKVIHRDIKGQNVLLTENAIEVKLVDPGVSAQLDR  
181 TVGRRNTFIGTPYWMapeviACDENPDATYDFKSDLWSLGITAIEMAGAPPLCDMHPMR  
241 ALFLIPRNPAPRLKSKKWSKKFQSFIESCLVKNHSQRPATEQLMKHPFIRDQPNEROVRI  
301 QLKDHIDRTKKRGEKDETEYEYSGSEEEEEENDSGEPSSIINLPGESTLRDRDFLRQLA  
361 NKERSEALRRQQLQEQQRENEEHKRQLLAERQKRIEQQEQRRLLEEQQREKELRKQQE  
421 REQRRHYEEQMRREERERRAEHEQEYIRRLQLEEQRLQLEILQQQLLHEQALLLEYKRKQL  
481 EEQRQAERLQRLQKQERDYLVSLLQHQREQORPVEKKPLYHYKEGMSPSEKPAWAKEIPLH  
541 VAVKSQGPALTASQSVHEQPTKGLSGFQEQALNVTSHRVEMPRQNSDPTSENPLPTRIEK  
601 FDRSSWLRQEEDIIPKVPQRTTISPALARKNSPGNGSALGPRLGSPQIRASNPDLRRTTE  
661 PILESPLOQTSSGSSSSSTPSSQPSQGSQPSQAGSSERTVRANSKSEGSFVLPHE  
721 PAKVKPEESRDITRPSRPASYKKAIDEDLTALAKELELRLEETNRPMKKVTDYSSSSEE  
781 SESSEEEEEDEGESETHDGTVAVSDIPLRIPTGAPGSNEQYNVGMVGTGLETSHADSPSG  
841 SISREGTLMIRETSGEKKRSGHSDSNGFAGHINLPDLVQSSHSPAGTPTGELGRVSTHSQ  
901 EMDSGTEYGMGSSTKASFTPFVDPRVYQTSPTDEDEDEESSAALFTSELLRQEQAKLN  
961 EARKISVVNVNPTNIRPHSDTPEIRKYKKRFNSEILCAALWGVNLLVGTENGLMLLDRSG  
1021 QGKVYNLINRRFPQMDVLEGLNVLVTISGKKNKLRVYVYLSWLRNRIILHNDPEVEKKQGW  
1081 ITVGDEGCIHYKVVKYERIKFLVIALKNAVEIYAWAPKYHKFMAFKSFADLQHKPLLV  
1141 DLTVEEGQRLKVI FGSHTGFHVIDVDSGNSYDIYIPSHIQGNITPHAIVILPKTGMEMLV  
1201 VCYEDEGVVNTYGRITKDVVLQWGMPTSVAYIHSNQIMGWGEKAIERSVETGHLDGV  
1261 FMHKRAQRLKFLCERNDKVFFASVRSGSSQVFFMTLNRNSMNTWZ

Figure 31

```

1  MASDSPARSLDEIDLALRDPAGIFELVELVGNNGTYGQVYKGRHVKTGQLAAIKVMDVTG
61  DEEEIEKQEINMLKCYSHRNIAITYGAFIKNPPGMDQLWLVMFECGAGSVTDLIKNT
121 KGNLTLEKEWIAIYICREILRGLSHLHQHKVIHRDIKGNVLLTENAELVDFGVSAQLDR
181 TVGRRNTFIGTFYMAPEVIACDENPDATYDFKSDLWSLGITAEMABGAPPLCDMHFMR
241 ALFLIPRNPAPRLKSKKWSKFKQSFIESCLVKXNSORPATEQLMKHPFIRDQPNRQVRI
301 QLKDHIDRTKKKRGKEDETEYEYSGSEEEEEENDSGEPSSIINLPGESTLRRDFLRLQLA
361 NKERSEALRRQLEQQQRENEEHKRQLLAERQKRIEBQKEQRRRLLEEQQRRREKLRKQQE
421 REQRRHYEEQMRREEERRRAEHEQEYIRRLQLEEBQQRLEILQQQLLHEQALLLEYKRKQL
481 EEQRQAERLQRQLKQERDYLVSLOHQHQEQRPVEKKPLYHYKEGMSPEKPAWAKEVEER
541 SRLNRQSSPAMPKVKANRISDPNLP PRSEFSISGVQPARTPPMLRPVDPQIPHILVAVKS
601 QGPALTASQSVHEQPTKGLSGFQEAALNVTSHRVEMPRQNSDPTSENPLPTRIEKFDRSS
661 WLRQEEIDPPKVPQRTTSSISPALARKNSPGNGSALGPRLSQPIRASNPDLRRTTEPILES
721 PLQRTSSGSSSSSTPSSQSSQGGSQGSSQAGSSERTVRANSKSEGSFVLPHEPAKVK
781 PEESRDITRPSRPADLTALAKELRELRIEETNRPMMKVTDYSSSESESESESEEDGES
841 ETHDGTAVASDIPRLIPTGAPGSNEQYNVGMVGTHTGLETSHADSFSGSISREBGLMIRET
901 SGEKKRSGHSDSNGFAGHINLPDLVQQSHSPAGTPTTEGLGRVSTHSQEMDSGTGYMGSS
961 TKASFTPFVDRVYQTSPTDEDEDEESSAAALFTSELLRQEQAKLNEARKISVNVNPT
1021 NIRPHSDTPEIRKYKRFNSEILCAALWGVNLLVGTENGMLLDRSGQGVYNLNRRF
1081 QQMDVLEGLNVLTISGKKNKLRVYLSWLRNRLHNDPEVEKKQGWITVGDLEGCIIHYK
1141 VVKYERIKFLVIALKNAVEIYAWAPKPYHKFMFKSPADLQHKPLLDLTVEEGQRLKVI
1201 FGSHTGFHVIDVDSGNSYDIYIPSHIQGNITPHAIVILPKTDGMEMLVCYDEGVYVNTY
1261 GRITKDVVLQWGEPTSVAIYHSNQIMGWGEKAIERSVETGHLDGVMHKRAQRLKFLC
1321 ERNDKVFPASVRSGGSSQVFMTNLNRNMMNWN

```



Figure 32

```

1  MASDSPARSLDEIDLALRDPAGIFELVELVNGTYGQVYKGRHVKTGQLAAIKVMDVTG
61  DEEEEEIKQEINMLKKYSHHRNIATYYGAFIKKNPPGMDDQLWLVMFCGAGSVTDLIKNT
121 KGNTLKREWIAYICREILRGLSHLHQHKVHIRDIKGQNVLLTENAELVCLVDFGVSAQLDR
181 TVGRRNTFTIGTPYWMAPFVIACDENPDATYDFKSDLMSLGITAIEMAEGAPPLCDMHMPMR
241 ALFLIPRNPAPRLKSKKKKFKFSFIESCLVKNHSQRPATEQLMKHPFIRDQPNERQVRI
301 QLKDHIDRTKKRGEKDETEYSGSEEEEEENDSGEPSSIINLPGESTLRRDFLRLQLA
361 NKERSEALRRQQLQQQRENEHQRQLLAERQKRIEEQKEQRRRLLEEQQRRKELRKQQE
421 REQRRHYEBQMRREERRRAEHEQBYKRKQLEEQQAERLQRQLKQERDYLVSLOHQREQE
481 QRPVEKKPLYHYKEGMSPEKPAWAKEIPHILVAVKSQGPALTASQSVHEQPTKGLSGFQE
541 ALNVTSHRVEMPRQNSDPTSENPLPTRIEKFDRSSWLRQEEDIIPKVPQRTTISIPALA
601 RKNSPGNGSALGPRLGSPQIRASNPDLRRTEPILESPLQRTSSGSSSSSTPSSQFSSQG
661 GSQPGSQAGSSERTVRANSKSEGSVLPHEPAKVKEESRDI TRPSRPASYKKAIDEDL
721 TALAKELRELRIEETNRPMMKVTDYSSSSSEESSESEEEEEEDGESETHDGTAVASDIPRLI
781 PTGAPGSNEQYNVMVGTHGLETSHADSFSGSISREGTLMIRETSGEKKRSGHSDSNGFA
841 GHINLPDLVQQSHSPAGTPTTEGLGRVSTHSQEMDSGTEYGMGSSTKASFTFPVDPVRYQT
901 SPTDEDEEDEESSAAALFTSELLRQEQAALNEARKISVVNVNPTNIRPHSDTPEIRKYKK
961 RFNSEILCAALWGVNLVGTENGLMLLDRSGQGKQVYNLINRRRFQQMDVLEGLNVLVTIS
1021 GKKNKLRVYYLSWLRNRILHNDPEVEKKQGWITVDGLEGCIIHYKVYKVERIKFLVIALKN
1081 AVEIYAWAPKPYHKFMAFKSFADLQHKPLLVLDLTVBEGQLKVI FGSHTGFHV IDVDVSGN
1141 SYDIYIPSHIQGNITPHAI VILPKTDGMEMLVCYEDEGVVNTYGRITKDVVLQWGENPT
1201 SVAYIHSNIMGWGEKALIEIRSVETGHLDGVMHKRAQLKFLCERNDKVFFASVRSRGS
1261 SQVFFMTLNRNSMNNWZ

```

Figure 33

1 MASDSPARSLDEIDLSALRDPAGIFELVELVNGTYGQVYKGRHVKTGQLAAIKVMDVTG  
61 DEEEEEIKQEIINMLKKYSHHRNIATYGYGAFIKKNPPGMDDQLWLVMEFCGAGSVTDLIKNT  
121 KGNTLKEEWIAYICREILRGLSHLHQHKVIHRDIKGQNVLLTENAEBVLVD FGVSAQLDR  
181 TVGRRNTFIGTPYWMapeviACDENPDATYDFKSDLWSLGITAIEMAEAGAPPLCDMHMPMR  
241 ALFLIPRNPApRLKSKKWSKKQSPFIESCLVKNHNSQRpATEQLMKHPFIRDQPNERQVRI  
301 QLKDHIDRTKKKRGEKDETEYEYSGSEEEEEENDSGEPSSIINLPGESTLRDRFLRLQLA  
361 NKERSEALRRQQLLEQQQRENEEHKRQLLAERQKRIEEQKEQRRRLLEEQQRRREKELRKQQE  
421 REQRRHYEEQMRREEERRRAEHEQEYKRKQLEEQRQAERLQRQLKQERDYLVSILQHQRQE  
481 QRPVEKKPLYHYHKEGMSPEKKPAWAKEVEERSRLNRQSSPAMPHKVANRISDPNLPPRSE  
541 SFSISGVQPARTPPMLRPVDPQIPHVLVAKSQGPALTASQSVHEQPTKGLSGFQEAALNVT  
601 SHRVEMPRQNSDPTSENPLPTRIEKFDRSSWLQEEEDIPPKVPQRTTISIPALARKNSP  
661 GNGSALGPRLGSQPIRASNPDLRRTTEPILESPLQRTSSGSSSSSTPSSQPSQGGSPQG  
721 SQAGSSERTVRANSKSEGSPVLPHPAKVKEESRDITRPSRPADLTALAKELRELRIE  
781 ETNRPMKKVTDYSSSSSESESESEEEEEDEGESETHDGTAVASDIPRLIPTGAPGSNEQYVNV  
841 GMVGTGHLETSHADSFGSISREGTLMIRETSGEKKRSGHSDSNGFAGHINLPDLVQQSH  
901 SPAGTPTEGLGRVSTHSQEMDSGTEYMGSSSTKASFTPFVDPVRVYQTSPTDEDEDEDESS  
961 AAALFTSELLRQEQAKLNEARKISVNVNPTNIRPHSDTPEIRKYKRFNSEILCAALWG  
1021 VNLLVGTENGMLLDRSGQGVNVLINRRRFQQMDVLEGLNVLVTISGKKNKLrvYYLSW  
1081 LNRNLIHNDPEVEKKQGWITVGDLEGCihYKVVKYERIKFLVIALKNAVEIYAWAPKPYH  
1141 KFMAFKSFADLQHKPLLVDLTVEEGQRLKVI FGSHTGFHVIDVDSGNSYDIYIPSHIQGN  
1201 ITPHAIVILPKTDGMEMLVCYEDEGVVNTYGRITKDVVLQWGENMPTSVAYIHNSQIMGW  
1261 GEKAIEIRSVETGHLDGVMFMHKRAQLKFLCERNDKVFFASVRSGSSSQVFFMTLNRNSM  
1321 MNWZ

Figure 34

```

1  MASDSPARSLDEIDLSALRDPAGIFELVELVGNNGTYGQVYKGRHVKTGQLAAIKVMDVTG
61  DEEEEIKQEIINMLKKYSHHRNIATYYGAFIKKNPPGMDQLWLVMFECGAGSVTDLIKNT
121 KGNLTKEEWIAYICREILRGLSHLHQHKVIHRDIKGNVLLTENAEVKLVDFGVSAQLDR
181 TVGRRNTFIGTPYWMapevIACDENPDATYDFKSDLWSLGITAIEMABGAPPLCDMHPMR
241 ALFLIPRNPAPRLKSKKWSKKFQSFIESCLVKNHSQRPAEQLMKHPIFRDQPNERQVRI
301 QLKDHIDRTKKKRGEKDETEYEYSGSEEEEEENDSGEPSSIINLPGESTLRRDFLRLQLA
361 NKERSEALRRQQLBQQQRENEEHKRQLLAERQKRIEEQKEQRRRLBEEQQRRREKELRQQE
421 REQRRHYEEQMRREERRRAEHEQEYIRRLQLEEEQRQLEILQQQLLHEQALLLEYKRKQL
481 EEQRQAERLQRQLKQERDYLVSLLQHQRQEQRPVEKKPLHYHYKEGMSPEKPAWAKEI PHL
541 VAVKSGQFPALTASQSVHEQPTKGLSGFQEA LNVTSHRVEMPRQNSDPTSENPP LPTRIE
601 FDRSSWLRQEEDIPPKVPQRTTSISPALARKNSPGNGSALGPRLGSQPIRASNPDLRRTE
661 PILESPLQRTSSGSSSSSTPSSQPSQGGSGQSGAGSSERTVRVANSKSEGSVPVLPHE
721 PAKVKPEESRDITRPSRPADLTALAKELRELRIEETNRPMKKVTDYSSSESESESESESE
781 EDGESETHDGTVAVSDIPRLIPTGAPGSNEQYNVGMVGTGLETSHADSFSGSISREGTL
841 MIRETSGEKKRSGHSDNSNGFAGHINLPDLVQQSHSPAGTPTEGLGRVSTHSQEMDSGTEY
901 GMGSSTKASFPTFVDPVRVYQTSPTDEDEDEESSAAALFTSELLRQEQAKLNEARKISV
961 NVNPTNIRPHSDTPEIRKYKRFNSEILCAALWGVNLLVGTENGLMLLDRSGGQKVYNLI
1021 NRRRFQMQDVLEGLNVLVITISGKKNKL RVYVLSWLRNRI LHNDPEVEKKQGWITVGDLEG
1081 CIHYKVVKYERIKFLVIALKNAVEIYAWAPKPYHKFMAFKSFADLQHKPLLVLTVEEGQ
1141 RLKVI FGSHTGFHVIDVDSGNSYDIYIPSHIQGNITPHAIVILPKTDGMEMLVCYEDEGV
1201 YVNTYGRITKDVVLQWGEMPTSVAYIHSNQIMGWGEKAIEIRSVETGHLDGVMHKAQRA
1261 LKFLCERNDKVFFASVRSGGSSQVFFMTLNRNSMMNWZ

```


bioRxiv preprint doi: <https://doi.org/10.1101/000000>; this version posted January 1, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.



Figure 35

1 MASSDPSRSLDLDLSALRPDPAGIFELVFLVGNVTGYGVQYKGRHVKTGQLAASLKVMDVTG  
61 DEEBEIKKEIQENLKLKQYSHHRNIATYGAFLKNIPGMDQLVLVMEFGCSQVTDLKNKT  
121 KGNTLKKEEYATYCREILRGLSHLHQHKV IHRD IKQGNVLITENAELVKLDFVGSQAQLDR  
181 TVGRRNTFITGTYPYMAPEVATCENPDATVDFKSLDWSLGTATIAEMAGPAGLCPMHMR  
241 ALFLIPRNPAPRLSKKWSKKFQSP IESCLVKNKQSRPATEQLKQVPIRDPQNERQVFR  
301 QLKDHIDRTKKRGEKDETEVYSGSEEEENNDSPSSITLNLPGSETRRDFLRDLQLA  
361 NKERSEALRRQOLEQQRENEEHKQLLAERQKRIEQQORRLEEQRRKEELKQKQLE  
421 REQRRHYEEQMRREEERAEHBQYKRRKQLEBQRQAERLQRLQKQERDYLVSLSHQHQE  
481 QRVPYKELPHYKQSGSPSEKPAWAKEIPLHVLAVSQGPALTASQSBQRTKGLSGSGE  
541 ALNVTSHRVEMPRQNDSPTEPNPLPIETKDVSSSLWRQEEIPKPVQRTSIPALAA  
601 RNSPGMGSLAGPRLGSCQPTIRASNDPLRTEPELIPSLRTSGGSSSSSTSSQSSQSG  
661 QSGPQSGQSSERTVRANSKSEGSVPLRHEPAKVPEESRDI TRSPRADLTALAKELR  
721 ELRIEETNRPMKKVTDYSSSSSEESSESEEEEDGESETHDGTVAVSDIPRLIPTGAPGNS  
781 EQYNVNGVMTGHTLESHADSPSGSIREGTLMTIRTSCEKKGSHGSDNSGAGFILNDPL  
841 VQSHSGPMGTPEGLGRVSTHSGEMDSTGYQMGSSATFTFVDPVRVGYTSPTEDEE  
901 DEESSAANLPTSELRLQRLAKNEARKISVVNNVTNPIRPHSDPTIRIKYKRFNSEILC  
961 AALWGVPLTPTENGMLRQBSQKGVKVLNIRRRFQMDLGBLNVLTITSGKNKLKQ  
1021 YYLSWLRNRLIHNDEPEVEKKQGWITVGDLEGCIVKYKVKYERIKFVLIALKNVAEIIYAWA  
1081 PKPYHKMPAFSFDALQMKLVLVDLTVEBQRRQLVIFGSHGTGFVINDGNSGYIYPS  
1141 IHQGNITPHAVIYLPKTDGHEMLVCYEGEDGVYNTYGRITKDVVLQWEMTSPVAIHSN  
1201 QMGWGEBKAIETRSVETGHLDDGVFMHKAQRQLKFLCERNDKVFSVFSRSGSSGVFFMTL  
1261 NRNSMMNWX

United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



Application deficiencies were found during scanning:

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☒ Scanned copy is best available. *of Drawings*